

Kim Reynolds Governor Adam Gregg Lt. Governor Jerry R. Foxhoven Director

For Human Services use only:

General Letter No. 8-AP-482 Employees' Manual, Title 8 Medicaid Appendix

September 14, 2018

PRESCRIBED DRUGS MANUAL TRANSMITTAL NO. 18-2

- ISSUED BY: Division of Medical Services
- SUBJECT: **Prescribed Drugs Manual**, Chapter III, Provider-Specific Policies, Contents (pages 1, 2, and 3), revised; pages 1 through 63, revised; and the following forms:

470-5507	Request for Prior Authorization: Codeine or Tramadol, new	Age Edit Override –
470-5018	Request for Prior Authorization: Release, revised	Alpha ₂ Agonists, Extended-
470-5259	Request for Prior Authorization: Agents, revised	Anti-Diabetic Non-Insulin
470-5098	Request for Prior Authorization:	Antidepressants, revised
470-4094	Request for Prior Authorization: Oral/Injectable, revised	Antifungal Drugs –
470-5293	Request for Prior Authorization:	Apremilast (Otezla), revised
470-4521	Request for Prior Authorization: Spondylitis, revised	Biologicals for Ankylosing
470-4522	Request for Prior Authorization: revised	Biologicals for Arthritis,
470-4523	Request for Prior Authorization:	Biologicals for
	Inflammatory Bowel Disease, re	vised
470-4524	Request for Prior Authorization: Psoriasis, revised	Biologicals for Plaque
470-5142	<i>Request for Prior Authorization:</i> revised	Buprenorphine/Naloxone,
470-4551	<i>Request for Prior Authorization:</i> revised	Chronic Pain Syndromes,
470-4116	Request for Prior Authorization: Atomoxetine, revised	CNS Stimulants and
470-5497	Request for Prior Authorization:	Dupilumab (Dupixent), new
470-4550	Request for Prior Authorization: Formulations, revised	Extended Release
470-4099	Request for Prior Authorization: Stimulating Factor, revised	Granulocyte Colony
470-5270	Request for Prior Authorization: revised	Hepatitis C Treatments,

470-5531	Request for Prior Authorization:	<i>High Dose Opioids</i> , new
470-5040	<i>Request for Prior Authorization: Topical</i> , revised	Immunomodulators-
470-4111	Request for Prior Authorization: revised	Insulin, Pre-Filled Pens,
470-5117	Request for Prior Authorization: revised	Ivacaftor (Kalydeco),
470-5175	Request for Prior Authorization: Inhibitors, revised	Janus Kinase (JAK)
470-5548	Request for Prior Authorization:	Letermovir (Prevymis), new
470-4898	Request for Prior Authorization:	Lidocaine Patch, revised
470-4275	Request for Prior Authorization:	Linezolid (Zyvox), revised
470-5294	Request for Prior Authorization: revised	Methotrexate Injection,
470-4705	<i>Request for Prior Authorization:</i> revised	Modified Formulations,
470-5174	Request for Prior Authorization: revised	Oral Constipation Agents,
470-4327	Request for Prior Authorization: Hypertension Agents, revised	Pulmonary Arterial
470-4113	Request for Prior Authorization: Agonists, revised	Serotonin 5-HT1 Receptor
470-5188	Request for Prior Authorization: revised	Testosterone Products,
470-5549	Request for Prior Authorization: (Symdeko), new	Tezacaftor/Ivacaftor
470-5426	Request for Prior Authorization: Products, revised	Topical Acne and Rosacea
470-5398	Request for Prior Authorization: (Entresto), revised	Valsartan/Sacubitril
470-5534	Request for Prior Authorization: Transporter (VMAT) 2 Inhibitors,	<i>Vesicular Monoamine</i> new

Summary

The Prescribed Drug manual is revised to:

- Revise 29 forms for requesting drug prior authorization.
- Add six forms for requesting drug prior authorization.
- Remove the following forms for requesting drug prior authorization:
 - 470-4593, Request for Prior Authorization: Angiotensin Receptor Blocker Before ACE Inhibitor
 - 470-5462, Request for Prior Authorization: Daclizumab (Zinbryta[®])
- Add definitions for active pharmaceutical ingredients (API) and excipients.
- Add an Iowa Administrative Code reference for prospective drug reviews.
- Update the Iowa Administrative Code for patient counseling.
- Update prescriber qualifications and guidelines.

- Remove the nonprescription (OTC) prescribed drugs list and add a reference to the website.
- Update medical supplies DME billing.
- Update prior authorization submission options.
- Remove prior authorization criteria and add a reference to the website.
- Update the reimbursement effective date and add language for 340B, federal supply schedule, nominal price, and Indian health facilities.
- Update the reimbursement for vaccinations.
- Rename Non Drug Products to Active Pharmaceutical Ingredients (API) and Excipients. The list is removed and replaced with a reference to the website.
- Update the age edit chart.
- Add 340B covered entity requirement.
- Update paper claim billing instructions for federal supply schedule and nominal price claims.

Date Effective

Upon receipt.

Material Superseded

This material replaces the following pages from the *Prescribed Drugs Manual*:

<u>Page</u>	<u>Date</u>
Chapter III	
Contents (page 1)	June 1, 2016
Contents (pages 2-4)	January 1, 2018
Contents (page 5)	April 1, 2017
Contents (page 6)	June 1, 2016
1	November 1, 2016
2	January 1, 2018
3	September 1, 2015
4, 5	June 1, 2016
6, 7	August 1, 2013
8	September 1, 2015
9, 10	October 1, 2014
11-14	September 1, 2015
15	June 1, 2016
16	September 1, 2015
17	June 1, 2016
18	January 1, 2018
19	June 1, 2016
20-22	January 1, 2018
23-26	June 1, 2016

470-5018	4/17
27	April 1, 2017
28	June 1, 2016
470-4593	10/17
29, 30	November 1, 2016
470-5259	
	1/18
470-5098	7/14
31, 32	November 1, 2016
470-4094	6/17
470-5293	6/15
33, 34	November 1, 2016
470-4521	1/17
35, 36	November 1, 2016
470-4522	1/17 and 1/18
37, 38	November 1, 2016
470-4523	1/16
470-4524	1/17 and 1/18
39	April 1, 2017
40	January 1, 2018
470-5142	1/17
41, 42	January 1, 2018
470-4551	7/15
42a, 42b	January 1, 2018
470-4116	1/18
42c, 42d	January 1, 2018
470-5462	4/17
43-50	January 1, 2018
470-4550	10/16
51, 52	January 1, 2018
	1/16 and 1/18
470-4099	
53-56	January 1, 2018
470-5270	1/18
57, 58	January 1, 2018
470-5040	10/15
59, 60	January 1, 2018
470-4111	1/18
61, 62	January 1, 2018
470-5117	10/15
470-5175	10/16
63, 64	January 1, 2018
470-4898	6/14
65, 66	January 1, 2018
470-4275	1/16
67-72	January 1, 2018
470-5294	6/15
470-4705	6/17
73-78, 78a, 78b	January 1, 2018
470-5174	10/17
79-88	January 1, 2018

470-4327	10/16
89, 90, 90a-90g, 91-114	January 1, 2018
470-4113	1/18
115-118	January 1, 2018
470-5188	1/17
119, 120	January 1, 2018
470-5426	1/17
121, 122	January 1, 2018
470-5398	6/16
123, 124	January 1, 2018
125	November 1, 2016
126	January 1, 2018
127	November 1, 2016
128	June 1, 2016
129	November 1, 2016
130-144	June 1, 2016
145	April 1, 2017
146	June 1, 2016
147	November 1, 2016
148	June 1, 2016
149-152	January 1, 2018
153	June 1, 2016
154-156	April 1, 2017
157	January 1, 2018
158	November 1, 2016
159-162	June 1, 2016
163	November 1, 2016
164	June 1, 2016

Additional Information

The updated provider manual containing the revised pages can be found at: <u>http://dhs.iowa.gov/sites/default/files/Drugs.pdf</u>

If any portion of this manual is not clear, please contact the Iowa Medicaid Enterprise Provider Services Unit at 800-338-7909 or locally (in Des Moines) at 515-256-4609, or email at <u>imeproviderservices@dhs.state.ia.us</u>.




Table of Contents

<u>Page</u>

CHA	PTER	RIII. PROVIDER-SPECIFIC POLICIES 1
Α.	GEN	ERAL PHARMACY GUIDELINES 1
	1.	Definitions 1
	2.	Entities Involved in Developing Medicaid Drug Policies
		a. Drug Utilization Review Commission
		b. Pharmaceutical and Therapeutics Committee
	3.	Pharmacies Eligible to Participate
		a. Licensure
		b. Survey Participation
	4.	Pharmacist Responsibilities
		a. Prospective Drug Utilization Review
		b. Dispensing Requirements
		c. Patient Counseling
		d. Reason for Denial
	5.	Drug Use Review
В.	cov	ERAGE OF SERVICES12
	1.	Prescription Requirements12
		a. Prescriber Qualifications
		b. Prescriber Guidelines13
	2.	Drugs Excluded From Coverage13
	3.	Drugs for Medicare Eligibles14
	4.	Preferred or Recommended Drugs15
	5.	Nonpreferred Drugs
	6.	Newly Released Drugs
		a. New Drug Entities
		b. Exceptions to the Nonpreferred Default Policy for New PDL Drugs 16
		c. Existing PDL Drugs With Supplemental Rebates17
	7.	Nonprescription Drugs
	8.	Medical Supplies
C.	PRIC	DR AUTHORIZATION REQUIREMENTS
	1.	Prior Authorization (PA) Criteria
	2.	Prior Authorization (PA) Forms
	3.	Completing a Prior Authorization Request
	4.	Submitting a Prior Authorization Request
	5.	Prior Authorization Response



Chapter III. Provider-Specific Policies

Page

Date

August 1, 2018

<u>Page</u>

D.	BAS	IS OF PAYMENT FOR DRUGS
	1.	Reimbursement Effective April 1, 201727
		a. Generic and Nonprescription Drugs27
		b. Brand-Name Drugs27
		c. 340B Purchased Drugs27
		d. Federal Supply Schedule (FSS) Drugs28
		e. Nominal Price (NP) Drugs28
		f. Indian Health Facilities
	2.	Drugs Subject to Federal Upper Limit (FUL)
		a. FUL Development
		b. Reimbursement for FUL Drugs
	3.	Reimbursement for Unit-Dose Packaging29
	4.	Reimbursement for Vaccinations
		a. Vaccine for Children (VFC) Program
		b. Other Vaccines
_		
Ε.		ING SYSTEM
	1.	Point of Sale Claim Submission
		a. Claims Rejected Due to Other Insurance Coverage
	_	b. Correction of Insurance Information
	2.	Claiming Payment for Retroactively Eligible Member
	3.	Claim Attachment Control, Form 470-3969
	4.	Paper Claim Submission
F.	FDI	TS AND SPECIAL BILLING INFORMATION43
	1.	Claims for Deceased Members
	2.	Common Billing Errors
	3.	Compounded Prescriptions
	4.	Coverage of Active Pharmaceutical Ingredients (APIs) and Excipients45
	5.	Date of Birth Verification
	6.	Override Codes
	7.	Proper Reporting of NDCs
	8.	Prospective Drug Utilization Review (Pro-DUR)
		a. Age Edits
		b. Cost Effectiveness Edit
		c. Dosage Form Edits
		d. Excessive Days Supply53
		e. Gender Edits



Page

Date

3

August 1, 2018

<u>Page</u>

		f.	High-Dollar Claims	53
		g.	Hospice Edits	53
		h.	Refill Too Soon	54
		i.	Step Therapy Edits	54
		j .	Tablet Splitting	54
		k.	Therapeutic Duplication	54
	9.	Stat	tus Change for Preferred Brand Name Drugs	55
	10.	Trav	vel or Vacation Supplies of Medication	55
	11.	340	B Drug Pricing Program	56
		a.	Covered Entity (CE)	56
		b.	Iowa Medicaid Billing/Reimbursement for CE Outpatient In-Hou	use
			Pharmacy or Contracted Pharmacy	57
	12.	Inte	erpreter Services	58
		a.	Documentation of the Service	58
		b.	Qualifications	59
G.	REM	ΙΙΤΤΑ	NCE ADVICE AND FIELD DESCRIPTIONS	59
	1.	Ren	nittance Advice Explanation	59
	2.	Ren	nittance Advice Field Descriptions	60

Chapter III. Provider-Specific Policies



Page

Date

Prescribed Drugs

Chapter III. Provider-Specific Policies

August 1, 2018

1

CHAPTER III. PROVIDER-SPECIFIC POLICIES

A. GENERAL PHARMACY GUIDELINES

This manual gives general information about Medicaid drug coverage and billing policies. For more detailed information, see the following websites:

www.iadur.org	Drug Utilization Review (DUR) Commission
www.dhs.iowa.gov/ime/about	Iowa Medicaid Enterprise (IME)
www.iowamedicaidpdl.com	Pharmaceutical and Therapeutics (P&T) Committee and Preferred Drug List (PDL)
www.mslc.com/Iowa	Pharmacy Reimbursement
www.iowamedicaidpos.com	Point of Sale (POS) system for pharmacy claims

1. Definitions

340B Program means the federal 340B Drug Pricing program as set forth in Section 340B of the Public Health Service (PHS) Act (1992) and managed by Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA). The program allows certain designated facilities to purchase prescription medications at discounts, so these facilities can offer some medications to their patients at reduced prices.

340B Actual acquisition cost (340B AAC) means the net cost of a drug paid by a pharmacy for drugs purchased through the 340B drug pricing program. A drug's 340B AAC includes discounts, rebates, chargebacks and other adjustments to the price of the drug, but excludes dispensing fees.

340B Covered entity (CE) means facilities and programs listed in the 340B statute as eligible to purchase drugs through the 340B program and appear on the HRSA 340B database.

340B Contract pharmacies means a pharmacy under contract with a CE that lacks its own pharmacy. The contract pharmacy is authorized to dispense 340B-discounted drugs on behalf of the CE.

Active Pharmaceutical Ingredient (API) means any substance that is intended for incorporation into a finished drug product and is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body pursuant to 21 CFR 207.1. Active pharmaceutical ingredient does not include intermediates used in the synthesis of the substance.



Average actual acquisition cost (average AAC) means the average prices that retail pharmacies paid to acquire drug products.

Compendium of drug information means one of the following:

- The American Hospital Formulary Service Drug Information (AHFS);
- The United States Pharmacopeia Drug Information (USP-DI); or
- DRUGDEX Information System.

DESI drugs means drug products identified by the federal Food and Drug Administration, in the Drug Efficacy Study Implementation Program, as lacking substantial evidence of effectiveness.

Drug rebates means payments provided by pharmaceutical manufacturers to state Medicaid programs under the terms of the manufacturers' agreements with the Department of Health and Human Services or with the individual state.

Drug utilization review (DUR) means a quality review of covered outpatient drugs that assures that prescriptions are appropriate, medically necessary, and not likely to result in adverse medical outcomes.

Drug Utilization Review Commission means a quality assurance body of nine members that seeks to improve the quality of pharmacy services and ensure rational, cost-effective medication therapy for Medicaid members in Iowa. The website for the Commission is <u>www.iadur.org</u>.

Equivalent products means those products that meet therapeutic equivalence standards as published in the federal Food and Drug Administration document, *Approved Prescription Drug Products with Therapeutic Equivalence Evaluations*.

Excipient means an inactive substance used in drug compounding.

Federal upper limit (FUL) means the maximum allowable reimbursement set by the Centers for Medicare and Medicaid Services for a multiple-source drug. The list is available at the federal pharmacy reimbursement website: <u>https://www.medicaid.gov/medicaid/prescription-drugs/federal-upper-limits/index.html</u>



Fee-for-Service (FFS) means providers bill Iowa Medicaid directly for prescriptions they provide to FFS members.

Grandfather clause means a clause creating an exemption based on previously existing circumstances. The Pharmaceutical and Therapeutics Committee considered select therapeutic classes for grandfathering existing drug regimens. For claims processing, "drug history" means the most recent 90-day period. If a patient has a history with a specific drug within these classes, the prescriber is not required to obtain prior authorization even if the drug has a nonpreferred status on the <u>Preferred Drug List</u>.

Legend drugs are drugs that bear the federal caution: "Federal Law Prohibits Dispensing a Drug Without a Prescription."

Less than effective drug or DESI drug means a drug for which:

- The Food and Drug Administration (FDA) has withdrawn approval of the drug application for safety or efficacy reasons as a result of the drug efficacy study implementation (DESI) review; or
- The secretary of the U.S. Department of Health and Human Services has issued a notice of a hearing under section 505(e) of the federal Food, Drug, and Cosmetic Act on a proposed order to withdraw approval of the drug application because the secretary has determined that the drug is less than effective for some or all of the conditions of use prescribed, recommended, or suggested in the drug's labeling.

Medicaid Carve-In means a 340B entity has elected to use drugs purchased at 340B prices to bill for Medicaid patients. If an entity chooses to use 340B drugs to bill Medicaid, it must indicate this on the Medicaid Exclusion File and list the appropriate Medicaid provider numbers or NPIs.

Medicaid Carve-Out means a 340B entity has elected to use non-340B drugs to bill for Medicaid patients. Entities may choose to do this so they can receive regular Medicaid reimbursement.

Medically accepted indication means any use for a covered outpatient drug which is approved under the federal Food, Drug, and Cosmetic Act, or the use of which is supported by one or more citations included or approved for inclusion in any of the compendia described in section 1927(g)(1)(B)(i) of the Social Security Act.



National drug code (NDC) means the eleven-digit number the manufacturer or labeler assigns to a pharmaceutical product and attaches to the product container at the time of packaging that identifies the product's manufacturer, dose form and strength, and package size.

Nonpreferred drug means a drug on the Preferred Drug List that requires prior authorization, with the primary criteria being failure on the preferred agents rather than clinical guidelines. A nonpreferred drug is designated "N" on the Preferred Drug List.

Nonprescription drugs or **over-the-counter (OTC) drugs** means drugs that may be lawfully sold without a prescription.

Nonrecommended drug means a drug placed on a voluntary list designed to inform prescribers of cost-effective alternatives and, if used, will be more costly to the Medicaid program. The drug does not require a prior authorization unless a number is in the comments column to indicate a prior authorization is required. A nonrecommended drug is designated "NR" on the Preferred Drug List.

Pharmaceutical and Therapeutics (P&T) Committee means a committee of nine members appointed by the Governor that is charged with developing and providing ongoing review of the Preferred Drug List pursuant to Iowa Code section 249A.20A.

Preferred drug means a drug on the Preferred Drug List that provides medical equivalency to the Medicaid member in a cost-effective manner (by virtue of OBRA '90 and Supplemental Rebate) and does not require a prior authorization. A preferred drug is designated "P" on the Preferred Drug List.

Preferred Drug List (PDL) means a list comprised of drugs recommended to the Iowa Department of Human Services by the Iowa Medicaid Pharmaceutical and Therapeutics Committee that have been identified as being therapeutically equivalent within a drug class and that provide cost benefit to the Medicaid program.

Preferred drug with conditions means a drug is a "preferred" agent but before getting the drug a patient must meet medical criteria and guidelines that coincide with current prior authorization criteria. A preferred drug with conditions is designated "P" on the Preferred Drug List and has a number in the comments column to indicate a prior authorization is required, as defined on the first page of the Preferred Drug List (PDL).



Prior authorization (PA) means obtaining approval for a drug before the drug is provided to a member, as a precondition for provider reimbursement. Prior authorization is requested at the prescriber level and is primarily a prescriber fax-only system using the forms provided by the Iowa Medicaid Enterprise.

Professional dispensing fee means payment provided for the costs incurred by a pharmacy to dispense a drug. The fee reflects the pharmacist's professional services and costs associated with ensuring that possession of the appropriate covered outpatient drug is transferred to a Medicaid member.

Prospective drug utilization review (Pro-DUR) means a process in which a request for a drug product for a particular patient is screened for potential drug therapy problems before the product is dispensed.

Recommended drug means a drug placed on a voluntary list designed to inform prescribers of cost-effective alternatives and, if used, will result in a cost savings to the Medicaid program. The drug does not require a prior authorization unless a number is in the comments column to indicate a prior authorization is required. A recommended drug is designated "R" on the Preferred Drug List.

Recommended drug list (RDL) means a voluntary list of drugs recommended to the Department of Human Services by the Iowa Medicaid Pharmaceutical and Therapeutics Committee that informs prescribers of costeffective alternatives that do not require a prior authorization unless otherwise indicated in the comments column. The RDL is a component of the PDL.

Retrospective drug utilization review (Retro-DUR) means the process in which patient drug utilization is periodically reviewed to identify patterns of fraud, abuse, gross overuse, or inappropriate or unnecessary care.

Usual and customary charge means the fee that the provider typically charges the general public for the product or service.

Wholesale Acquisition Cost (WAC) represents the cost reported to Medi-Span by a manufacturer (updated in a number of ways) at which wholesalers purchase drug products from that manufacturer.



6

2. Entities Involved in Developing Medicaid Drug Policies

a. Drug Utilization Review Commission

The Iowa Medicaid Drug Utilization Review (DUR) Commission, established pursuant to Iowa Code section 249A.24, is a quality assurance body of nine members that seeks to improve the quality of pharmacy services and ensure rational, cost-effective medication therapy for Medicaid members in Iowa.

This Commission meets four times a year in a public forum. The Commission discusses potential medications or therapeutic classes where prior authorization may be beneficial, and discusses existing criteria to determine if the criteria continue to be therapeutically valid.

b. Pharmaceutical and Therapeutics Committee

The Pharmaceutical and Therapeutics (P&T) Committee was established pursuant to Iowa Code section 249A.20A. The P&T Committee has nine members appointed by the Governor for a two-year term. The Committee meets three times a year in a public forum.

The P&T Committee is charged with developing and providing ongoing review of the Preferred Drug List (PDL). The PDL is a list of drugs that have been identified as being therapeutically equivalent within a drug class and that provide cost benefit to the Medicaid program.

The PDL was created in an effort to select medications for use by the members of Iowa Medicaid that are both clinically sound and cost-effective. The Department of Human Services is attempting to contain Medicaid drug expenditures while ensuring that members' access to effective drug solutions are preserved.

The P&T Committee's focus is maximizing the initial utilization of the most cost-effective clinical choices available. All drug manufacturers have been given the opportunity to state the therapeutic benefit of their drugs and to reduce the net cost to the state through a supplemental rebate program.



The Committee has reviewed each product within a therapeutic class for:

- Pharmacology,
- Indications,

- Comparative clinical trials,
- Adverse effects and safety,
- Evaluated relative cost of each product, and
- Compared products within the same class to identify the most clinically effective, cost efficient product in each class.

By first considering the therapeutics and then the cost, the P&T Committee ultimately decides which drugs to recommend to the Iowa Medicaid program as "preferred."

The P&T Committee holds public meetings, with public notice of its agenda and opportunity for public comment. The website for the Committee is <u>www.iowamedicaidpdl.com</u>.

3. Pharmacies Eligible to Participate

Under the Iowa Medicaid program, drugs must be furnished by a licensed pharmacy. (The Board of Pharmacy Examiners issues these licenses.)

a. Licensure

Participating retail pharmacies must be licensed in the state of Iowa or duly licensed in another state. Out-of-state retail pharmacies delivering, dispensing, or distributing drugs by any method to an ultimate user physically located in Iowa must be duly licensed by Iowa as a nonresident pharmacy for that purpose.

b. Survey Participation

As a condition of participation, retail pharmacies are required to make available drug acquisition cost invoice information, product availability information if known, dispensing cost information, and any other information deemed necessary by the Department to assist in monitoring and revising reimbursement rates pursuant to 441 IAC 79.1(8) or for the efficient operation of the pharmacy benefit.



8

- A pharmacy shall produce and submit all requested information in the manner and format requested by the Department or its designee at no cost to the Department or its designee.
- A pharmacy shall submit information to the Department or its designee within the time frame indicated following receipt of a request for information unless the Department or its designee grants an extension upon written request of the pharmacy.
- Any dispensing or acquisition cost information submitted to the Department that specifically identifies a pharmacy's individual costs shall be held confidential.

4. Pharmacist Responsibilities

a. Prospective Drug Utilization Review

Pharmacists shall review patient drug therapy at the point of sale to screen for potential drug therapy problems, following a prospective drug use review pursuant to rule 657 Iowa Administrative Code 8.21(155A), due to:

- Therapeutic duplication
- Drug-disease contraindications
- Drug-drug interactions
- Incorrect drug dosage or duration
- Drug-allergy interactions
- Clinical abuse or misuse

b. Dispensing Requirements

Pharmacists are required to:

- Dispense drugs in accordance with cost and quantity requirements established by state law.
- Dispense the **least costly item** in stock that meets the order of the doctor or other practitioner, as shown on the prescription.
- Pharmacies must bill once each month for the month's supply, or once every three months for the three month supply of contraceptives.



9

- Develop and implement policies and procedures for delivery of prescriptions in accordance with state law, including:
 - Establishment of effective controls against diversion of prescription drugs, as required by Iowa Code § 155A.15(2)(i); and
 - Policies and procedures regarding shipment or other delivery to ensure accountability, safe delivery, and compliance with temperature requirements, as required by 657 Iowa Administrative Code 8.15(2).
 - Maintain a record documenting receipt and delivery of the covered outpatient prescribed drug to the Medicaid member or the member's representative, as required by 441 IAC 79.3(1)"a"(2) and 79.3(2)"c"(3).

c. Patient Counseling

Pharmacists must offer to discuss with each Medicaid member or the member's caregiver presenting a prescription those matters that, in the pharmacist's professional judgment, will enhance or optimize drug therapy. Appropriate elements of patient counseling may include:

- The name and description of the drug
- The dosage form, dose, administration route and duration of therapy
- The intended use of the drug, if known and expected action
- Directions and precautions for preparation, administration, and use
- Common severe side or adverse effects or interactions and therapeutic contraindications that may be encountered, including their avoidance and the action required if they occur
- Techniques for self-monitoring drug therapy
- Proper storage
- Prescription refill information, including the approximate date when refill will be allowed (generally, 90 percent of the prescription is used)
- Actions to be taken in the event of a missed dose
- Comments relevant to the patient's drug therapy, including any other information peculiar to the specific patient or drug



10

Patient counseling is required in accordance with federal law at 42 USC Section 1396r(g)(2)(A)(ii)(I) and state rules at 657 Iowa Administrative Code 6.14(155A).

d. Reason for Denial

The pharmacist should explain the reason for any **denial** of a requested drug or item to the member or caregiver. For example, denial could be due to one of the following:

- Noncovered drug or item. Explain why the drug or item is not covered and suggest alternatives to the member, caregiver, or practitioner.
- **Prior authorization requirement**. Explain the prior authorization process and requirements to the member or caregiver.

When a patient presents a prescription for nonpreferred drug at a pharmacy and it is denied, contact the prescriber and ask if the prescriber wishes to choose a preferred drug.

- If the prescriber wishes to change to a preferred drug, the prescriber may dictate the new prescription order.
- If the prescriber views that the nonpreferred drug is medically necessary, the prescriber must obtain prior authorization.
- **Refill too soon**. Inform the member or caregiver of an approximate date the prescription can be refilled (after 90 percent of the previous supply is used).

In special circumstances, such as a change in dose, travel, or lost, stolen or destroyed medication, that result in an early refill, contact the IME Pharmacy Point of Sale (POS) Unit at (515) 256-4608 (local calls) or 877-463-7671 with the information. This information will be reviewed to determine if an override can be given to allow payment.

 Non-controlled medications that are lost, stolen or destroyed after delivery to the member are limited to a one time override allowance per 12 month period. Overrides for the first occurrence of a lost, stolen or destroyed medication can be obtained by contacting the IME Pharmacy Point of Sale (POS) Unit at (515) 256-4608 (local calls) or 877-463-7671.




11

- Requests exceeding the one time override allowance for non-controlled medications that are lost, stolen or destroyed after delivery to the member may be considered with additional documentation. Such requests involving stolen medications must include a copy of a police report.
- Override of refill too soon will not be allowed for controlled substances and/or tramadol containing products that are lost, stolen, or destroyed after delivery to the member.
- Override of refill limits will not be allowed for members residing in a long term care (LTC) facility.
- Prescription drugs that are not received by the member because they are lost or stolen in transit, before actual delivery to the member, or that are received in damaged or unusable condition will not be replaced through override of refill too soon. The original claim for the drug that was not properly delivered to the member should be reversed and a new claim for a replacement can then be submitted.
- Plan limits exceeded. Refer to the limits list posted on the website, <u>www.iowamedicaidpdl.com</u>, under "Billing/Quantity Limits." The number of doses should be reduced to meet the quantity limit.

If there are special circumstances where adherence to the quantity limit is not possible, the prescriber should complete form 470-4556, *Quantity Limit Override*, or form 470-5038, *Request for Fifteen Day Initial Prescription Supply Override*, and fax it to 1-800-574-2515. The clinical staff will review the information submitted and determine if an override can be given to allow payment.

If the member or caregiver is not satisfied with the explanation of the reason for a denial, refer the person to the member's DHS worker for assistance in filing an appeal or requesting an exception to policy. Appeal and exception requests may be filed on line through the following website: <u>http://dhs.iowa.gov/appeals</u>.



5. Drug Use Review

The drug use review (DUR) process was established to fulfill a federal requirement established by the federal Omnibus Budget Reconciliation Act of 1990. Iowa Medicaid has implemented both of the required DUR types:

- Prospective drug utilization review occurs when the pharmacist does the review of patient drug therapy at the point of sale. See <u>Pharmacist</u> <u>Responsibilities</u>.
- **Retrospective drug utilization review** occurs when the review takes place after the point of sale.

The retrospective DUR program provides ongoing periodic examination of claims data and other records in order to identify patterns of fraud, abuse, gross overuse, or inappropriate or medically unnecessary care among physicians, pharmacists, and members, or associated with specific drugs.

B. COVERAGE OF SERVICES

Payment will be made for legend and nonprescription drugs when prescribed by a practitioner who is legally qualified to prescribe the item, subject to the limitations described in this manual.

1. Prescription Requirements

Prescription records are required for all drugs as specified in Iowa pharmacy and drug laws, including Iowa Code sections 124.308, 126, 155A.27, and 155A.29.

For Medicaid purposes, prescriptions are required for nonprescription drugs and are subject to the same provisions. This includes the record-keeping requirements on refills. Maintain prescriptions on file in such a manner that they will be readily available for audit by the Department.

Prescriptions executed in writing (nonelectronic) for prescription drugs must be presented on a tamper-resistant pad, as required by Section 1903(i)(23) of the Social Security Act (42 U.S.C. Section 1396b(i)(23)).



13

August 1, 2018

a. Prescriber Qualifications

Payment is made for drugs prescribed by a legally qualified enrolled practitioner within the limits prescribed by law and in policies established by the Department.

Prescriptions by a therapeutically certified optometrist are limited to the following:

- Topical and oral antimicrobial agents
- Topical and oral antihistamines
- Topical and oral antiglaucoma agents
- Topical and oral analgesic agents, including controlled substances
- Topical anesthetic agents
- Topical anti-inflammatory agents

b. Prescriber Guidelines

Prescribers should review the therapy of their Medicaid patients for utilization of nonpreferred drugs and wherever medically appropriate, change patients to preferred drugs. New therapy should be initiated on a preferred drug unless a nonpreferred drug is medically necessary.

When a nonpreferred drug is medically necessary, the prescriber should request a prior authorization. See <u>PRIOR AUTHORIZATION</u> <u>REQUIREMENTS</u> for information on criteria for prior authorization and procedures.

In writing prescriptions, when it is not therapeutically contraindicated, the prescriber should prescribe a quantity of prescription medication sufficient for a month's supply. Contraceptives may be prescribed in three month quantities.

2. Drugs Excluded From Coverage

Medicaid payment will **not** be made for:

- Drugs used to cause anorexia, weight gain or weight loss.
- Drugs used for cosmetic purposes or hair growth.
- Drugs used for symptomatic relief of cough and colds, except for nonprescription drugs listed in <u>section B.7</u>.



14

- Drugs used for fertility purposes or for sexual or erectile dysfunction.
- Drugs prescribed for a use other than the drug's medically accepted use.
- Drugs classified as less than effective by the Centers for Medicare and Medicaid Services.
- Drugs marketed by manufacturers that have not signed a Medicaid rebate agreement.
- Covered outpatient drugs for which the manufacturer seeks to require as a condition of sale that associated tests or monitoring services be purchased exclusively from the manufacturer or designee.

3. Drugs for Medicare Eligibles

Prescription drugs for Medicaid members who also qualify for Medicare (referred to as "dual eligibles") are paid through Medicare Part D effective January 1, 2006. Medicaid does not cover any drugs covered under Medicare Part D for these members.

Iowa Medicaid covers drugs in the following categories for dual eligible members:

- Barbiturates (except when used in the treatment of epilepsy, cancer, or chronic mental health disorder diagnoses)
- Over-the-counter drugs (list posted at <u>www.iowamedicaidpdl.com</u>)
- Prescription vitamin and minerals, except prenatal vitamins and fluoride preparations

Iowa Medicaid will accept only secondary claims for these drugs. Medicaid should be listed as the secondary insurance for all dual eligibles. All claims should be submitted first to the primary insurance (Medicare Part D PDP).

Iowa Medicaid will **not** pay for any Medicare Part B drugs, such as:

- Oral immunosuppressant drugs,
- Inhalation drugs when used with a nebulizer,
- Oral chemotherapy drugs,
- Oral anti-emetic drugs,
- Blood clotting factors, or
- Epoetin.

A drug for which coverage is available to a dual eligible under Medicare Part A or Part B must be billed to Medicare Part A or Part B.



15

August 1, 2018

4. Preferred or Recommended Drugs

Drug products designated on the Preferred Drug List as "P" (preferred) or "R" (recommended) do not require prior authorization unless the drug has a number in the comments column to indicate a prior authorization is required, as defined on the first page of the Preferred Drug List. See <u>www.iowamedicaidpdl.com</u> for the current designations.

A **preferred drug with conditions** has "preferred" agents but must meet certain medical criteria and guidelines that coincide with current prior authorization guidelines.

5. Nonpreferred Drugs

Drug products designated "N" (nonpreferred) on the Preferred Drug List require prior authorization, with the primary criteria being failure on the preferred agents rather than clinical guidelines. See <u>www.iowamedicaidpdl.com</u> for the current designations.

Drug products within a therapeutic class that are not selected as preferred will be denied for payment unless the prescriber obtains prior authorization. Payment for drugs requiring a prior authorization will be made only when:

- The drugs are prescribed for treatment of one or more conditions set forth for each, and
- The Iowa Medicaid prior authorization criteria have been met, and
- Approval is obtained through the prior authorization process.

EXCEPTION: In the event of an emergency when the prescriber cannot submit a prior authorization request, the pharmacist may dispense a 72-hour supply of the drug and reimbursement will be made.



6. Newly Released Drugs

a. New Drug Entities

New drug entities (including new generic drugs) and new drug product dosage forms of existing drug entities will be identified weekly and immediately be coded as "Nonpreferred – Prior authorization required" until presented at the next scheduled P&T Committee meeting. If the drug category requires step therapy, the step therapy requirements must also be met, treating the new drug as a nonpreferred step 3 drug.

These prior authorization restrictions will continue through the review process, including while committee recommendations are being made, and lasting until DHS makes a final determination.

b. Exceptions to the Nonpreferred Default Policy for New PDL Drugs

There are two major potential exceptions to the nonpreferred default policy for new PDL drugs:

- If the FDA classifies a new medication as a priority drug, the state may indicate that such a drug is preferred until the P&T Committee reviews the drug at its next scheduled meeting.
- The state may decide to designate a new drug as "draft preferred" and provide immediate access and increased therapeutic choice to physicians until the P&T Committee reviews the drug at its next scheduled meeting if:
 - A new drug is therapeutically equivalent or superior to existing preferred or nonpreferred choices, and
 - Is as safe or safer than existing preferred or nonpreferred choices, and
 - The net cost, adjusted for all rebates, is less expensive than all existing preferred choices.



c. Existing PDL Drugs With Supplemental Rebates

Although the state discourages supplemental rebate offers on existing PDL drugs between annual bidding periods, it may entertain such bids and may accept them if they:

- Are determined to represent significant additional savings, or
- Would replace a delinquent manufacturer's product or a preferred drug pulled from the marketplace or significantly restricted by the FDA.

This interim preferred status will remain in effect until the P&T Committee reviews the drug at its next scheduled meeting.

Supplemental rebates will be invoiced only for approved drugs under contract. Draft preferred drugs with supplemental rebates will not be invoiced until approved by the Committee and accepted by the state. At that time, the supplemental rebates will be invoiced back to the effective date of the agreement, which is the date the drug began to benefit from preferred status.

7. Nonprescription Drugs

Payment will be made for nonprescription drugs or over-the-counter (OTC) drugs with a prescription, subject to prior authorization requirements as specified in the preferred drug list. These drugs are identified on the Nonprescription (OTC) Prescribed List by Therapeutic Category located on the website <u>www.iowamedicaidpdl.com</u> under the <u>Preferred Drug Lists</u> tab.

Nonprescription drugs cannot be billed to IME Medicaid POS for members residing in Nursing Facilities (NF), Intermediate Care Facilities for Individuals with Intellectual Disabilities (ICF/ID), and Psychiatric Medical Institutions for Children (PMIC) facilities. These are considered 'stock items' and are to be included in the facility's Medicaid cost report and reimbursed through per diem calculations.

The only exclusions to this policy are as follows:

- OTC insulin: Bill dual eligible member's Medicare Part D plan; for the Medicaid only, bill Medicaid as a POS claim.
- Pseudoephedrine: Since these agents are classified as controlled substances in Iowa, for the dual eligible and Medicaid only, bill Medicaid as a POS claim.



Select nonprescription medications are covered although the manufacturers have not entered into a rebate agreement with CMS. Payment will be made in the same manner as for prescription drugs.

Nonprescription vitamins and minerals may also be payable under conditions specified under <u>PRIOR AUTHORIZATION REQUIREMENTS</u>.

8. Medical Supplies

Pharmacies that dispense medical equipment and supplies should follow the <u>MEDICAL EQUIPMENT AND SUPPLY DEALER PROVIDER MANUAL</u> and purchase a supply of <u>CMS-1500</u> claim forms from any supplier.

Preferred durable medical equipment (DME) diabetic supplies (test strips, syringes, and lancets) may be submitted through Pharmacy Point of Sale (POS) based on a prescription issued by a licensed prescriber, with reimbursement based on the lower of WAC or submitted, with no dispensing fee paid. Preferred blood glucose meters should not be billed to Medicaid and should be processed through the manufacturer free meter program. Additional information is available at http://www.iowamedicaidpos.com/diabetic-monitors-test-strips.

All nonpreferred durable medical equipment (DME) brands of diabetic supplies require prior authorization (PA) through the IME Medical Prior Authorization (PA) Unit. See the <u>MEDICAL EQUIPMENT AND SUPPLY DEALER PROVIDER</u> <u>MANUAL</u>.

C. PRIOR AUTHORIZATION REQUIREMENTS

1. Prior Authorization (PA) Criteria

Refer to the most current PA criteria chart located at <u>http://www.iowamedicaidpdl.com/pa_criteria</u>.

2. Prior Authorization (PA) Forms

PA forms are required for the following and can be found at the links below:

- <u>Age edit override Codeine or Tramadol</u>
- <u>Alpha₂ agonists, extended release</u>
- <u>Alpha₁ proteinase inhibitor enzymes</u>
- <u>Amylino mimetic (Symlin)</u>
- Anti-diabetic, non-insulin agents



Request for Prior Authorization Age Edit Override – Codeine or Tramadol

FAX Completed Form To 1 (800) 574-2515

Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB		
Patient address				
Provider NPI	Prescriber name	Phone		
Prescriber address		Fax		
Pharmacy name	Address	Phone		
Prescriber must complete all informa	tion above. It must be legible, correct, and complete	e or form will be returned.		
Pharmacy NPI	Pharmacy fax NDC			
An age edit override for codeine of considered under the following c	or tramadol is required for patients under 18 ye onditions:	ars of age. Payment will be		
1. Member is 12 years of age of	or older; and			
2. Medication is not being pre- members 12 to 18 years of a	scribed to treat pain after surgery following ton age; and	sil and/or adenoid procedure for		
3. If member is between 12 an have obstructive sleep apne	d 18 years of age, member is not obese (BMI gr ea, or severe lung disease.	eater than 30kg/m2), does not		
Drug Name & Strength	Quantity & Days Supply	Dosing Instructions		
Anticipated duration of treatment:				
Diagnosis:				
For Members between 12 and 18 years of age:				
Is medication being used to treat pain after surgery following tonsil and/or adenoid procedure? 🗌 Yes 🗌 No				
Provide member's BMI: Date of measure:				
Does member have obstructive sleep apnea? Yes No				
Does member have severe lung disease?				

Attach lab results and other documentation as necessary.

Prescriber signature (Must match prescriber listed above.)	Date of submission	

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for continues to be eligible for Medicaid.



Request for Prior Authorization ALPHA₂ AGONISTS, EXTENDED-RELEASE

FAX Completed Form To 1 (800) 574-2515

> **Provider Help Desk** 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name		DOB		
Patient address					
Provider NPI	Prescriber name		Phone		
Prescriber address			Fax		
Pharmacy name	Address		Phone		
Prescriber must complete all inform	ation above. It must be legible, corre	ct, and complete or f	form will be returned.		
Pharmacy NPI	Pharmacy fax	NDC			
therapeutic dose with one preferred amphetamine and one preferred non-amphetamine stimulant. The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated. Preferred (no PA required) Non-Preferred (PA required) Guanfacine ER Clonidine ER Intuniv					
Strength	Dosage Instructions	Quantity I	Days Supply		
Diagnosis:					
	ase product of same chemical ent ates: Failu		Dose:		
Trial of preferred amphetamine s	timulant: Drug Name & Dose:				
Trial Dates: Failure Reason:					
Trial of preferred non-amphetam Trial dates:	ine stimulant: Drug Name & Dose _ Failure Reason:	:			
Medical or contraindication reas	on to override trial requirements:				
Attach lab results and other doc					
Prescriber signature (Must match pre	escriber listed above.)	Date of sub	omission		
	quests for prior authorization the consulta this request is granted, this does not ind				

medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.



Request for Prior Authorization ANTI-DIABETIC NON-INSULIN AGENTS

FAX Completed Form To 1 (800) 574-2515

> Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

	-		
IA Medicaid Member ID #	Patient name	DOB	
Patient address			
Provider NPI	Prescriber name	Phone	
Prescriber address		Fax	
Pharmacy name	Address	Phone	
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.			
Pharmacy NPI	Pharmacy fax	NDC	

Prior authorization is required for preferred anti-diabetic, non-insulin agents subject to clinical criteria. Payment will be considered under the following conditions: 1) A diagnosis of Type 2 Diabetes Mellitus, and 2) Patient is 18 years of age or older; and 3) The patient has not achieved HgbA1C goals after a minimum three month trial with metformin at a maximally tolerated dose. Payment for a non-preferred anti-diabetic, non-insulin agent subject to clinical criteria will be authorized only for cases in which there is documentation of previous trials and therapy failures with metformin, a preferred DPP-4 Inhibitor or DPP-4 Inhibitor combination, a preferred Incretin Mimetic, and a preferred SGLT2 Inhibitor at maximally tolerated doses. The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated. Initial authorizations will be approved for six months. Additional prior authorizations will be considered on an individual basis after review of medical necessity and documented continued improvement in HgbA1C.

Preferred DPP-4 In	hibitors and Combined to the second	nations No	on- Preferred DPP-4 Inh	hibitors and Combin	ations
Janumet	Jentadueto] Alogliptin	Jentadueto XR	🗌 Nesina
Janumet XR	🗌 Tradjenta		Alogliptin-Metformin	🗌 Kazano	🗌 Onglyza
🗌 Januvia			Alogliptin-Pioglitazone	Kombiglyze XR	🗌 Oseni
] Glyxambi		
Preferred Incretin	<u> Vimetics</u>	No	on-Preferred Incretin M	imetics	
Byetta	Victoza] Adlyxin	Ozempic	
Bydureon			Bydureon BCise	Trulicity	
Preferred SGLT2 In	hibitors and Combi	inations <u>No</u>	on-Preferred SGLT2 Inh	nibitors and Combin	ations
Farxiga	🗌 Synjardy XR		Invokamet	Qtern	🗌 Steglujan
	🔲 Xigduo XR		Invokamet XR	Segluromet	
Synjardy			Invokana	Steglatro	
			•		
	Strength	Dosage Instructions	Quantity	Days Supply	
Diagnosis:					

Request for Prior Authorization ANTI-DIABETICS NON-INSULIN AGENTS (PLEASE PRINT – ACCURACY IS IMPORTANT)

Metformin Trial: Trial start date:	Trial end date:	Trial dose:	
Reason for Failure:			
Medical or contraindication reason to o	verride trial requirements:		
Most recent HgbA1C Level:			
Requests for Non-Preferred Drugs:			
Preferred DPP-4 Trial: Drug Name/De	ose:		
Trial start date:	Trial end date:		
Reason for Failure:			
Preferred Incretin Mimetic Trial: Dru	g Name/Dose:		
Trial start date:			
Reason for Failure:			
Preferred SGLT2 Trial: Drug Name/D	ose:		
Trial start date:	Trial end date:		
Reason for Failure:			
Reason for use of Non-Preferred drug	requiring prior approval:		

Attach lab results and other documentation as necessary.

Prescriber signature (Must match prescriber listed above.)	Date of submission	

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for continues to be eligible for Medicaid.



Request for Prior Authorization ANTIDEPRESSANTS

FAX Completed Form To 1 (800) 574-2515

> Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB		
Patient address				
Provider NPI	Prescriber name	Phone		
Prescriber address		Fax		
Pharmacy name	Address	Phone		
-				
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.				
Pharmacy NPI	Pharmacy fax NDC			

Prior authorization is required for non-preferred antidepressants subject to clinical criteria. Requests for doses above the manufacturer recommended dose will not be considered. Payment will be considered for patients when the following criteria are met: 1) The patient has a diagnosis of Major Depressive Disorder (MDD) and is 18 years of age or older; and 2) Documentation of a previous trial and therapy failure at a therapeutic dose with two preferred generic SSRIs; and 3) Documentation of a previous trial and therapy failure at a therapeutic dose with one preferred generic SNRI; and 4) Documentation of a previous trial and therapy failure at a therapeutic dose with one non-SSRI/SNRI generic antidepressant . 5) If the request is for an isomer, prodrug or metabolite of a medication indicated for MDD, one of the trials must be with the preferred parent drug of the same chemical entity that resulted in a partial response with a documented intolerance. The required trials may be overridden when documented evidence is provided that the use of these agents would be medically contraindicated.

Non-Preferred

Aplenzin Fetzima Khedezla Viibryd Other: Strength Dosage Instructions Quantity	Days Supply
Diagnosis:	
Preferred Generic SSRI Trial 1: Drug Name& Dose Failure Reason	Trial Dates:
Preferred Generic SSRI Trial 2: Drug Name& Dose Failure Reason	
Preferred Generic SNRI Trial: Drug Name& Dose	Trial Dates:
Preferred Non-SSRI/SNRI Generic Antidepressant Trial: Drug Name& Dose_ Trial Dates: Failure Reason	
Medical or contraindication reason to override trial requirements:	

Prescriber signature (Must match prescriber listed above.)	Date of submission
IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of	
medical necessity only. If approval of this request is granted, this does not indicate that	t the member continues to be eligible for
Medicaid. It is the responsibility of the provider who initiates the request for prior author	rization to establish by inspection of the
member's Medicaid eligibility card and, if necessary by contact with the county Departm	nent of Human Services, that the member

continues to be eligible for Medicaid.



FAX Completed Form To 1 (800) 574-2515

Provider Help Desk 1 (877) 776-1567

Request for Prior Authorization ANTIFUNGAL DRUGS- ORAL / INJECTABLE

(PLEASE PRINT -	ACCURACY IS	IMPORTANT)
-----------------	-------------	--------------------

IA Medicaid Member ID #	Patient name		DOB
Patient address			
Provider NPI	Prescriber name		Phone
Prescriber address			Fax
Pharmacy name	Address		Phone
Prescriber must complete all informa	ation above. It must be legible, correct, and c	omplete or for	rm will be returned.
Pharmacy NPI	Pharmacy fax	NDC	
the Iowa Medicaid Preferred Drug will be authorized only for cases preferred agent(s). Payment for a patient has a diagnosis of an imm authorization requirement does r		Payment for ious trial(s) a vill be author nic fungal inf	a non-preferred antifungal and therapy failure with a rized in cases where the ection. This prior
Preferred (PA required after 90 data Clotrimazole Troche Fluconazole Griseofulvin Suspension Terbinafine Voriconazole Other:	ays) Non-Preferred (PA r □ Cresemba □ Diflucan □ Grifulvin V □ Gris-Peg □ Griseofulvin Table □ Ketoconazole Table	ets	Lamisil Lamisil Noxafil Onmel Oravig Sporanox Vfend Other:
Strength	Dosage Instructions	Qua	ntity Days Supply
Diagnosis:			
Does the patient have an immunocoust of thave an immunocoust of the patient have an im			
Does the patient have a systemic fu	ungal infection? 🗌 Yes 🔲 No		
	Type of infection:		
	(s): Drug Name		
	Trial Date to:		
Medical or contraindication reason	to override trial requirements:		
	ug requiring prior approval:		
Prescriber signature (Must match pre		Date of subm	nission
medical necessity only. If approval of the Medicaid. It is the responsibility of the	uests for prior authorization the consultant will c his request is granted, this does not indicate tha provider who initiates the request for prior autho if necessary by contact with the county Departn	t the member co rization to estab	ontinues to be eligible for blish by inspection of the



Request for Prior Authorization APREMILAST (OTEZLA®)

FAX Completed Form To 1 (800) 574-2515

> **Provider Help Desk** 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB		
Patient address				
Provider NPI	Prescriber name	Phone		
Prescriber address		Fax		
Pharmacy name	Address	Phone		
		prrect, and complete or form will be returned.		
Pharmacy NPI	Pharmacy fax			
Prior authorization is required for apremilast (Otezla [®]). Payment will be considered under the following conditions: 1) Patient is 18 years of age or older; and 2) Patient has a diagnosis of active psoriatic arthritis (\geq 3 swollen joints and \geq 3 tender joints) with documentation of a trial and inadequate response to therapy with the preferred oral DMARD, methotrexate (leflunomide or sulfasalazine may be used if methotrexate is contraindicated); or 3) Patient has a diagnosis of moderate to severe plaque psoriasis and has documentation of a trial and inadequate response to phototherapy, systemic retinoids, methotrexate, or cyclosporine; and 4) Patient does not have severe renal impairment (CrCl < 30mL/min);and 5) Patient has documentation of trials and therapy failures with two preferred biological agents indicated for the submitted diagnosis. The required trials may be overridden when documented evidence is provided that the use of these agents would be medically contraindicated.				
Non-Preferred	Deseus Instructions			
Otezla Strength	Dosage Instructions	Quantity Days Supply		
Diagnosis:				
Does patient have severe renal im	pairment (CrCl < 30mL/min)?	🗌 Yes 🔲 No (attach labs)		
Psoriatic Arthritis Treatment failure with oral methotres Drug Name & Dose:		e if methotrexate is contraindicated): al dates:		
Reason for failure:				
Plaque Psoriasis Treatment failure with phototherapy, Drug Name & Dose: Reason for failure:		Trial dates:		
Treatment failure with two preferre Trial 1: Drug name & dose: Reason for failure:	Tria	al dates:		
Trial 2: Drug name & dose: Reason for failure:				
Possible drug interactions/conflicting Attach lab results and other docu				
Prescriber signature (Must match pre		Date of submission		

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.



FAX Completed Form To 1 (800) 574-2515

Request for Prior Authorization BIOLOGICALS FOR ANKYLOSING SPONDYLITIS

Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB		
Patient address				
Provider NPI	Prescriber name	Phone		
Prescriber address		Fax		
Pharmacy name	Address	Phone		
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.				
Pharmacy NPI	Pharmacy fax NDC			

Prior authorization is required for biologicals used for ankylosing spondylitis. Request must adhere to all FDA approved labeling. Payment for non-preferred biologicals for ankylosing spondylitis will be considered only for cases in which there is documentation of previous trials and therapy failures with two preferred biological agents. Payment will be considered under the following conditions: 1) Patient has documentation of an inadequate response to at least two preferred non-steroidal anti-inflammatories (NSAIDs) at maximum therapeutic doses, unless there are documented adverse responses or contraindications to NSAID use. These trials should be at least three months in duration. Patients with symptoms of peripheral arthritis must also have failed a 30-day treatment trial with at least one conventional disease modifying antirheumatic drug (DMARD), unless there is a documented adverse response or contraindication, patient with latent TB will only be considered after one month of TB treatment and patients with active TB will only be considered upon completion of TB treatment; and 3) Patient has been screened for hepatitis B and C, patient with active hepatitis B will not be considered for coverage.

In addition to the above:

Requests for TNF Inhibitors: 1) Patient has not been treated for solid malignancies, nonmelanoma skin cancer, or lymphoproliferative malignancy within the last 5 years of starting or resuming treatment with a biological agent; and 2) Patient does not have a diagnosis of congestive heart failure (CHF) that is New York Heart Association (NYHA) class III or IV and with an ejection fraction of 50% or less.

Requests for Interleukins: Medication will not be given concurrently with live vaccines.

The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.

Preferred Cosentyx Enbrel	(after Humira tr	ial) 🗌 Humira	<u>Non-Prefer</u> ☐ Cimzia ☐ Remica		🗌 Simponi
	Strength	Dosage Instructions	Quantity	Days Supply	/
Screening for	r Hepatitis B: [Date:Act	tive Disease:	Yes 🗌	No
Screening for	r Hepatitis C: D	Date:Act	tive Disease:	Yes 🗌	No
Screening for	r Latent TB infe	ection: Date:	Results:		

Request for Prior Authorization BIOLOGICALS FOR ANKYLOSING SPONDYLITIS

(PLEASE PRINT – ACCURACY IS IMPORTANT)

NSAID Trial #1 Name/Dose: Reason for Failure:		_Trial end date:					
NSAID Trial #2 Name/Dose: Reason for Failure:		_Trial end date:					
DMARD Trial (for peripheral arthritis diagnosis) Name/Dose:_							
Trial start date:Trial end date: Reason for Failure:							
Requests for TNF Inhibitors:							
Has patient received treatment for solid malignancies, nonmelanoma skin cancer, or lymphoproliferative malignancy within last 5 years of starting or resuming treatment with a biologic agent? Yes No							
Does patient have a diagnosis of NYHA class III or IV CHF diagnosis with ejection fraction of 50% or less? Yes No							
Requests for Interleukins:							
Will medication be given concurrently with live vaccines?	Yes 🗌 No						
Reason for use of Non-Preferred drug requiring prior approval							
Other medical conditions to consider:							
Possible drug interactions/conflicting drug therapies:							
Attach lab results and other documentation as necessary.							

Prescriber signature (Must match prescriber listed above.)	Date of submission

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for continues to be eligible for Medicaid.



Request for Prior Authorization BIOLOGICALS FOR ARTHRITIS

FAX Completed Form To 1 (800) 574-2515

> **Provider Help Desk** 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB			
Patient address					
Provider NPI	Prescriber name	Phone			
Prescriber address Fax					
Pharmacy name	Address	Phone			
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.					
Pharmacy NPI	Pharmacy fax NI				

Prior authorization is required for biologicals used for arthritis. Request must adhere to all FDA approved labeling. Payment for non-preferred biologicals for arthritis will be considered only for cases in which there is documentation of previous trials and therapy failures with two preferred biological agents. Payment will be considered under the following conditions: 1) Patient has been screened for latent TB infection, patients with latent TB will only be considered after one month of TB treatment and patients with active TB will only be considered upon completion of TB treatment; and 2) Patient has been screened for hepatitis B and C. Patients with evidence of active hepatitis B infection (hepatitis surface antigen positive > 6 months) must have documentation they are receiving or have received effective antiviral treatment.

In addition to the above:

Requests for TNF Inhibitors: 1) Patient has not been treated for solid malignancies, nonmelanoma skin cancer, or lymphoproliferative malignancy within the last 5 years of starting or resuming treatment with a biological agent; and 2) Patient does not have a diagnosis of congestive heart failure (CHF) that is New York Heart Association (NYHA) class III or IV and with an ejection fraction of 50% or less.

Requests for Interleukins: Medication will not be given concurrently with live vaccines.

The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.

Preferred		Non-Preferr	<u>ed</u>		
Cosentyx Enbrel Humira	(after Humira tria	· <u> </u>	a prefilled syringe)	KevzaraKineretOrencia	 Remicade Simponi Stelara Taltz
	Strength	Dosage Instruction	ns Quantity	y Days Su	ıpply
Screening for	Hepatitis B: Dat	:e:	_Active Disease	e: 🗌 Yes	No
Screening for	Hepatitis C: Dat	e:	_ Active Disease	e: 🗌 Yes	□ No
Screening for Latent TB infection: Date: Results:					
Requests for T	TNF Inhibitors:				
•		•	•		ncer, or eatment with a biologic

Does patient have a diagnosis of NYHA class III or IV CHF diagnosis with ejection fraction of 50% or less? Yes \square No

Iowa Department of Human Services	
Request for Prior Authorization BIOLOGICALS FOR ARTHRITIS (PLEASE PRINT – ACCURACY IS IMPO	RTANT)
Requests for Interleukins:	,
Will medication be given concurrently with live vaccines?	es 🗌 No
Rheumatoid arthritis (RA) (Humira, Enbrel, Actemra, Cimzia, Kineret, Payment will be considered upon a trial and inadequate response to tw antirheumatic drugs (DMARD) used concurrently. The combination mu preferred oral DMARD (hydroxychoroquine, sulfasalazine, or leflunom methotrexate trial in patients with established RA, the combination trial overridden if there is evidence of severe disease documented by radiog	o preferred disease modifying st include methotrexate plus another ide). Upon an unsuccessful with a second DMARD may be
Methotrexate trial: Dose:Tria	al dates:
Failure reason:	
Plus preferred oral DMARD trial: Drug Name & Dose: Failure reason:	Trial dates:
Radiographic evidence indicating erosions: Yes No	
Psoriatic arthritis, moderate to severe (Cimzia, Cosentyx, Enbrel, H Payment will be considered upon a trial and inadequate response to the (leflunomide or sulfasalazine may be used if methotrexate is contrainding)	e preferred oral DMARD, methotrexate
Methotrexate or preferred oral DMARD trial: Drug Name &Dose: Trial dates:Failure reason:	
Methotrexate contraindication if applicable:	
Juvenile idiopathic arthritis, moderate to severe (Enbrel, Humira, A	
Payment will be considered upon a trial and inadequate response to int the preferred oral DMARD, methotrexate (leflunomide or sulfasalazine contraindicated).	
Intraarticular Glucocorticoid Injections: Drug Name & Dose:	Trial dates:
Failure reason:	
Plus methotrexate or preferred oral DMARD trial: Drug Name & Dos Trial dates: Failure reason:	se:
Methotrexate contraindication if applicable:	
Reason for use of Non-Preferred drug requiring prior approval:	
Other medical conditions to consider: Attach lab results and other documentation as necessary.	
Prescriber signature (Must match prescriber listed above.)	Date of submission
IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will a medical necessity only. If approval of this request is granted, this does not indicate that	

Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.



Request for Prior Authorization BIOLOGICALS FOR INFLAMMATORY BOWEL DISEASE FAX Completed Form To 1 (800) 574-2515

> Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB	
Patient address			
Provider NPI	Prescriber name	Phone	
Prescriber address		Fax	
Pharmacy name	Address	Phone	
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.			
Pharmacy NPI	Pharmacy fax	NDC	

Prior authorization is required for biologicals used for inflammatory bowel disease. Request must adhere to all FDA approved labeling. Payment for non-preferred biologicals for inflammatory bowel disease will be considered only for cases in which there is documentation of a previous trial and therapy failure with a preferred agent. Payment will be considered under the following conditions: 1) Patient has been screened for hepatitis B and C, patients with active hepatitis B will not be considered for coverage; and 2) Patient has been screened for latent TB infection, patients with latent TB will only be considered after one month of TB treatment and patients with active TB will only be considered upon completion of TB treatment. In addition to the above:

Requests for TNF Inhibitors: 1) Patient has not been treated for solid malignancies, nonmelanoma skin cancer, or lymphoproliferative malignancy within the last 5 years of starting or resuming treatment with a biological agent; and 2) Patient does not have a diagnosis of congestive heart failure (CHF) that is New York Heart Association (NYHA) class III or IV and with an ejection fraction of 50% or less.

Requests for Interleukins: Medication will not be given concurrently with live vaccines.

The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.

Preferred Humira Humira St	arter Kit	Non-Preferred Cimzia (prefilled syr Remicade	inge)	SimponiStelara
Strength	Dosage Instructions	Quantity	Days Su	pply _
Screening for	r Hepatitis B: Date:	Active Disease:	Yes	□ No
Screening for	r Hepatitis C: Date:	Active Disease:	Yes	□ No
Screening for	r Latent TB infection: Date:	Results:		
Requests for	TNF Inhibitors:			
-	eceived treatment for solid malign erative malignancy within last 5 ye Yes	•		•
Does patient less?	have a diagnosis of NYHA class II es 🔲 No	l or IV CHF diagnosis	with ejec	tion fraction of 50% or

	t for Prior Authorization FOR INFLAMMATORY BOWEL DISEASE
(PLEASE PR	RINT – ACCURACY IS IMPORTANT)
Requests for Interleukins:	
Will medication be given concurrently wit	h live vaccines? 🗌 Yes 🔲 No
	sidered following an inadequate response to two preferred licylates (mesalamine, sulfasalazine), azathioprine/6-
Trial Drug Name/Dose:	Trial dates:
Reason for failure:	
	Trial dates:
Reason for failure:	
	ing prior approval:
Reason for use of Non-Preferred drug requiri	
Reason for use of Non-Preferred drug requiri	ng prior approval: - Payment will be considered following an inadequate herapies including aminosalicylates and azathioprine/6-
Reason for use of Non-Preferred drug requiri	ng prior approval: - Payment will be considered following an inadequate herapies including aminosalicylates and azathioprine/6- Trial dates:
Reason for use of Non-Preferred drug requiri	ng prior approval: - Payment will be considered following an inadequate herapies including aminosalicylates and azathioprine/6- Trial dates:
Reason for use of Non-Preferred drug requiri	ng prior approval: - Payment will be considered following an inadequate herapies including aminosalicylates and azathioprine/6- Trial dates: Trial dates:

Attach lab results and other documentation as necessary.

Prescriber signature (Must match prescriber listed above.)	Date of submission



Request for Prior Authorization BIOLOGICALS FOR PLAQUE PSORIASIS

FAX Completed Form To 1 (800) 574-2515

> Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB	
Patient address			
Provider NPI	Prescriber name	Phone	
Prescriber address		Fax	
Pharmacy name	Address	Phone	
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.			
Pharmacy NPI	Pharmacy fax NE)C	

Prior authorization is required for biologicals used for plaque psoriasis. Request must adhere to all FDA approved labeling. Payment for non-preferred biologicals for plaque psoriasis will be considered only for cases in which there is documentation of previous trials and therapy failures with two preferred biological agents. Payment will be considered under the following conditions: 1) Patient has been screened for hepatitis B and C, patients with active hepatitis B will not be considered for coverage; and 2) Patient has been screened for latent TB infection, patients with latent TB will only be considered after one month of TB treatment and patients with active TB will only be considered upon completion of TB treatment; and 3) Patient has documentation of an inadequate response to phototherapy, systemic retinoids (oral isotretinoin), methotrexate, or cyclosporine. In addition to the above:

Requests for TNF Inhibitors: 1) Patient has not been treated for solid malignancies, nonmelanoma skin cancer, or lymphoproliferative malignancy within the last 5 years of starting or resuming treatment with a biological agent; and 2) Patient does not have a diagnosis of congestive heart failure (CHF) that is New York Heart Association (NYHA) class III or IV and with an ejection fraction of 50% or less.

Requests for Interleukins: Medication will not be given concurrently with live vaccines.

The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.

Preferred Cosentyx (Enbrel	(after Humira trial)	🗌 Humira	Non-Preferred	☐ Siliq ☐ Stelara	☐ Taltz ☐ Tremfya
	•	Dosage Instruction	•	Days Sup	ply
Screening for	r Hepatitis B: Dat	e:	Active Disease:	Yes	No No
Screening for	r Hepatitis C: Dat	e:	Active Disease:	🗌 Yes	No No
Screening for	r Latent TB infect	ion: Date:	Results:		
Treatment fai	lure with a prefe	red oral therapy: T	rial Drug Name: _		
Trial start date):	_ Trial end date:		_	
Failure reasor	ו:				

Request for Prior Authorization BIOLOGICALS FOR PLAQUE PSORIASIS

(PLEASE PRINT - ACCURACY IS IMPORTANT)

Non-Pharmacological T	reatments Tried:
Trial start date:	Trial end date:
Failure reason:	
Requests for TNF Inhibi	tors:
	atment for solid malignancies, nonmelanoma skin cancer, or ignancy within last 5 years of starting or resuming treatment with a biologic] No
	gnosis of NYHA class III or IV CHF diagnosis with ejection fraction of 50% or No
Requests for Interleukin	IS:
Will medication be give	n concurrently with live vaccines? Yes No
Reason for use of Non-Pr	referred drug requiring prior approval:
Other medical conditions	to consider:
Possible drug interactions	s/conflicting drug therapies:
Attach lab results and o	ther documentation as necessary.

Prescriber signature (Must match prescriber listed above.)	Date of submission
IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consultan	

medical necessity only. If approval of this requests for pror authorization the consultant will consider the treatment norm the standpoint of Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.



Request for Prior Authorization Buprenorphine/Naloxone

FAX Completed Form To 1 (800) 574-2515

> Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB	
Patient address			
Provider NPI	Prescriber name	Phone	
Prescriber address		Fax	
Pharmacy name	Address	Phone	
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.			
Pharmacy NPI	Pharmacy fax	NDC	

Prior authorization is required for oral buprenorphine or buprenorphine/naloxone. Requests for doses above 24 mg per day or greater than once daily dosing will not be considered. Initial requests will be considered for up to 3 months. Requests for maintenance doses above 16 mg per day will not be considered on a long-term basis. Concomitant use with opioids or tramadol will be prohibited. Payment for a non-preferred agent will be authorized only for cases in which there is documentation of previous trial and therapy failure with a preferred agent, unless evidence is provided that use of these agents would be medically contraindicated. Requests for surgically implanted buprenorphine products will not be considered through the pharmacy benefit and should be directed to the member's medical benefit. Payment will be considered when the following is met:

- 1) Patient has a diagnosis of opioid dependence and meets the FDA approved age; AND
- 2) Prescriber meets qualification criteria to prescribe buprenorphine/naloxone for opioid dependence and has an "X" DEA number; AND
- 3) Patient is participating in and compliant with formal substance abuse counseling/psychosocial therapy; AND
- 4) Documentation the Iowa Prescription Monitoring Program website has been reviewed for the patient's use of controlled substances; AND
- 5) A projected treatment plan is provided with initial request (see below requirements); AND
- 6) A treatment plan is provided for patients taking buprenorphine in combination with a benzodiazepine or central nervous system (CNS) depressant (see below requirements); AND
- 7) Documentation is provided that transmucosal buprenorphine will not be used concomitantly with the buprenorphine implant.
- 8) Requests for single ingredient buprenorphine will only be considered for pregnant patients.

Requests for renewal must include updated treatment plan and additional documentation as indicated below.

Preferred Suboxone SL Film	Non-Preferred Bunavail Buprenorphine (Please verify pa Buprenorphine/Naloxone SL Tab Zubsolv		Yes
Strength	Dosage Instructions	Quantity	Days Supply
Diagnosis:			

Iowa Departr	nent of Hu	uman Services
--------------	------------	---------------

Request for Prior Authorization Buprenorphine/Naloxone

(PLEASE PRINT – ACCURACY IS IMPORTANT)

	meets	qualifications to prescribe and treat opioid dependence and possess "X" DEA number:				
Patient pa	rticipate	es in and is compliant with counseling: 🗌 No 📋 Yes				
Date of mo	ost rece	nt counseling session:				
Is patient	using tra	ansmucosal buprenorphine with buprenorphine implant? 🗌 No 🛛 Yes				
Initial Rec	-	Include projected treatment plan. May attach treatment plan or provide at a minimum the below				
•	Anticipa	ated induction/stabilization dose:				
•	Anticipa	ated maintenance dose:				
•	Expecte	ed frequency of office visits:				
•	Expecte	ed frequency of counseling/psychosocial therapy visits:				
•	Treatm	ent plan for patients taking buprenorphine in combination with a benzodiazepine or CNS depressant:				
	0	Patient has been educated on the serious risks of combined use?				
	0	Plan to taper benzodiazepine or CNS depressant if possible:				
	0	Consideration of alternate anxiety or insomnia treatment options when the benzodiazepine or CNS depressant is used for anxiety or insomnia:				
	0	Other prescribers involved in the care of the patient are aware of the patient's use of buprenorphine?				
		○ No ○ Yes Date contacted:				
		ts: Please provide the below information:				
•	Update	d treatment plan, including:				
		eration of a medical taper to the lowest effective dose based on a self assessment scale. Date of most aper attempt:				
	Assess	ment of concomitant benzodiazepine or CNS depressant use (if applicable):				
	 Patient has been educated on the serious risks of combined use? 					
 Plan to taper benzodiazepine or CNS depressant if possible: 						
	0	Consideration of alternate anxiety or insomnia treatment options when the benzodiazepine or CNS depressant is used for anxiety or insomnia:				
	0	Other prescribers involved in the care of the patient are aware of the patient's use of buprenorphine?				

Request for Prior Authorization Buprenorphine/Naloxone

(PLEASE PRINT – ACCURACY IS IMPORTANT)

- Documentation the Iowa Prescription Monitoring Program (PMP) website has been reviewed for the patient's use of controlled substances since the last prior authorization request.
 No
 Yes
 Date reviewed:
- Documentation of a current, negative drug screen. Date of most recent drug screen:

Prescriber signature (Must match prescriber listed above.)	Date of submission



Request for Prior Authorization CHRONIC PAIN SYNDROMES

FAX Completed Form To 1 (800) 574-2515

> **Provider Help Desk** 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB				
Patient address						
Provider NPI Prescriber name Phone						
Prescriber address		Fax				
Pharmacy name	Address	Phone				
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.						
Pharmacy NPI	Pharmacy fax NDC					

Prior authorization is required for pregabalin (Lyrica[®]) and milnacipran (Savella[™]). These drugs will be considered for their FDA indication(s) and other conditions as listed in the compendia. Requests for doses above the manufacturer recommended dose will not be considered. The trial examples below are not an all inclusive list. Please refer to the Preferred Drug List (PDL) located at <u>www.iowamedicaidpdl.com</u> for a complete list of preferred drugs in these therapeutic classes. For patients with a chronic pain diagnosis who are currently taking opioids, as seen in pharmacy claims, a plan to decrease and/or discontinue the opioid(s) must be provided with the initial request. Initial authorization will be given for three (3) months. Requests for renewal must include an updated opioid treatment plan and documentation of improvement in symptoms and quality of life. Requests for non-preferred brand drugs, when there is a preferred A-rated bioequivalent generic product available, are also subject to the Selected Brand Name prior authorization criteria and must be included with this request. Payment will be considered under the following conditions:

Preferred (no PA required within quantity limit) Duloxetine		Non-Preferred		Lyrica		Savella	
	Strength	Dosage Instructions	-	-	Days Supply		
	a) A trial and therapy failu	r Savella[™]): A diagnosis of fib ure at a therapeutic dose with	gabapentin plus one	of the fo	ollowing preferr		neric agents:
		amitriptyline, nortriptyline) or S					
	Reason for Failure:						
	Preferred Drug Trial #2	Name/Dose:	Trial	start dat	e: Trial	end d	ate:
	Reason for Failure:						
	b) Documented non-phar	macologic therapies (such as	cognitive behavior the	herapies	, exercise, etc,)	

Non-Pharmacological Treatments Tried:

Request for Prior Authorization-Continued CHRONIC PAIN SYNDROMES

(PLEASE PRINT – ACCURACY IS IMPORTANT)

	Post-Herpetic Neuralgia (Lyrica®): A diagnos	sis of post-herpetic neuralg	gia with the follo	owing documente	ed trials:
	A trial and therapy failure at a therapeutic dos (amitriptyline, nortriptyline), topical lidocaine, o		e of the followin	ig: tricyclic antide	epressant
	Gabapentin Trial Dose:	Trial start date:	Trial end	date:	_
	Reason for Failure:				
	Preferred Drug Trial#2 Name/Dose:	Trial st	tart date:	Trial end dat	e:
	Reason for Failure:				
	Diabetic Peripheral Neuropathy (duloxetine following documented trials:	e or L<i>yrica</i>®): A diagnosis o	of diabetic perip	oheral neuropath	y with the
	A trial and therapy failure at a therapeutic dos (amitriptyline, nortriptyline) or duloxetine.	e with gabapentin plus one	e of the followir	ig: tricyclic antide	epressant
	Gabapentin Trial Dose:	Trial start date:	Trial end	d date:	-
	Reason for Failure:				
	Preferred Drug Trial #2 Name/Dose:	Trial s	start date:	Trial end d	ate:
	Reason for Failure:				
	Neuropathic Pain associated with spinal co Other Diagnosis of Use:				_
	st complete for chronic pain diagnosis:				
	al Requests:	X N (5			— N
	es the member have current opioid use?				
If ye	es, provide specific plan, including time line, to c	decrease and/or discontinu	e opioid use: _		
Rer	newal Requests:				
Doe	es the member have current opioid use?	Yes Name/Dose:			🗌 No
lf ye	es, provide updated opioid treatment plan:				
Doc	ument improvement in symptoms and quali	ty of life:			_
Oth	er relevant information:				
	ach lab results and other documentation as l		I		
Pres	scriber signature (Must match prescriber listed abo	ove.)	Date of subm	nission	
	ORTANT NOTE: In evaluating requests for prior aut lical necessity only. If approval of this request is grai				

Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.



Request for Prior Authorization CNS STIMULANTS AND ATOMOXETINE

FAX Completed Form To 1 (800) 574-2515

> Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB		
Patient address				
Provider NPI	Prescriber name	Phone		
Prescriber address		Fax		
Pharmacy name	Address	Phone		
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.				
Pharmacy NPI	Pharmacy fax NDC			

Prior Authorization (PA) is required for CNS stimulants and atomoxetine for patients 21 years of age or older. Requests will be considered for an FDA approved age for the submitted diagnosis. Prior to requesting PA for any covered diagnosis, the prescriber must review the patient's use of controlled substances on the lowa Prescription Monitoring Program (PMP) website. Payment for CNS stimulants and atomoxetine will be considered under the following conditions: 1) Attention Deficit Hyperactivity Disorder (ADHD) meeting the DSM-5 criteria and confirmed by a standardized rating scale (such as Conners, Vanderbilt, Brown, Snap-IV). Symptoms must have been present before twelve (12) years of age and there must be clear evidence of clinically significant impairment in two or more current environments (social, academic, or occupational). Documentation of a recent clinical visit that confirms improvement in symptoms from baseline will be required for renewals or patients newly eligible that are established on medication to treat ADHD. Adults (≥ 21 years of age) are limited to the use of long-acting agents only. If a supplemental dose with a short-acting agent is needed for an adult in the mid to late afternoon, requests will be considered under the following circumstances: the dose of the long-acting agent has been optimized, documentation is provided a short-acting agent of the same chemical entity is medically necessary (e.g. employed during the day with school in the evening), and will be limited to one unit dose per day. 2) Narcolepsy with diagnosis confirmed with a recent sleep study (ESS, MSLT, PSG). 3) Excessive sleepiness from obstructive sleep apnea/hypopnea syndrome (OSAHS) with documentation of non-pharmacological therapies tried (weight loss, position therapy, CPAP at maximum titration, BiPAP at maximum titration or surgery) and results from a recent sleep study (ESS, MSLT, PSG) with the diagnosis confirmed by a sleep specialist.

Payment for a non-preferred agent will be authorized only for cases in which there is documentation of previous trial and therapy failure with a preferred agent. * If a non-preferred long-acting medication is requested, a trial with the preferred extended release product of the same chemical entity (methylphenidate class) or chemically related agent (amphetamine class) is required. The required trials may be overridden when documented evidence is provided that the use of these agents would be medically contraindicated.

Requests for Vyvanse for Binge Eating Disorder must be submitted on the Binge Eating Disorder Agents PA form.

Preferred		Non-Preferred			
Amphetamine Salt Combo	Methylphenidate LA Caps	Adderall	Methylphenidate Chew		
Amphetamine ER Caps	Modafinil	Adderall XR*	Methylphenidate ER		
Aptensio XR	Quillichew ER	Adzenys XR ODT	Tabs		
Armodafinil	Quillivant XR	Cotempla*	Mydayis*		
Atomoxetine	🗌 Vyvanse	Desoxyn	Nuvigil		
Concerta		Dexedrine*	Procentra		
Daytrana		Dexmethylphenidate ER Caps	Provigil		
Dexmethylphenidate Tabs		Dextroamphetamine ER Caps*	Ritalin		
Focalin XR		Dyanavel XR	Ritalin LA		

lowa Depar	tment of Hu	uman Services
------------	-------------	---------------

Request for Prior Authorization CNS STIMULANTS AND ATOMOXETINE

(PLEASE PRINT – ACCURACY IS IMPORTANT)

Methylin Solution	Evekeo	Straterra
 Methylphenidate CD Caps Methylphenidate IR Tabs 		
Methylphenidate ER 20mg Tabs		
Strength Dosage Instructions	SQuantity	Days Supply
Diagnosis:		
Attention Deficit Hyperactivity Disor	[.] der (ADHD)	
Age of patient at onset of symptoms:		
Date of most recent clinical visit confirming	improvement in symptoms from baseline	e:
Rating scale used to determine diagnosis:		
Documentation of clinically significant impa occupational).	airment in two or more current environme	ents (social, academic, or
Current Environment 1 & description:		
Current Environment 2 & description:		
Requests for short-acting agents for adults	s:	
Has dose of long-acting agent been optimi	ized? 🛛 Yes 🗳 No	
Provide medical necessity for the addition	of a short-acting agent:	
Narcolepsy (Please provide results)	s from a recent ESS, MSLT, and PSG)	
🗔 Evenneive electrices from chotmus		(0004110)
	c tive sleep apnea/hypopnea syndrome s been tried? No Yes <i>If</i> Y	· /
Weight Loss	Position therapy	
CPAP Date:	Maximum titration?	Yes 🗌 No
BiPAP Date:	Maximum titration?	Yes 🗌 No
Surgery D Specifics:	ate:	
Diagnosis confirmed by a sleep speci	alist? Yes No	
Other (specify)		
Prescriber review of patient's controlled su		e:
No Yes Date Reviewed:		
Please document prior psychostimulant trial(s) and failure reasons:	and failures(s) including drug name(s) st	trength, dose, exact date ranges

Request for Prior Authorization CNS STIMULANTS AND ATOMOXETINE

(PLEASE PRINT – ACCURACY IS IMPORTANT)

Other - Please provide all pertinent medication trial(s) relating to the diagnosis including drug name(s) strength, dose and exact date ranges:

Reason for use of Non-Preferred drug requiring approval:

Prescriber signature (Must match prescriber listed above.)	Date of submission



Request for Prior Authorization Dupilumab (Dupixent)

Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	er ID # Patient name [
Patient address					
Provider NPI Prescriber name Phone					
Prescriber address		Fax			
Pharmacy name	Address	Phone			
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.					
Pharmacy NPI	Pharmacy fax				

Prior authorization is required for Dupixent (dupilumab). Payment will be considered for patients when the following criteria are met:

- 1) Patient has a diagnosis of moderate-to-severe atopic dermatitis; and
- 2) Patient is within the FDA labeled age; and
- 3) Is prescribed by or in consultation with a dermatologist; and
- 4) Patient has failed to respond to good skin care and regular use of emollients; and
- 5) Patient has documentation of an adequate trial and therapy failure with one preferred medium to high potency topical corticosteroid for a minimum of 2 consecutive weeks; and
- 6) Patient has documentation of a previous trial and therapy failure with a topical immunomodulator for a minimum of 4 weeks; and
- 7) Patient has documentation of a previous trial and therapy failure with cyclosporine or azathioprine; and
- 8) Patient will continue with skin care regimen and regular use of emollients; and
- 9) Dose does not exceed an initial one-time dose of 600mg and maintenance dose of 300mg thereafter given every other week.

If criteria for coverage are met, initial authorizations will be given for 16 weeks to assess the response to treatment. Requests for continuation of therapy will require documentation of a positive response to therapy. The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.

Non-Preferred

Strength	Usage Instructions	Quantity	Day's Supply
Diagnosis:			
Is prescriber a dermatol	ogist?		
Yes I No If no, note consultation with dermatologist:			
Consultation date:	Physician na	me & phone:	

Iowa Department of Human Services				
Request for Prior Authorization Dupilumab (Dupixent)				
(PLEASE PRINT – ACCURACY	Í IS IMPORTANT)			
Did patient fail to respond to good skin care and regular use of emollients?				
Yes No If yes, provide documentation below:				
Provide skin care regimen, including name and dates of emoll	ient use:			
Will patient continue skin care regimen and regular use of	f emollients? 🗌 Yes 🗌 No			
Preferred medium to high potency topical corticosteroid t	rial:			
Drug name & dose:	Trial dates:			
Failure reason:				
Topical immunomodulator trial:				
Drug name & dose:	Trial dates:			
Failure reason:				
Cyclosporine or Azathioprine trial:				
Drug name & dose: Trial dates:				
Failure reason:				
Medical or contraindication reason to override trial requirements:				
Renewal requests:				
Document positive response to therapy:				

Attach lab results and other documentation as necessary.

Prescriber signature (Must match prescriber listed above.)	Date of submission



Request for Prior Authorization EXTENDED RELEASE FORMULATIONS

FAX Completed Form To 1 (800) 574-2515

Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB			
Patient address					
Provider NPI	Phone				
Prescriber address	Prescriber address Fax				
Pharmacy name	armacy name Address				
Prescriber must complete all informa	ation above. It must be legible, correct, and	d complete or form will be returned			
Pharmacy NPI	Pharmacy fax	NDC			
	ended release formulation will be consi				
coverage are met: 1) Previous trial and therapy failure with the preferred immediate release product of the same chemical entity at a therapeutic dose that resulted in a partial response with a documented intolerance and 2) Previous trial and therapy failure at a therapeutic dose with a preferred drug of a different chemical entity indicated to treat the submitted diagnosis. The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated. Prior Authorization is required for the following extended release formulations: Adoxa , Amoxicillin ER, Astagraf XL, Augmentin XR, Cardura XL, Carvedilol ER, Cipro XR, Coreg CR, Doryx, Envarsus XR, Fortamet, Glumetza, Gocovri, Gralise, Keppra XR, Lamictal XR, Luvox CR, Memantine ER, Mirapex ER, Moxatag, Namenda XR, Oleptro, Osmolex ER, Oxtellar XR, pramipexole ER, Prozac Weekly, Qudexy XR, Rayos, Requip XL, Rythmol SR, Solodyn ER, topiramate er, Trokendi XR, Ximino.					
Drug Name:	Strengt	h:			
Dosage Instructions: Quantity: Days Supply:					
Diagnosis:					
Previous therapy with immediate release product of same chemical entity (include strength, exact date ranges, and reason for failure):					
Previous therapy with a preferred drug of a different chemical entity (include strength, exact date ranges, and reason for failure):					
Contraindication(s) to using immediate release product and/or a preferred drug of a different chemical entity:					
Possible drug interactions/conflicting drug therapies:					
Attach lab results and other documentation as necessary.					
Prescriber signature (Must match pre	scriber listed above.)	Date of submission			
IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for eligible for Medicaid.					



FAX Completed Form To 1 (800) 574-2515

Request for Prior Authorization GRANULOCYTE COLONY STIMULATING FACTOR

Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB			
Patient address					
Provider NPI	Provider NPI Prescriber name Phone				
Prescriber address Fax					
Pharmacy name	Pharmacy name Address Phone				
Prescriber must complete all information	ation above. It must be legible, correct, and	complete or form will be returned.			
Pharmacy NPI	Pharmacy fax				
Prior authorization is required for therapy with granulocyte colony stimulating factor agents. Payment for non-preferred granulocyte colony stimulating factor agents will be authorized only for cases in which there is documentation of previous trial(s) and therapy failure with a preferred agent(s). Laboratory values for complete blood and platelet count must be obtained as directed by the manufacturer's instructions. Dosage reduction and discontinuation of therapy may be required based on the manufacturer's guidelines. Preferred Non-Preferred Granix Neupogen Vials (members < 18 years of age) 					
Strength	Dosage Instructions	Quantity Days Supply			
Diagnosis (or indication for the product): Prevention or treatment of febrile neutropenia in patients with malignancies who are receiving myelosuppressive anticancer therapy. Treatment of neutropenia in patients with malignancies undergoing myelopblative chemotherapy followed by a bone marrow transplant. Moibilization of progenitor cells into the peripheral blood stream for leukapheresis collections to be used after myeloblative chemotherapy. Treatment of congenital, cyclic, or idopathyic neutropenia in symptomatic patients. On current chemotherapy drug(s) that would cause severe neutropenia (specify) Other condition specify)					
 transplant. Moibilization of progenitor cells chemotherapy. Treatment of congenital, cyclic On current chemotherapy drug 	s into the peripheral blood stream for leukapher c, or idopathyic neutropenia in symptomatic pati	esis collections to be used after myeloblative ents.			
 transplant. Moibilization of progenitor cells chemotherapy. Treatment of congenital, cyclic On current chemotherapy drug 	s into the peripheral blood stream for leukapher c, or idopathyic neutropenia in symptomatic pati g(s) that would cause severe neutropenia (spec	esis collections to be used after myeloblative ents.			
transplant. Moibilization of progenitor cells chemotherapy. Treatment of congenital, cyclic On current chemotherapy drug Other condition specify) Absolute Neutrophil Count (ANC):	s into the peripheral blood stream for leukapher c, or idopathyic neutropenia in symptomatic pati g(s) that would cause severe neutropenia (spec	esis collections to be used after myeloblative ents. fy)			
transplant. Moibilization of progenitor cells chemotherapy. Treatment of congenital, cyclic On current chemotherapy drug Other condition specify) Absolute Neutrophil Count (ANC): Dates of routine CBC:	s into the peripheral blood stream for leukapher c, or idopathyic neutropenia in symptomatic pati g(s) that would cause severe neutropenia (spec	esis collections to be used after myeloblative ents. fy)			
transplant. Moibilization of progenitor cells chemotherapy. Treatment of congenital, cyclic On current chemotherapy drug Other condition specify) Absolute Neutrophil Count (ANC): Dates of routine CBC: Platelet Counts:	s into the peripheral blood stream for leukapher c, or idopathyic neutropenia in symptomatic pati g(s) that would cause severe neutropenia (spec	esis collections to be used after myeloblative ents. fy)			
transplant. Moibilization of progenitor cells chemotherapy. Treatment of congenital, cyclic On current chemotherapy drug Other condition specify) Absolute Neutrophil Count (ANC): Dates of routine CBC: Platelet Counts: Pertinent Lab data:	s into the peripheral blood stream for leukapher c, or idopathyic neutropenia in symptomatic pati g(s) that would cause severe neutropenia (spec	esis collections to be used after myeloblative ents. fy)			
transplant. Moibilization of progenitor cells chemotherapy. Treatment of congenital, cyclic On current chemotherapy drug Other condition specify) Absolute Neutrophil Count (ANC): Dates of routine CBC: Platelet Counts: Pertinent Lab data: Previous therapy (include drug name	s into the peripheral blood stream for leukapher c, or idopathyic neutropenia in symptomatic pati g(s) that would cause severe neutropenia (spec	esis collections to be used after myeloblative ents. fy)			
transplant. Moibilization of progenitor cells chemotherapy. Treatment of congenital, cyclic On current chemotherapy drug Other condition specify) Absolute Neutrophil Count (ANC): Dates of routine CBC: Platelet Counts: Pertinent Lab data: Previous therapy (include drug name Reason for use of Non-Preferred drug	s into the peripheral blood stream for leukapher c, or idopathyic neutropenia in symptomatic pati g(s) that would cause severe neutropenia (spec	esis collections to be used after myeloblative ents. fy)			
transplant. Moibilization of progenitor cells chemotherapy. Treatment of congenital, cyclic On current chemotherapy drug Other condition specify) Absolute Neutrophil Count (ANC): Dates of routine CBC: Platelet Counts: Pertinent Lab data: Previous therapy (include drug name Reason for use of Non-Preferred drug	s into the peripheral blood stream for leukapher c, or idopathyic neutropenia in symptomatic pati g(s) that would cause severe neutropenia (spec	esis collections to be used after myeloblative ents. fy)			



Request for Prior Authorization HEPATITIS C TREATMENTS

FAX Completed Form To 1 (800) 574-2515

Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB		
Patient address	Patient phone			
Provider NPI	Prescriber name	Phone		
Prescriber address		Fax		
Pharmacy name	Address	Phone		
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.				
Pharmacy NPI	Pharmacy fax	NDC		
	-			

Prior authorization (PA) is required for hepatitis C treatments. Requests for non-preferred agents may be considered when documented evidence is provided that the use of the preferred agents would be medically contraindicated. Payment will be considered under the following conditions: 1) Patient has a diagnosis of chronic hepatitis C; and 2) Patient's age and/or weight is within the FDA labeled age and/or weight; and 3) Patient has had testing for hepatitis C virus (HCV) genotype; and 4) Patient has an active HCV infection verified by a detectable viral load within 12 months of starting treatment; and 5) Patient has been tested for hepatitis B (HBV) prior to initiating treatment of HCV and individuals with active HBV infection are treated (either at same time as HCV therapy or before HCV therapy is started); and 6) Viral load will be submitted by the prescriber 12 weeks after the completion of therapy; and 7) Patient has advanced liver disease corresponding to a Metavir score of 3 or greater fibrosis as confirmed by one of the following: a) liver biopsy confirming a Metavir score ≥3; or b) transient elastography (FibroScan) score ≥ 9.5kPa; or c) FibroSURE (FibroTest) score ≥0.58; or d) APRI score >1.5; or e) radiological imaging consistent with cirrhosis (i.e., evidence of portal hypertension); or f) physical findings or clinical evidence consistent with cirrhosis; or g) patients at highest risk for severe complications: organ transplant, type 2 or 3 essential mixed cryoglobulinemia with end-organ manifestations (e.g. vasculitis), proteinuria, nephrotic syndrome, or membranoproliferative glomerulonephritis: and 8) Patient's prior treatment history is provided (treatment naïve or treatment experienced); and 9) If patient has a history of non-compliance, documentation that steps have been taken to correct or address the causes of non-compliance are provided; and 10) Patient has abstained from the use of illicit drugs and alcohol for a minimum of three (3) months as evidenced by a negative urine confirmation test; and 11) For regimens containing sofosbuvir (Sovaldi/Harvoni/Epclusa/Vosevi), patient does not have severe renal impairment (creatinine clearance <30ml/min) or end stage renal disease requiring hemodialysis; and 12) HCV treatment is prescribed by a digestive disease, liver disease, or infectious disease provider practice; and 13) For patients on a regimen containing ribavirin, documentation of the following on the PA form: a) Patient is not a pregnant female or a male with a pregnant female partner; and b) Women of childbearing potential and their male partners must use two forms of effective contraception during treatment and for at least 6 months after treatment has concluded; and c) Monthly pregnancy tests will be performed during treatment; and 14) Prescriber has reviewed the patient's current medication list and acknowledged that there are no significant drug interactions with the HCV medication; and 15) Documentation is provided for patients who are ineligible to receive ribavirin. 16) Non-FDA approved or non-compendia indicated combination therapy regimens will not be approved. 17) Patient does not have limited life expectancy (less than 12 months) due to non-liver-related comorbid conditions. 18) If patient is recently eligible for Iowa Medicaid, and has been started and stabilized on therapy while covered under a different plan, documentation of how long the patient has been on medication will be required. Patient will be eligible for the remainder of therapy needed, based on established length of therapy for the particular treatment (defined below). 19) Lost or stolen medication replacement requests will not be authorized. 20) The 72-hour emergency supply rule does not apply to hepatitis C treatments.

Preferred:	Epclusa	Non-Preferred:	🗌 Daklinza	🗌 Sovaldi
	Mavyret		🗌 Harvoni	🗌 Vosevi
	Zepatier			

Instructions for completing the Hepatitis C Treatments PA form:

Section 1 of the PA form lists the various regimens and clinical situations for which hepatitis C treatments will be considered medically necessary according to Iowa Medicaid PA criteria. Section 2 includes additional supporting documentation that is required on the PA form.

- Check ONE box in Section 1 Treatment Regimen.
- Review and complete each numbered item in Section 2 Supporting Documentation.

(PLEASE PRINT – ACCURACY IS IMPORTANT)

Attach lab results, chart notes, and other documentation, sign, and fax the completed form to (800) 574-2515.
 SECTION 1 – TREATMENT REGIMEN

Check ONE box below to indicate the requested treatment regimen based on the patient's genotype, treatment history, and extent of liver disease.

Genotype 1 (Note: the subtype is listed if there are differences in the recommended treatments)				
Treatment naïve, no cirrhosis				
Mavyret 100/40 mg, three (3) tablets daily for 8 weeks				
Epclusa 400/100 mg daily for 12 weeks				
In the second				
 Ib: Zepatier 50/100 mg daily for 12 weeks 				
Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)				
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
Epclusa 400/100 mg daily for 12 weeks				
1a: Zepatier 50/100 mg daily for 12 weeks in patients without baseline NS5A polymorphisms				
□ 1b: Zepatier 50/100 mg daily for 12 weeks				
Treatment experienced (PEG-IFN/RBV ONLY), no cirrhosis				
Mavyret 100/40 mg, three (3) tablets daily for 8 weeks				
Epclusa 400/100 mg daily for 12 weeks				
1a: Zepatier 50/100 mg daily for 12 weeks in patients without baseline NS5A polymorphisms				
□ 1b: Zepatier 50/100 mg daily for 12 weeks				
Treatment experienced (PEG-IFN/RBV ONLY), compensated cirrhosis (Child-Pugh A ONLY)				
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
Epclusa 400/100 mg daily for 12 weeks				
1a: Zepatier 50/100 mg daily for 12 weeks in patients without baseline NS5A polymorphisms				
□ 1b: Zepatier 50/100 mg daily for 12 weeks				
Treatment experienced (PEG-IFN/RBV + NS3/4A protease inhibitor, no prior NS5A, no prior sofosbuvir), no cirrhosis				
A Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
Epclusa 400/100 mg daily for 12 weeks				
1a: Zepatier 50/100 mg plus weight-based RBV daily for 12 weeks in patients without baseline NS5A polymorphisms				
1b: Zepatier 50/100 mg plus weight-based RBV daily for 12 weeks				
Treatment experienced (PEG-IFN/RBV+NS3/4A protease inhibitor, no prior NS5A, no prior sofosbuvir), compensated				
cirrhosis (Child-Pugh A ONLY)				
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
Epclusa 400/100 mg daily for 12 weeks				
1a: Zepatier 50/100 mg plus weight-based RBV daily for 12 weeks in patients without baseline NS5A polymorphisms				
1b: Zepatier 50/100 mg plus weight-based RBV daily for 12 weeks				
Treatment experienced (sofosbuvir + ribavirin +/- PEG-IFN OR simeprevir, no NS5A), no cirrhosis				
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
1b: Epclusa 400/100 mg daily for 12 weeks				
Treatment experienced (sofosbuvir + ribavirin +/- PEG-IFN OR simeprevir, no NS5A), compensated cirrhosis (Child-				
Pugh A ONLY)				
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
1b: Epclusa 400/100 mg daily for 12 weeks				
Treatment experienced, any NS5A inhibitor but NO NS3/4A protease inhibitor (prior therapy ONLY with				
daclatasvir+sofosbuvir, ledipasvir+sofosbuvir or sofosbuvir +velpatasvir), no or compensated cirrhosis (Child-Pugh A				
ONLY)				
Mavyret 100/40 mg, three (3) tablets daily for 16 weeks				
Vosevi 400/100/100 mg daily for 12 weeks Treatment experienced (prior treatment with any NS5A inhibitor (ledipasvir (Harvoni), velpatasvir (Epclusa/Vosevi),				
elbasvir (Zepatier), dasabuvir (Viekira), pibrentasvir (Mavyret) and daclatasvir (Daklinza), including those given with a				
□ Vosevi 400/100/100 mg daily for 12 weeks				
NS3/4A protease inhibitor), no cirrhosis or compensated cirrhosis (Child-Pugh A ONLY)				

(PLEASE PRINT – ACCURACY IS IMPORTANT)

Re-infection of allograft liver after transplant, no cirrhosis				
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
Re-infection of allograft liver after transplant, compensated cirrhosis (Child-Pugh A ONLY)				
Harvoni 90/400 mg plus weight based ribavirin daily for 12 weeks				
Re-infection of allograft liver after transplant, decompensated cirrhosis (Child-Pugh B or C ONLY)				
Harvoni 90/400 mg plus low dose ribavirin [#] daily for 12 weeks				
Decompensated cirrhosis, no prior sofosbuvir or NS5A				
Epclusa 400/100 mg plus weight-based ribavirin daily for 12 weeks (low dose ribavirin [#] if Child-Pugh Class C)				
Epclusa 400/100 mg daily for 24 weeks (will be approved only for patients with documented ineligibility for ribavirin¶)				
Decompensated cirrhosis, prior treatment with sofosbuvir or NS5A				
Epclusa 400/100 mg plus weight-based ribavirin daily for 12 weeks (low dose ribavirin if Child-Pugh Class C)				
Recurrent HCV infection post–liver transplantation, no cirrhosis				
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
Recurrent HCV infection post-liver transplantation, compensated cirrhosis (Child-Pugh A ONLY)				
Harvoni 90/400 mg plus weight based ribavirin daily for 12 weeks				
Recurrent HCV infection post-liver transplantation, decompensated cirrhosis (Child-Pugh B and C ONLY)				
□ Harvoni 90/400 mg plus low dose ribavirin [#] daily for 12 weeks				
Genotype 2				
Treatment naïve, no cirrhosis				
Mavyret 100/40 mg, three (3) tablets daily for 8 weeks				
Epclusa 400/100 mg daily for 12 weeks				
Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)				
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
Epclusa 400/100 mg daily for 12 weeks Treatment experienced (PEG-IFN + ribavirin), no cirrhosis				
Epclusa 400/100 mg daily for 12 weeks				
Treatment experienced (PEG-IFN + ribavirin), with compensated cirrhosis (Child-Pugh A only)				
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
Epclusa 400/100 mg daily for 12 weeks				
Treatment experienced (sofosbuvir + ribavirin) (no cirrhosis)				
Mavyret 100/40 mg, three (3) tablets daily for 8 weeks (label indication) or 12 (guideline recommendation) weeks				
Epclusa 400/100 mg plus weight-based ribavirin daily for 12 weeks				
Treatment experienced (sofosbuvir + ribavirin) with compensated cirrhosis (Child-Pugh A only)				
Avyret 100/40 mg, three (3) tablets daily for 12 weeks				
Epclusa 400/100 mg plus weight-based ribavirin daily for 12 weeks Decompensated cirrhosis, no prior sofosbuvir or NS5A failure				
Decompensated cirriosis, no prior solosbavir or NSSA failure				
Epclusa 400/100 mg plus weight-based ribavirin daily for 12 weeks				
Epclusa 400/100 mg daily for 24 weeks (will be approved only for patients with documented ineligibility for ribavirin¶)				
Decompensated cirrhosis, prior sofosbuvir or NS5A failure				
Epclusa 400/100 mg plus weight based ribavirin daily for 12 weeks (low dose ribavirin if Child-Pugh C)				
Recurrent HCV infection post-liver transplantation, no cirrhosis				
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
Recurrent HCV infection post-liver transplantation, compensated cirrhosis (Child-Pugh A ONLY)				
Daklinza 60 mg^ daily plus Sovaldi 400mg daily plus low dose ribavirin [#] for 12 weeks				
Epclusa 400/100 mg plus weight-based ribavirin daily for 12 weeks				
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
Recurrent HCV infection post-liver transplantation, decompensated cirrhosis				
Daklinza 60 mg^ daily plus Sovaldi 400mg daily plus low dose ribavirin [#] for 12 weeks				
Epclusa 400/100 mg plus weight-based ribavirin daily for 12 weeks				

(PLEASE PRINT – ACCURACY IS IMPORTANT)

Genotype 3					
Treatment naive, no cirrhosis					
Mavyret 100/40 mg, three (3) tablets daily for 8 weeks					
Epclusa 400/100 mg daily for 12 weeks					
Treatment naive, with compensated cirrhosis (Child-Pugh A only)					
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks (Child-Pugh A only)					
Epclusa 400/100 mg daily for 12 weeks					
Treatment experienced (PEG-IFN + ribavirin), no cirrhosis, Y93H negative					
Epclusa 400/100 mg daily for 12 weeks					
Mavyret 100/40 mg, three (3) tablets daily for 16 weeks					
Treatment experienced (PEG-IFN + ribavirin), no cirrhosis, Y93H positive					
Epclusa 400/100 mg plus weight-based ribavirin daily for 12 weeks					
Mavyret 100/40 mg, three (3) tablets daily for 16 weeks					
Treatment experienced (PEG-IFN + ribavirin), compensated cirrhosis (Child-Pugh A ONLY)					
Mavyret 100/40 mg, three (3) tablets daily for 16 weeks					
Epclusa 400/100 mg plus weight-based ribavirin daily for 12 weeks					
Zepatier 50/100 mg daily plus Sovaldi 400 mg daily for 12 weeks (will only be approved for patients with documented					
ineligibility for ribavirin¶)					
Treatment experienced (any direct acting antiviral including NS5A), no or compensated cirrhosis (Child-Pugh A ONLY)					
Vosevi 400/100/100 mg daily for 12 weeks (add weight based ribavirin if both prior NS5A and cirrhosis)					
Decompensated cirrhosis, no prior sofosbuvir or NS5A failure					
Epclusa 400/100 mg plus weight-based ribavirin daily for 12 weeks					
Epclusa 400/100 mg daily for 24 weeks (will only be approved for patients with documented ineligibility for ribavirin¶)					
Decompensated cirrhosis, prior sofosbuvir or NS5A failure					
Epclusa 400/100 mg plus weight-based ribavirin daily for 12 weeks (low dose ribavirin [#] if Child-Pugh C) Recurrent HCV infection post–liver transplantation, no cirrhosis					
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks					
Recurrent HCV infection post-liver transplantation, compensated cirrhosis (Child-Pugh A ONLY)					
Daklinza 60 mg [^] daily plus Sovaldi 400mg daily plus low dose ribavirin [#] for 12 weeks					
Epclusa 400/100 mg plus weight-based ribavirin daily for 12 weeks					
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks					
Recurrent HCV infection post-liver transplantation, decompensated cirrhosis (Child-Pugh B and C ONLY)					
Daklinza 60 mg [^] daily plus Sovaldi 400mg daily plus low dose ribavirin [#] for 12 weeks					
Epclusa 400/100 mg plus weight-based ribavirin daily for 12 weeks					
Genotype 4					
Treatment naïve, no cirrhosis					
Mavyret 100/40 mg, three (3) tablets daily for 8 weeks					
Zepatier for 12 weeks					
Epclusa 400/100 mg daily for 12 weeks					
Treatment naïve, compensated cirrhosis (Child-Pugh A only)					
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks					
Zepatier for 12 weeks					
Epclusa 400/100 mg daily for 12 weeks Treatment experienced (PEG-IFN/RBV ONLY), no cirrhosis					
Mavyret 100/40 mg, three (3) tablets daily for 8 weeks					
Zepatier for 12 weeks, only if prior virologic relapse after PEG-IFN therapy, NOT if prior failure to suppress or breakthrough					
Epclusa 400/100 mg daily for 12 weeks					
Treatment experienced (PEG-IFN/RBV ONLY), compensated cirrhosis (Child-Pugh A only)					
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks					
Zepatier for 12 weeks only if prior virologic relapse after PEG-IFN therapy, NOT if prior failure to suppress or breakthrough					

(PLEASE PRINT – ACCURACY IS IMPORTANT)

Epclusa 400/100 mg daily for 12 weeks			
Treatment experienced (any direct acting antiviral including NS5A), with or without compensated cirrhosis (Child-Pugh			
A ONLY)			
Vosevi 400/100/100 mg daily for 12 weeks			
Decompensated cirrhosis, no prior sofosbuvir or NS5A			
Epclusa 400/100 mg plus weight-based ribavirin daily for 12 weeks			
Epclusa 400/100 mg daily for 24 weeks (will only be approved for patients with documented ineligibility for ribavirin¶) Decompensated cirrhosis, prior treatment with sofosbuvir or NS5A			
Epclusa 400/100 mg plus weight-based ribavirin daily for 12 weeks (low dose ribavirin [#] if Child-Pugh C)			
Recurrent HCV infection post-liver transplantation, no cirrhosis			
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks			
Recurrent HCV infection post-liver transplantation, compensated cirrhosis (Child-Pugh A ONLY)			
Harvoni 90/400 mg plus weight-based ribavirin daily for 12 weeks			
Recurrent HCV infection post-liver transplantation, decompensated cirrhosis			
Harvoni 90/400 mg plus low dose ribavirin [#] daily for 12 weeks			
Genotype 5 or 6			
Treatment naïve, no cirrhosis			
Mavyret 100/40 mg, three (3) tablets daily for 8 weeks			
Epclusa 400/100 mg daily for 12 weeks			
Treatment naïve, compensated cirrhosis (Child-Pugh A only)			
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks			
Epclusa 400/100 mg daily for 12 weeks			
Treatment experienced (PEG-IFN/RBV), no cirrhosis			
□ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks			
Epclusa 400/100 mg daily for 12 weeks			
Treatment experienced (PEG-IFN/RBV), compensated cirrhosis (Child-Pugh A ONLY)			
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks			
Epclusa 400/100 mg daily for 12 weeks			
Treatment experienced (any Direct Acting HCV Antiviral (DAA) including NS5A inhibitors, with no or compensated			
cirrhosis (Child-Pugh A ONLY)			
Vosevi 400/100/100 mg daily for 12 weeks			
Decompensated cirrhosis, no prior sofosbuvir or NS5A			
Epclusa 400/100 mg plus weight-based ribavirin daily for 12 weeks			
Epclusa 400/100 mg daily for 24 weeks (will only be approved for patients with documented ineligibility to ribavirin¶)			
Decompensated cirrhosis, prior treatment with sofosbuvir or NS5A			
Epclusa 400/100 mg plus weight-based ribavirin daily for 24 weeks (low dose ribavirin [#] if Child-Pugh C)			
Recurrent HCV infection post–liver transplantation, no cirrhosis			
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks			
Recurrent HCV infection post-liver transplantation, compensated cirrhosis (Child-Pugh A ONLY)			
Harvoni 90/400 mg plus weight-based ribavirin daily for 12 weeks Recurrent HCV infection post-liver transplantation, decompensated cirrhosis			
□ Harvoni 90/400 mg plus low dose ribavirin [#] daily for 12 weeks			
Other Treatment Regimen			
Genotype, treatment history, and extent of liver disease:			
Drug name, dose and duration: Clinical rationale for selecting regimens other than those outlined above:			
Clinical rationale for selecting regimens other than those outlined above:			

Abbreviations: PEG-IFN=peg-interferon; RBV=ribavirin; PI=protease inhibitor; DAA=direct acting antiviral

low dose ribavirin = 600 mg/day and increase as tolerated

[^]Dose of Daklinza (daclatasvir) MUST BE ADJUSTED with certain co-administered drugs (reduced to 30 mg daily with concurrent CYP3A4 inhibitors and increased to 90 mg daily with concurrent moderate CYP3A4 inducers)

lowa Department of Human Services **Request for Prior Authorization HEPATITIS C TREATMENTS** (PLEASE PRINT – ACCURACY IS IMPORTANT)

SECTION 2 – SUPPORTING DOCUMENTATION

Review and complete each numbered item below to provide the supporting documentation for the PA request.

Dia	Diagnosis:				
1. Pretreatment viral load (attach results):		ent viral load (attach results):	Date Obtained:		
2.	. Documentation of advanced liver disease (attach results):		Date Obtained:		
	□ T □ F □ A □ R □ P □ P	iver biopsy confirming a Metavir score \geq F3 iransient elastography (FibroScan) score \geq 9.5kPa ibroSURE (FibroTest) score \geq 0.58 PRI score $>$ 1.5 Radiological imaging consistent with cirrhosis (i.e. evidence of po Physical findings or clinical evidence consistent with cirrhosis Patients at highest risk for severe complications: organ transplan rgan manifestations (e.g. vasculitis), proteinuria, nephrotic synd	t, type 2 or 3 essential mixed cryoglobulinemia with end-		
Pat	ient Histor	y:			
3.	 Does the patient have a history of non-compliance? Yes No If yes, submit chart notes documenting the steps taken to correct or address the non-compliance (attach chart notes) 				
4.	4. Documentation in provider notes (must be submitted) showing that member has had no abuse of alcohol and drugs for the previous 3 months. MUST submit urine drug screen for members with history of abuse of drugs other than alcohol. Counseling MUST be provided and documented regarding non-abuse of alcohol and drugs as well as education on how to prevent HCV transmission				
5.	Is the patie	ent receiving dialysis? □Yes □No			
6.	Is the patie	ent's creatinine clearance ≥30 ml/min?			
7.	. Has patient been screened for Hepatitis B? No Yes Date: Active Disease: No Yes If yes, has patient been treated or currently being treated? No Yes				
8.	Patient weight: Date obtained:				
9.	9. Does patient have a limited life expectancy (less than 12 months) due to non-liver-related comorbid conditions? Tes No				
-	scriber Info Provider P	ormation: Practice: Digestive Disease Liver Disease Infectious	s Disease		
Reg	gimens Cor	ntaining Ribavirin:			
11.		ent is female and of childbearing potential, or the patient is male must acknowledge the following:	with a female partner of childbearing potential, the		
	d D B tr	The patient is not pregnant (or a male patient with a pregnant fen uring treatment or within 6 months of stopping treatment. Noth partners will use two forms of effective contraception during reatment. Nonthly pregnancy tests will be performed throughout treatment.			
12.	Complete	blood count with differential (attach results)			
13.	If the patie	ent is ineligible for ribavirin \P , select the appropriate reason from t	he list below:		
	□ P □ D □ H □ B □ B	listory of severe or unstable cardiac disease Pregnant women and men with pregnant partners Diagnosis of hemoglobinopathy (e.g., thalassemia major, sickle of Pypersensitivity to ribavirin Baseline platelets <70,000 cells/µL Baseline absolute neutrophil count <1,500 cells/µL Baseline hemoglobin <12 g/dL in women or <13 g/dL in men Dther:	ell anemia)		
		ory values will be reviewed and requests will not be conside ml/min (moderate or severe renal dysfunction, ESRD, HD) s			

Potentially Significant Drug Interactions:

- 14. Coadministration of Hepatitis C treatments with the following medications is not recommended. By checking one of the following boxes, the prescriber attests that they have reviewed the patient's medications for potentially significant drug interactions with the Hepatitis C treatment. If the medication list contains one or more of the following medications, the medication(s) will be changed to another agent.
 - Harvoni: The patient's current medication list does NOT include: carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifabutin, rifampin, rifapentine, St. John's Wort, ritonavir, tipranavir, Stribild, rosuvastatin, H₂-receptor antagonists above the following daily doses: famotidine 80 mg, ranitidine/nizatidine 600 mg or cimetidine 1600 mg; or proton-pump inhibitors above the following daily doses: esomeprazole 20 mg, lansoprazole or 30 mg, dexlansoprazole 60 mg, omeprazole 20 mg, pantoprazole 40 mg, rabeprazole 20 mg
 - Sovaldi: The patient's current medication list does NOT include: carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifabutin, rifampin, rifapentine, St. John's Wort, or tipranavir/ritonavir
 - **Epclusa:** The patient's current medication list does NOT include: all meds listed under Sovaldi plus efavirenz, proton pump inhibitors other than omeprazole 20 mg, topotecan or rosuvastatin at doses > 10 mg/day
 - Daklinza: The patient's current medication list does NOT include significant drug interactions or dose is adjusted appropriately. Consult the full prescribing information for potential drug interactions including MANY that require dosage adjustment.
 - **Zepatier:** The patient's current medication list does NOT include significant drug interactions. Consult the full prescribing information for potential drug interactions.
 - □ **Mavyret:** The patient's current medication list does NOT include atazanavir or rifampin, Consult the full prescribing information for other potential "not recommended" drug interactions.
 - □ **Vosevi:** Medication list does NOT include rifampin. Consult the full prescribing information for other potential "not recommended" drug interactions.

Attach lab results and other documentation

Prescriber signature (Must match prescriber listed above.)	Date of submission



Request for Prior Authorization High Dose Opioids

FAX Completed Form To 1 (800) 574-2515

> Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB
Patient address		
Provider NPI	Prescriber name	Phone
Prescriber address		Fax
Pharmacy name	Address	Phone
Prescriber must complete all informa	ation above. It must be legible, correct, and c	complete or form will be returned.
Pharmacy NPI <t< td=""><td>Pharmacy fax</td><td></td></t<>	Pharmacy fax	

Prior authorization is required for use of high-dose opioids \geq 200 morphine milligram equivalents (MME) per day. (See CDC Guideline for Prescribing Opioids for Chronic Pain at <u>https://www.cdc.gov/drugoverdose/prescribing/guidleine.html</u>.) Patients undergoing active cancer treatment or end-of-life care will not be subject to the criteria below. Payment will be considered when the following is met:

- 1. Requests for non-preferred opioids meet criteria for coverage (see criteria for Long-Acting Opioids and/or Short-Acting Opioids); and
- 2. Patient has a diagnosis of severe, chronic pain with a supporting ICD-10 code. Requests for a diagnosis of fibromyalgia or migraine will not be considered; and
- Patient has tried and failed at least two nonpharmacologic therapies (physical therapy; weight loss; alternative therapies such as manipulation, massage, and acupuncture; or psychological therapies such as cognitive behavior therapy (CBT); and
- 4. Patient has tried and failed at least two nonopioid pharmacologic therapies (acetaminophen, NSAIDs, or selected antidepressants and anticonvulsants); and
- 5. There is documentation demonstrating an appropriate upward titration or an appropriate conversion from other opioid medications; and
- Pain was inadequately controlled at the maximum allowed dose without prior authorization for the requested opioid(s); and
- 7. Pain was inadequately controlled by two other chemically distinct preferred long-acting opioids at the maximum allowed dose without prior authorization; and
- 8. Chart notes from a recent office visit for pain management is included documenting the following: a) Treatment plan, including all therapies to be used concurrently (pharmacologic and nonpharmacologic); and b) Treatment goals; and
- 9. Patient has been informed of the risks of high-dose opioid therapy; and
- 10. The prescriber has reviewed the patient's use of controlled substances on the Iowa Prescription Monitoring Program website and determined that use of high-dose opioid therapy is appropriate for this patient; and
- 11. The patient's risk for opioid addiction, abuse and misuse has been reviewed and prescriber has determined the patient is a candidate for high-dose opioid therapy; and
- 12. A signed chronic opioid therapy management plan between the prescriber and patient dated within 12 months of this request is included; and
- 13. The requested dosing interval is no more frequent than the maximum FDA-approved dosing interval; and
- 14. Patient has been provided a prescription for a preferred naloxone product for the emergency treatment of an opioid overdose; and
- 15. Patient has been educated on opioid overdose prevention; and
- 16. Patient's household members have been educated on the signs of opioid overdose and how to administer naloxone; and
- 17. Patient will not be using opioids and benzodiazepines concurrently or a taper plan to discontinue the benzodiazepine must be submitted with initial and subsequent requests; and
- 18. A documented dose reduction is attempted at least annually.

If criteria for coverage are met, initial requests will be given for three months. Requests for continuation of high-dose opioid therapy will be considered every six months with the following:

- 1. High-dose opioid therapy continues to meet treatment goals, including sustained improvement in pain and function; and
- 2. Patient has not experienced an overdose or other serious adverse event; and

Request for Prior Authorization High Dose Opioids

(PLEASE PRINT – ACCURACY IS IMPORTANT)

- 3. Patient is not exhibiting warning signs of opioid use disorder; and
- 4. The benefits of opioids continue to outweigh the risks; and
- 5. A documented dose reduction has been attempted at least annually, and the prescriber has determined the dose cannot be reduced at this time; and
- 6. The prescriber has reviewed the patient's use of controlled substances on the Iowa Prescription Monitoring Program website and determined that continued use of high-dose opioid therapy is appropriate for this patient; and
- 7. Patient will not be using opioids and benzodiazepines concurrently or a taper plan to discontinue the benzodiazepine must be submitted with subsequent requests; and
- 8. Patient has been provided a prescription for a preferred naloxone product for the emergency treatment of an opioid overdose; and
- 9. Patient has been reeducated on opioid overdose prevention; and
- 10. Patient's household members have been reeducated on the signs of opioid overdose and how to administer naloxone.

Drug name:	Strength:		
Dosage instructions:	Quantity:	Days supply:	
Drug name:	Strength:		
Dosage instructions:	Quantity:	Days supply:	
Diagnosis:		ICD-10 code:	
* Dracad to Dracaribar Signature for active of	anaar traatment or and of life care diagnoop		

* Proceed to Prescriber Signature for active cancer treatment or end of life care diagnoses.

Initial Requests:

Document non-pharmacologic therapies (such as physical therapy; weight loss; alternative therapies such as manipulation, massage, and acupuncture; or psychological therapies such as cognitive behavior therapy (CBT), etc.)

Non-pharmacological treatment tria	l #1:				
Trial dates:	Failure reason:				
Non-pharmacological treatment trial #2:					
Trial dates:	Failure reason:				
Document two nonopioid pharma anticonvulsants)	acologic therapies (acetaminophen, NSAIDs, or selected antidepressants, and				
Nonopioid pharmacologic trial #1: I	Name/dose:				
Trial dates:	Failure reason:				
Nonopioid pharmacologic trial #2: I	Name/dose:				
Trial dates: Failure reason:					
Document upward titration or conversion from other opioid medications:					
	t the maximum dose allowed without prior authorization for the requested opioid(s)? and trial dates:				
	y two other chemically distinct preferred long-acting opioids at the maximum dose				
Preferred long-acting narcotic trial #	#1: Name/dose:				
Trial dates:	Failure reason:				
Preferred long-acting narcotic trial #	#2: Name/dose:				
Trial dates:	Failure reason:				
470-5531 (7/18)	Page 2 of 3				

Iowa Department of Human Services		
Request for Prior Authorization High Dose Opioids (PLEASE PRINT – ACCURACY IS IMPORTANT)		
Attach notes from a recent office visit for pain management documenting both of the following: Treatment plan, including all therapies to be used concurrently (pharmacologic and nonpharmacologic) Treatment goals		
Has patient been informed of the risks of high-dose opioid therapy?		
Prescriber review of patient's controlled substance use on the Iowa PMP website: No Yes Date reviewed:		
Is long-acting opioid use appropriate for patient based on PMP review and patient's risk for opioid addiction, abuse and misuse? INO Yes		
Attach a signed chronic opioid therapy management plan between the prescriber and patient dated within 12 months of this request.		
Has patient been provided a prescription for a preferred naloxone product for the emergency treatment of an opioid overdose?		
Has patient been educated on opioid overdose prevention?		
Has patient's household members been educated on the signs of opioid overdose and how to administer naloxone?		
Is patient using opioids and benzodiazepines concurrently?		
Date of patient's most recent documented dose reduction:		
Renewals:		
Does high-dose opioid therapy continue to meet treatment goals, including sustained improvement in pain and function?		
Has patient experienced an overdose or other serious adverse event? 🗌 No 🔲 Yes		
Is patient exhibiting warning signs of opioid use disorder?		
Do the benefits of opioids continue to outweigh the risks?		
Date of patient's most recent documented dose reduction:		
Updated prescriber review of patient's controlled substances use on the Iowa PMP website: No Yes Date reviewed:		
Is patient using opioids and benzodiazepines concurrently?		
Has patient been provided a prescription for a preferred naloxone product for the emergency treatment of an opioid overdose?		
Has patient been reeducated on opioid overdose prevention?		
Has patient's household members been reeducated on the signs of opioid overdose and how to administer naloxone?		
Attach a signed chronic opioid therapy management plan between the prescriber and patient dated within 12 months of this request.		
Prescriber signature (Must match prescriber listed above.) Date of submission		



Request for Prior Authorization IMMUNOMODULATORS-TOPICAL

FAX Completed Form To 1 (800) 574-2515

Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name		DOB
Patient address			
Provider NPI	Prescriber name		Phone
Prescriber address			Fax
Pharmacy name	Address		Phone
Prescriber must complete all informa	ation above. It must be legible,	correct, and complete o	r form will be returned.
Pharmacy NPI	Pharmacy fax	NDC	
tacrolimus (Protopic [®]) 0.1% for patients 16 years of age and older when there is an adequate trial and therapy failure with one preferred topical corticosteroid, except on face or groin. If criteria for coverage are met, requests will be approved for one tube per 90 days to ensure appropriate short-term and intermittent utilization of the medication. Quantities will be limited to 30 grams for use on the face, neck, and groin, and 60 grams or 100 grams for all other areas. The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated. Non-Preferred Image: Protopic Tacrolimus Ointment			
Elidel Pro	Usage Instructions	Quantity	Days Supply
Elidel Pro	Usage Instructions	Quantity	Days Supply
Elidel Pro	Usage Instructions	Quantity	
Elidel Pro Strength Diagnosis: Preferred Drug Trial 1: Drug Na	Usage Instructions ame& Dose	Quantity	
Elidel Pro Strength Diagnosis: Preferred Drug Trial 1: Drug Na Failure Reason Does the patient have an immur	Usage Instructions ame& Dose	Quantity	

Attach lab results and other documentation as necessary.

Prescriber signature (Must match prescriber listed above.)	Date of submission



Date

Prescribed Drugs

Chapter III. Provider-Specific Policies

August 1, 2018

19

Antidepressants

Department

of Human

Services

- Antiemetic-5HT3 receptor antagonists/substance P neurokinin products
- <u>Antifungal</u>

Iowa

- Antihistamines
- Apremilast (Otezla)
- Becaplermin (Regranex)
- Benzodiazepines
- Binge eating disorder agents
- Biologicals for ankylosing spondylitis
- Biologicals for arthritis
- Biologicals for Hidradenitis Suppurativa
- Biologicals for inflammatory bowel disease
- Biologicals for plaque psoriasis
- <u>Buprenorphine/Naloxone (Suboxone)</u>
- <u>Calcifediol (Rayaldee)</u>
- Cholic acid (Cholbam)
- <u>Chronic pain syndrome agents</u>
- <u>CNS Stimulants and Atomoxetine</u>
- <u>Concurrent IM/PO antipsychotic use</u>
- Crisaborole (Eucrisa)
- Dalfampridine (Ampyra)
- Deferasirox
- Deflazacort (Emflaza)
- Dextromethorphan and Quinidine (Nuedexta)
- Dornase alfa (Pulmozyme)
- Dupilumab (Dupixent)
- Duplicate Therapy Edits
- Eluxadoline (Viberzi)
- Eplerenone (Inspra)
- <u>Erythropoiesis stimulating agents</u>
- Eteplirsen (Exondys 51)
- Extended release formulations
- Febuxostat (Uloric)
- <u>Fentanyl, short-acting products</u>
- GLP-1 Agonist/Basal Insulin Combinations
- Granulocyte colony stimulating factor agents
- Growth hormones
- Hepatitis C treatments
- High dose opioids
- Idiopathic pulmonary fibrosis
- Immunomodulators, topical



Page

Date

Prescribed Drugs

Chapter III. Provider-Specific Policies

August 1, 2018

20

- Insulin, pre-filled pens
- Isotretinoin (oral)

Iowa

Department

of Human

Services

- Ivabradine (Corlanor)
- Ivacaftor (Kalydeco)
- Janus Kinase Inhibitors
- <u>Ketorolac tromethamine (Toradol)</u>
- Lesinurad (Zurampic)
- Letermovir (Prevymis)
- Lidocaine patch (Lidoderm)
- Linezolid (Zyvox)
- Long acting opioids
- Lumacaftor/Ivacaftor (Orkambi)
- Lupron Depot adult
- Lupron Depot pediatric
- Mepolizumab (Nucala)
- Methotrexate injection
- Mifepristone (Korlym)
- Modified formulations
- <u>Multiple Sclerosis-oral agents</u>
- <u>Muscle relaxants</u>
- Narcan (Naloxone) nasal spray
- <u>Narcotic agonist-antagonist nasal sprays</u>
- <u>Nebivolol (Bystolic)</u>
- New-to-market drugs
- <u>Nicotine replacement products</u>
- <u>Non-parenteral vasopressin derivatives of posterior pituitary hormone</u> products
- <u>Non-preferred drugs</u>
- Nonsteroidal anti-inflammatory drugs
- <u>Novel oral anticoagulants</u>
- Oral constipation agents
- Oral immunotherapy
- Palivizumab (Synagis)
- PCSK9 inhibitors
- Potassium binders
- Proton pump inhibitors
- Pulmonary arterial hypertension agents
- <u>Quantity limit override</u>
- <u>Repository Corticotropin injection (H.P. Acthar Gel)</u>
- <u>Rifaximin (Xifaxan)</u>



Request for Prior Authorization INSULIN, PRE-FILLED PENS

FAX Completed Form To 1 (800) 574-2515

> Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT - ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB
Patient address		
Provider NPI	Prescriber name	Phone
Prescriber address		Fax
Pharmacy name	Address	Phone
Prescriber must complete all informa	tion above. It must be legible, correct, and co	omplete or form will be returned.
Pharmacy NPI	Pharmacy fax	NDC

Prior authorization (PA) is required for pre-filled insulin pens as designated on the Preferred Drug List (PDL). For pre-filled insulin pens requiring PA where the requested insulin is available in a vial, payment will be considered for a diagnosis of diabetes mellitus and FDA approved age in addition to the following criteria: 1) The patient's visual or motor skills are impaired to such that they cannot accurately draw up their own insulin (not applicable for pediatric patients), and 2) There is no caregiver available to provide assistance, and 3) Patient does not reside in a long-term care facility, and 4) For requests for non-preferred pre-filled pens, patient has documentation of a previous trial and therapy failure with a preferred pre-filled insulin pen within the same class (i.e. rapid, regular or basal). For pre-filled insulin pens requiring PA where the requested insulin is not available in a vial, payment will be considered for a diagnosis of diabetes mellitus and FDA approved age in addition to the following criteria: 1) Preferred pre-filled insulin pens- Patient has documentation of a previous trial and therapy failure with a preferred insulin agent, and 2) Non-preferred pre-filled insulin pens- Patient has documentation of a previous trial and therapy failure with a preferred insulin agent, and 2) Non-preferred pre-filled insulin pens- Patient has documentation of a previous trial and therapy failure with a preferred insulin agent, and 2) Non-preferred pre-filled insulin pens- Patient has documentation of a previous trial and therapy failure with a preferred insulin agent, and 2) Non-preferred pre-filled insulin pens- Patient has documentation of a previous trial and therapy failure with a preferred insulin agent within the same class (i.e. rapid, regular or basal). 3) Requests for Toujeo will require clinical rationale as to why the patient cannot use Lantus and patient must be using a minimum of 100 units of Lantus per day.

Preferred (no PA required)

□ Lantus SoloSTAR □ Leve	mir FlexTouch 🛛 NovoLog FlexF	en/PenFill	Novolog Mix FlexPen	
PA Required:				
Non-Preferred (available in vialAdmelog SoloSTARApidra SoloSTARFiasp FlexTouchHumalog Kwik PenHumulog Mix 75/25 PenHumulog Mix 50/50 PenHumulin N KwikPen) ☐ Humulin R KwikPen ☐ Humulin 70/30 KwikPen	☐ Basagla ☐ Toujeo	rred (not available in vial) ar KwikPen SoloStar ı FlexTouch	
Number of Units	How Often Numb	per of Cartri	idges/Pens/PenFills (circle requested i	item)
Diagnosis:				
□ Requests for insulin age	nts available in a vial:			
What visual or physical condit	ions limit the patient's ability to pr	epare their ov	wn syringes (adult patients only)?	
Does the patient lack capable	assistance residing with them?	□ Yes □	No	
Does the patient reside in a lo	ng-term care facility?	🗆 No		



Request for Prior Authorization INSULIN, PRE-FILLED PENS

FAX Completed Form To 1 (800) 574-2515

> Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT - ACCURACY IS IMPORTANT)

Requests for a non-preferred pre-filled insulin pen, document preferred pre-filled insulin pen trial within the same class:

Drug Name and Dosage Instructions:	Trial start date:	Trial end date:
Failure Reasons:		

□ Requests for insulin agents not available in a vial:

Document Preferred Insulin Trial in same class as requested agent:

Drug Name and Dosage Instructions:	Trial start date:	Trial end date:
Failure Reasons:		

Toujeo:

Patient's current daily Lantus dose: _____

Clinical rationale as to why patient cannot use Lantus: _____

Attach lab results and other documentation as necessary.

Prescriber signature (Must match prescriber listed above.)

Date of submission



Request for Prior Authorization IVACAFTOR (KALYDECO[™])

FAX Completed Form To 1 (800) 574-2515

> **Provider Help Desk** 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

	(FLEASE FRINT - ACCORACT	S INFORTANT)		
IA Medicaid Member ID #	Patient name		DOB	
Patient address				
Provider NPI	Prescriber name		Phone	
Prescriber address			Fax	
Pharmacy name	Address		Phone	
Prescriber must complete all information	ation above. It must be legible, co	rrect, and complete or	form will be returned.	
Pharmacy NPI	Pharmacy fax			
function tests (AST/ALT) are provi 3 months. Additional approvals wi Adherence to ivacaftor therapy is during the first year of treatment a ☐ Kalydeco [™] Strength	II be granted for 6 months at a confirmed; and 2) Liver function	time if the following n tests (AST/ALT) a	criteria are met: 1)	
Diagnosis (Attach copy of FDA		sults):		
Attach copy of baseline liver fu	nction test (AST/ALT).			
Prescriber Specialty: CF Specialist Pulmonologist Other (specify):				
Renewal Requests:				
Patient is adherent to ivacaftor	therapy: 🗌 Yes 🗌 No			
Liver function tests (AST/ALT) thereafter:	are assessed every 3 month Most recent lab date:		of treatment and annually	
Ivacaftor Therapy Start Date: _				
Attach lab results and other do	cumentation as necessary.			
Prescriber signature (Must match pre	scriber listed above.)	Date of su	bmission	
IMPORTANT NOTE: In evaluating requ				

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.

470-5117 (Rev. 4/18)



Request for Prior Authorization JANUS KINASE (JAK) INHIBITORS

FAX Completed Form To 1 (800) 574-2515

> **Provider Help Desk** 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB			
Patient address					
Provider NPI	Prescriber name	Phone			
Prescriber address Fax					
Pharmacy name	Address	Phone			
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.					
Pharmacy NPI	Pharmacy fax NDC				
Prior authorization is required for Janus kinase (JAK) inhibitors. Payment will be considered when the following conditions are met: 1. Patient meets the FDA approved age; and					

- 2. Patient is not using or planning to use tofacitinib in combination with biologic DMARDs or potent immunosuppressants (azathioprine or cyclosporine); and
- 3. Has been tested for latent tuberculosis prior to initiating therapy and will be monitored for active tuberculosis during treatment; and
- 4. Recommended laboratory monitoring of lymphocytes, neutrophils, hemoglobin, liver enzymes and lipids are being conducted according to the manufacturer labeling; and
- 5. Patient does not have a history of malignancy, except for those successfully treated for non-melanoma skin cancer (NMSC); and
- 6. Patient is not at an increased risk of gastrointestinal perforation.
- 7. Patient does not have an active, serious infection, including localized infections; and
- 8. Medication will not be given concurrently with live vaccines; and
- 9. Follows FDA approved dosing based on indication; and
- 10. Patient has a diagnosis of:
 - a. Moderate to severe rheumatoid arthritis with
 - i. A documented trial and inadequate response to two preferred oral disease modifying antirheumatic drugs (DMARD) used concurrently. The combination must include methotrexate plus another preferred oral DMARD (hydroxychloroquine, sulfasalazine, or leflunomide); and
 - ii. A documented trial and inadequate response to two preferred biological DMARDS; or
 - b. Psoriatic arthritis with
 - i. A documented trial and inadequate response to therapy with the preferred oral DMARD, methotrexate (leflunomide or sulfasalazine may be used if methotrexate is contraindicated); and
 - ii. Documented trial and therapy failure with two preferred biological agents used for psoriatic arthritis.

The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.

Non-Preferred

🗌 Xeljanz 🗌 Xeljanz X	R				
Strength D	osage Instructions		Quantity	_ Days	Supply
Diagnosis:					
Will tofacitinib be used in	combination with biologic	DMARDs or p	otent immund	suppres	sants?
Screening for Latent TB in	fection: Date:	Results:			
Will patient be monitored	for active tuberculosis duri	ng treatment?	? 🗌 Yes	🗌 No	
470-5175 (Rev. 10/18)					Page 1 of 2

Iowa Department of Human Services						
Request for Prior Authorization JANUS KINASE (JAK) INHIBITORS (PLEASE PRINT – ACCURACY IS IMPORTANT) Does patient have a history of malignancy, except successfully treated not (NMSC)?	on-melanoma skin cancer					
Does patient have an increased risk of gastrointestinal perforation?	Yes 🗌 No					
Recommended laboratory monitoring will be conducted according to main (lymphocytes, neutrophils, hemoglobin, liver enzymes and lipids)? Yes No Date of most recent labs:	nufacturer labeling					
Does patient have an active, serious infection, including localized infection	Does patient have an active, serious infection, including localized infections?					
Will requested medication be given concurrently with live vaccines? Yes No						
Moderate to Severe Rheumatoid Arthritis (RA)						
Methotrexate trial: Dose:	Trial dates:					
Failure reason:						
Plus preferred oral DMARD trial: Drug Name & Dose: Failure reason:	Trial dates:					
Preferred Biological DMARD Trial #1: Name/Dose: Failure reason:	Trial Dates:					
Preferred Biological DMARD Trial #2: Name/Dose: Failure reason:	Trial Dates:					
Psoriatic Arthritis						
Methotrexate trial (leflunomide or sulfasalazine if methotrexate is contrain Dose: Trial dates: Failure reason:	_					
Preferred Biological DMARD Trial #1: Name/Dose: Failure reason:						
Preferred Biological DMARD Trial #2: Name/Dose: Failure reason:						
Other medical conditions to consider:						

Attach lab results and other documentation as necessary.

Prescriber signature (Must match prescriber listed above.)	Date of submission



FAX Completed Form To 1 (800) 574-2515

Request for Prior Authorization Letermovir (Prevymis™)

Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB		
Patient address				
Provider NPI	Prescriber name	Phone		
Prescriber address		Fax		
Pharmacy name	Address	Phone		
Prescriber must complete all information	ation above. It must be legible, corre	ect, and complete or form will be returned.		
Pharmacy NPI	Pharmacy fax			
Prior authorization is required for oral letermovir. Requests for intravenous letermovir should be directed to the member's medical benefit. Payment will be considered under the following conditions:				
1) Medication is to be used for t	he prophylaxis of cytomegaloviru	us (CMV) infection and disease; and		
2) Patient or donor is CMV-sero	positive R+ (attach documentation	on); and		
 Patient has received an allogenic hematopoietic stem cell transplant (HSCT) within the last 28 days (provide date patient received HSCT); and 				
 Is prescribed by or in consultation with a hematologist, oncologist, infectious disease or transplant specialist; and 				
5) Patient is 18 years of age or older; and				
6) Dose does not exceed:a) 240mg once daily when co-administered with cyclosporine				

- b) 480 mg once daily; and
- 7) Patient must not be taking the following medications:
 - a) pimozide; or
 - b) ergot alkaloids (e.g., ergotamine, dihydroergotamine); or
 - c) rifampin; or
 - d) atorvastatin, lovastatin, pitavastatin, simvastatin, or repaglinide when co-administered with cyclosporine; and
- 8) Patient does not have severe (Child-Pugh Class C) hepatic impairment (provide score); and
- 9) Therapy duration will not exceed 100 days post- transplantation.
 - □ Prevymis[™]

	Strength	Dosage Instructior	IS	Quantity	Days Supply	
Diagnosis:						
Is patient or	donor CMV-ser	opositive R+?	🗌 Yes (a	ttach documenta	ation) 🗌 No	
Has patient I	received HSCT v	vithin the last 28 days?	🗌 Yes; d	ate	No	
Other (sp	ecify and provide	natologist Oncologist consultation with one of t	he above s	specialists):		
Consultation	date:	Physician r	name, phor	ie & speciality:		

Iowa Department of Human Services
Request for Prior Authorization Letermovir (Prevymis™) (PLEASE PRINT – ACCURACY IS IMPORTANT)
Will letermovir be co-administered with cyclosporine?
Yes; dose does not exceed 240mg once daily
No; dose does not exceed 480mg once daily
 Does patient have concurrent therapy with any of the following? Yes No Pimozide; or Ergot alkaloids (e.g., ergotamine, dihydroergotamine); or Rifampin; or Atorvastatin, lovastatin, pitavastatin, simvastatin, or repaglinide with co-administered with cyclosporine
Does patient have severe (Child-Pugh Class C) hepatic impairment (provide score)?
Yes No Score:
Is patient established on medication?
Yes; provide therapy start date:

Attach lab results and other documentation as necessary.

Prescriber signature (Must match prescriber listed above.)	Date of submission

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.

No No



Request for Prior Authorization LIDOCAINE PATCH

FAX Completed Form To 1 (800) 574-2515

> Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name			DOB	
Patient address					
Provider NPI	Prescriber name			Phone	
Prescriber address				Fax	
Pharmacy name	Address			Phone	
Prescriber must complete all information	ation above. It must be le	gible, correct, and o	omplete or fo	orm will be retu	ırned.
Pharmacy NPI	Pharmacy fax	-	NDC		
Prior authorization is required fo there is a diagnosis of pain asso					
with the initial prescription to de		io neuraigia. A m		- -	,
					,
with the initial prescription to de Non-Preferred	termine efficacy.	Quantity	Days S		,, ,
with the initial prescription to de Non-Preferred Lidoderm	termine efficacy.	-			,,,
with the initial prescription to de Non-Preferred Lidoderm	termine efficacy. Lidocaine Patch structions	Quantity			

Attach lab results and other documentation as necessary.

Prescriber signature (Must match prescriber listed above.)	Date of submission
5 ()	

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for eligible for Medicaid.



Request for Prior Authorization LINEZOLID (ZYVOX[®])

FAX Completed Form To 1 (800) 574-2515

> Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name		DOB
Patient address			
Provider NPI	Prescriber name		Phone
Prescriber address			Fax
Pharmacy name	Address		Phone
Prescriber must complete all informa	ation above. It must be legible,	correct, and complete or	form will be returned.
Pharmacy NPI	Pharmacy fax	NDC	
Prior authorization is required for Zyvox [®] . infectious disease (ID) physician or has co and meets one of the following diagnostic efficacy, Methicillin-resistant Staph aureus patient is intolerant to vancomycin. Preferred	nsulted ID physician (Telephone co criteria: Vancomycin-resistant Ento (MRSA) and patient is intolerant to	onsultation is acceptable), Ale erococcus (VRE) and no alter	ND Patient has an active infection native regimens with documented
		yvox	
Strength	Dosage Instructions	Quantity D	ays Supply
VRE is a body par Patient has Is patient re Does patier Methicillin-resistan **Patient has se o Severe rash administrat o Red-man's	rt other than lower urinary to severe renal insufficiency? aceiving hemodialysis? In have known hypersensitive t Staph aureus (MRSA) and t Staph epidermis (MRSE) a evere intolerance to vancom h, immune-complex mediate ion syndrome (histamine-media nged IV infusion, premedica Specialist?	ract? Yes No If Yes No Yes No vity to nitrofurantion? patient is intolerant to nd patient is intolerant d, determined to be directed ted), refractory to tradi ted with diphenhydram	□ Yes □ No vancomycin** to vancomycin** ectly related to vancomycin tional counter measures ine) □ ID Specialist: Consultation
Pertinent Lab data:			
Additional relevant information:			
Possible drug interactions/conflicting			
Attach lab results and other docu	- .		
Prescriber signature (Must match pres		Date of sub	mission
IMPORTANT NOTE: In evaluating requ	ests for prior authorization the co	Insultant will consider the tre	atment from the standpoint of

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for continues to be eligible for Medicaid.



Request for Prior Authorization METHOTREXATE INJECTION

Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB
Patient address		
Provider NPI	Prescriber name	Phone
Prescriber address		Fax
Pharmacy name	Address	Phone
Prescriber must complete all informa	tion above. It must be legible, correct, and complete or f	orm will be returned.
Pharmacy NPI	Pharmacy fax NDC	
Prior authorization is required for	r non-preferred methotrexate injection Payment wi	Il be considered under the

Prior authorization is required for non-preferred methotrexate injection. Payment will be considered under the following conditions: Patient's visual or motor skills are impaired to such that they cannot accurately draw up their own preferred generic methotrexate injection and there is no caregiver available to provide assistance in addition to: 1) Diagnosis of severe, active rheumatoid arthritis or polyarticular juvenile idiopathic arthritis and ALL of the following: a) Prescribed by a rheumatologist; and b) Patient has documented trial and intolerance with oral methotrexate; and c) Patient has documented trial and therapy failure or intolerance with at least one other non-biologic DMARD; or 2) Diagnosis of severe, recalcitrant, disabling psoriasis and ALL of the following: a) Patient is 18 years of age or older; and b) Prescribed by a dermatologist; and c) Patient has documentation of an inadequate response to all other standard therapies (oral methotrexate, topical corticosteroids, vitamin D analogues, cyclosporine, systemic retinoids, tazarotene, and phototherapy). The required trials may be overridden when documented evidence is provided that use of these agents would be medially contraindicated.

Non-Preferred

	Otrexup	Rasuvo			
	Strength	Dosage Instructions	Quantity	Days Supply	
Diagr	nosis (additional criter	ia below):			
Limit	ations to use of a pref	erred generic methotrexate inject	on:		
What	visual or physical cond	itions limit the patient's ability to prep	pare their own injection	าร?	
		e assistance residing with them?	_		
Does	the patient reside in a l	ong-term care facility?] Yes 🗌 No		
S	evere, active rheumat	oid arthritis (RA) or polyarticular j	uvenile idopathic art	hritis (pJIA):	
Preso	criber Specialty: 🗌 R	Rheumatologist			
Intole	erance with oral metho	btrexate:			
Dose	:		Trial dates:		

Request for Prior Authorization METHOTREXATE INJECTION

(PLEASE PRINT - ACCURACY IS IMPORTANT)

Specific Intolerance:	
Treatment failure with one other non-biologic DMARD (hydroxyd	chloroquine, leflunomide, or sulfasalazine):
Drug name & dose: Tria	al dates:
Reason for failure:	
Severe, recalcitrant disabling psoriasis (Patient must be 18 y	years of age or older):
Prescriber Specialty: Dermatologist Other	
Treatment failure with all standard therapies (include trial dates,	, dose & failure reason for each):
Oral methotrexate:	
Topical corticosteroids:	
Vitamin D analogues:	
Cyclosporine:	
Systemic retinoids:	
Tazarotene:	
Phototherapy:	
Possible drug interactions/conflicting drug therapies:	

Attach lab results and other documentation as necessary.

Prescriber signature (Must match prescriber listed above.)	Date of submission

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for continues to be eligible for Medicaid.



Request for Prior Authorization MODIFIED FORMULATIONS

FAX Completed Form To 1 (800) 574-2515

> Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

		SIMPORTANT)	
IA Medicaid Member ID #	Patient name		DOB
Patient address			
Provider NPI	Prescriber name		Phone
Prescriber address			Fax
Pharmacy name	Address		Phone
	nation above. It must be legible, correct,		orm will be returned.
Pharmacy NPI	Pharmacy fax		
Previous trial with a preferred paresponse with a documented interpreferred drug of a different chemay be overridden when documedically contraindicated.	omer, prodrug or metabolite will be c arent drug of the same chemical ent tolerance and 2) Previous trial and th emical entity indicated to treat the su nented evidence is provided that the	ity at a therapeut herapy failure at a Ibmitted diagnosi use of these pref	ic dose that resulted in a partial a therapeutic dose with a is if available. The required trial erred agent(s) would be
Horizant (trial of gabapentin)	Invega / Paliperidone ER (trial of rispe	ridone) 🗌 Tri	lipix (trial of Tricor)
Xopenex HFA / levalbuterol tartrat	te (trial of albuterol HFA)	Nebs / levalbuterol	nebs (trial of albuterol nebs)
	enative delivery system will only be contessary and there is a previous trial and ution)	l therapy failure wi	
Clozapine ODT / Fazaclo (trial of c	clozapine tablets)	e ODT (lamotrigine d	chew tablets)
Metoclopramide ODT (trial of meto	colopramide solution)	SolTab (trial of mirtaz	zapine tablets)
Risperdal M-Tab (trial of risperidor	ne solution)	ir oral suspension)	
Spritam (trial of levetiracetam solu	ition) 🔲 Zyprexa Zydis (trial of Zyprexa ta	blets)	
Strength:Dosage I	nstructions:	Quantity:	Days Supply:
Diagnosis:			
	Drug Name & Dose:		Trial dates:
	emical entity: Drug Name & Dose:		Trial dates:
-	· · · · · · · · · · · · · · · · · · ·		
Medical Necessity for alternative	e delivery system:		
Failure Reason of preferred altern	ative delivery system:		
Medical or contraindication reasor	n to override trial requirements:		
	cumentation as necessary.		
Prescriber signature (Must match p			submission
necessity only. If approval of this requ	equests for prior authorization the consultan uest is granted, this does not indicate that th ates the request for prior authorization to es	he member continue	s to be eligible for Medicaid. It is the

responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid. 470-4705 (Rev. 6/18)



Request for Prior Authorization ORAL CONSTIPATION AGENTS

FAX Completed Form To 1 (800) 574-2515

> **Provider Help Desk** 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

	(PLEASE PRINT - ACCURACT I	S IMPORTANT)	
IA Medicaid Member ID #	Patient name		DOB
Patient address			
Provider NPI	Prescriber name		Phone
Prescriber address			Fax
Pharmacy name	Address		Phone
Prescriber must complete all inform	ation above. It must be legible, corr		orm will be returned.
Pharmacy NPI	Pharmacy fax	NDC	
Prior authorization is required fo conditions:	r oral constipation agents. Payn	nent will be conside	ered under the following
1) Patient is 18 years of age or	older: and		
	ation of adequate trials and thera	apy failures with bo	th of the following:
Stimulant laxative (senna	a) plus saline laxative (milk of ma a) plus osmotic laxative (polyethy	gnesia); and	-
•	vn or suspected mechanical gas		•
If the criteria for coverage are me			
treatment. Requests for continu treatment.			
Non-Preferred			
Amitiza Dinzess	Movantik Relistor	Symproic	Trulance
Strength	Dosage Instructions	Quantity	Days Supply
-	-	-	
Treatment failures:			
Trial 1: Stimulant Laxative (se	nna) nlus Osmatic Lavativa (u	alvothylona alvo	ol / lactuloso)
Stimulant Laxative Trial: Nam	, .		•
Failure reason:			
Osmotic Laxative Trial: Name			
Trial Dates: Fa			
Trial 2: Stimulant Laxative (se		• /	Friel Detect
Stimulant Laxative Trial: Nam			Trial Dates:
Failure reason:			
Saline Laxative Trial: Name/De			
Failure reason:			
Does patient have a known or	suspected mechanical gastro	ointestinal obstru	ction: 🗌 Yes 🗌 No

lowa De	partment	of H	uman	Services
---------	----------	------	------	----------

Request for Prior Authorization ORAL CONSTIPATION AGENTS

(PLEASE PRINT - ACCURACY IS IMPORTANT)

Chronic Idionathic Constinution: (Amitiza Linzess or Trulance)

	Chronic laio	Dathic Constipation: (Amitiza, Linzess, or Trulance	?)
	•	Patient has less than 3 spontaneous bowel movem	ents (SBMs) per week:
		Yes No	
	•	Patient has two or more of the following symptoms	
		Straining during at least 25% of the bowel move	
		Lumpy or hard stools for at least 25% of bowel	
		Sensation of incomplete evacuation for at least	
	•	Documentation the patient is not currently taking co	
		Medication review completed: Yes No	
		Current constipation causing therapies:	
		Yes (please list)	No
	Irritable Bow	el Syndrome with Constipation: (Amitiza,Linzess	or Trulance)
	•	Patient is female (Amitiza requests only):	
	•	Patient has abdominal pain or discomfort at least 3	
		associated with two (2) or more of the following:	
		Improvement with defecation	
		Onset associated with a change in stool frequer	VOL
		Onset associated with a change in stool form	
	Opioid-Induc Symproic)	ed Constipation with Chronic, Non-Cancer Pain:	(Amitiza, Movantik, Relistor, or
	•	Patient has been receiving stable opioid therapy fo	r at least 30 days as seen in the
		patient's pharmacy claims: Yes No	
	•	Patient has less than 3 spontaneous bowel movem	ents (SBMs) per week, with at least
		25% associated with one or more of the following:	
		Hard to very hard stool consistency	
		Moderate to very severe straining	
		Sensation of incomplete evacuation	
	•	Patient has documentation of an adequate trial and	
		authorization request is for a different oral constipa	tion agent. 🔲 Yes 🔲 No
		Amitiza Trial: Dose:Trial dat	es:
		Failure Reason:	
_		-1-	
	Other Diagno	DSIS	
	Renewal Rec	uests: Provide documentation of adequate response	se to treatment:
Poss	ible drug intera	actions/conflicting drug therapies:	
Attac	ch lab results	and other documentation as necessary.	
Presc	riber signature (I	Aust match prescriber listed above.)	Date of submission

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.



Request for Prior Authorization PULMONARY ARTERIAL HYPERTENSION AGENTS

Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	DOB	
Patient address		
Provider NPI	Prescriber name	Phone
Prescriber address		Fax
Pharmacy name	Address	Phone
	ation above. It must be legible, correct, and comp	
Pharmacy NPI	Pharmacy fax ND	
Prior authorization is required for	r agents used to treat pulmonary hypertensi	on.
Preferred	Non-Preferred	
Epoprostenol Tracleer	Adcirca Opsumit	🗌 Revatio 📄 Uptravi
☐ Letairis ☐ Ventavis	🗌 Adempas 🗌 Orenitram	☐ Tracleer Sol Tab ☐ Veletri
 ☐ Sildenafil	☐ Flolan ☐ Remodulin	 Tyvaso
Strength	Dosage Instructions Quantity D	Days Supply
Diagnosis:		
Pulmonary arte	erial hypertension	
Other (please s	specify)	
Reason for use of Non-Preferred dr	ug requiring prior approval:	
Other medical conditions to conside	er:	

Attach lab results and other documentation as necessary.

Prescriber signature (Must match prescriber listed above.)	Date of submission

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for continues to be eligible for Medicaid.



FAX Completed Form To 1 (800) 574-2515

Request for Prior Authorization SEROTONIN 5-HT1 RECEPTOR AGONISTS

Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name			DOB		
Patient address	·					
Provider NPI Prescriber name					Phone	
Prescriber address				Fax		
Pharmacy name	Address			Phone		
Prescriber must complete all inform	nation above. It mus	t be legible, correct,	and complete or f	orm will be re	turned.	
Pharmacy NPI	Pharmacy fax	(NDC			
doses of tablets, syringes or sp will be considered on an individ required for all non-preferred se List beginning the first day of th authorized only for cases in whi agents. * Requests for non-pre trials and therapy failures with t supplied: 1. The diagnosis requi previous trials and therapy failu	ual basis after rev rotonin 5-HT1-rec erapy. Payment fo ch there is docum ferred combinatio he individual ingre iring therapy. 2. D	iew of submitted d eptor agonists as i or non-preferred se entation of previou n products may on edients. For consid ocumentation of cu	ocumentation. P ndicated on the rotonin 5-HT1-re is trials and ther ly be considered eration, the follo irrent prophylac	Prior authoriz lowa Medica eceptor agon rapy failures d after docur owing inform	cation will be aid Preferred Drug ists will be with two preferred nented separate ation must be	
Preferred (PA required after 12 d)NaratriptanRizatriptan ODTRizatriptan TabletsSumatriptan InjSumatriptan Nasal SpraySumatriptan Tablets	<u>loses in 30 days)</u> Zomig NS	Non- Preferred (P Almotriptan Amerge Axert Eletriptan Frova Frova	Imitrex Inj/ Maxalt Maxalt ML Onzetra X: Relpax	NS/Tabs T	 Treximet* Zembrace Zolmitriptan Zomig Tablets Zomig ZMT 	
Strength	Dosage Instr	uctions	Qu	antity	Days Supply	
Diagnosis:						
If Migraine, please document the different prophylactic medicatio						
Medical or contraindication reason						
Previous migraine therapy (include	e drug/dose/duratio	n):				
Reason for use of Non-Preferred of	Irug requiring prior	approval:				
Other medical conditions to consid	ler:					
Attach lab results and other doo	cumentation as ne	cessary.				
Prescriber signature (Must match pr	escriber listed above	9.)	Date of sub	mission		
IMPORTANT NOTE: In evaluating re necessity only. If approval of this requ responsibility of the provider who initia	iest is granted, this de	pes not indicate that th	e member continue	es to be eligible	for Medicaid. It is the	

card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.



Request for Prior Authorization TESTOSTERONE PRODUCTS

FAX Completed Form To 1 (800) 574-2515

> **Provider Help Desk** 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB	
Patient address			
Provider NPI	Prescriber name	Phone	
Prescriber address		Fax	
Pharmacy name	Address	Phone	
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.			
Pharmacy NPI	Pharmacy fax NDC		

Prior authorization is required for testosterone products. Payment will be considered with documentation of a specific testicular or hypothalamic/pituitary disease (primary hypogonadism or hypogonadotropic hypogonadism) that results in classic hypogonadism. Requests for FDA approved indications other than hypogonadism will not be subject to prior authorization criteria with adequate documentation of diagnosis. Payment for non-preferred testosterone products will be authorized only for cases in which there is documentation of previous trials and therapy failures with two preferred agents. Requests for erectile dysfunction, infertility, and age-related hypogonadism will not be considered. Payment will be considered under the following conditions:

- 1) Patient is male and 18 years of age or older (or 12 years of age and older for testosterone cypionate); and
- 2) Patient has two (2) morning pre-treatment testosterone levels below the lower limit of the normal testosterone reference range of the individual laboratory used (attach results); and
- 3) Patient has primary hypogonadism or hypogonadotropic hypogonadism (further defined below)
 - Primary hypogonadism (congenital or acquired) caused by testicular failure due to one of the following: cryptorchidism, bilateral torsion, orchitis, vanishing testes syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, toxic damage from alcohol or heavy metals
 - Hypogonadotropic hypogonadism: idiopathic gonadotropin or luteinizing hormone-releasing (LHRH) deficiency, pituitary-hypothalamic injury from tumors, trauma, or radiation
- 4) Patient does not have:
 - Breast or prostate cancer
 - Palpable prostate nodule or prostate-specific antigen (PSA) > 4ng/mL
 - Hematocrit > 50%
 - Untreated severe obstructive sleep apnea
 - Severe lower urinary tract symptoms
 - Uncontrolled or poorly controlled heart failure

If criteria for coverage are met, initial authorizations will be given for 3 months. Requests for continuation of therapy will require the following:

- An updated testosterone level (attach result); and
- Documentation the patient has not experienced a hematocrit > 54% or an increase in PSA > 1.4ng/mL in the past 12 months.

The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.

Request for Prior Authorization TESTOSTERONE PRODUCTS

(PLEASE PRINT - ACCURACY IS IMPORTANT)

Preferred Androderm Methitest Testosterone Cypionate Testosterone Enanthate Testosterone Gel 1% Packets	Non-Preferred Androgel Android Aveed Axiron	 Depo-Testostero Fortesta Methyltestostero Natesto 	ne 🗌 Testim	
Strength Dosage I	nstructions	C	Quantity	Days Supply
Complete for diagnosis of hypogona	adism:			
 Primary Hypogonadism (congenita Cryptorchidism Bilateral t Klinefelter's syndrome Ch Other: 	orsion 🗌 Orchit nemotherapy 🗌	is 🗌 Vanishing te Foxic damage from al	stes syndrome Icohol or heavy r	
 Hypogonadotropic Hypogonadism: Idiopathic gonadotropin or luteir Pituitary-hypothalamic injury from 	-	,	ю	
List & attach results of two (2) morn testosterone reference range of the			below the lowe	r limit of the normal
Level 1: Date:		Level 2:	Date	e:
Does patient have any of the followi Breast or prostate cancer: Palpable prostate nodule or prostate-s Hematocrit > 50%: Untreated severe obstructive sleep app Severe lower urinary tract symptoms: Uncontrolled or poorly controlled heart	Yes pecific antigen (PSA Yes nea: Yes Yes Yes	N) > 4ng/mL: Image: Constraint of the second seco	Yes 🗌 N	0
Renewal Requests:				
List & attach updated testosterone I	evel: Level:	D;	ate:	
Has patient experienced the followinHematocrit > 54%:Increase in PSA > 1.4ng/mL:	n g in the past 12 m] Yes 🔲 No] Yes 🗌 No	Most recent la		
Other medical conditions to consider:_				
Attach lab results and other docume	entation as necess	ary.		
Prescriber signature (Must match prescri	iber listed above.)		Date of submissi	ion
IMPORTANT NOTE: In evaluating request medical necessity only. If approval of this Medicaid. It is the responsibility of the prov	request is granted, thi	s does not indicate that	the member contin	nues to be eligible for

member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member

continues to be eligible for Medicaid. 470-5188 (Rev. 1/18)



Request for Prior Authorization Tezacaftor/Ivacaftor (Symdeko[™])

FAX Completed Form To 1 (800) 574-2515

Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

	-		
IA Medicaid Member ID # Patient name			DOB
Patient address			
Provider NPI	Prescriber name		Phone
Prescriber address			
Pharmacy name	Address		Phone
Prescriber must complete all informa	ation above. It must be legible, corre	ect, and complete or f	orm will be returned.
Pharmacy NPI <t< td=""><td>Pharmacy fax</td><td>NDC</td><td></td></t<>	Pharmacy fax	NDC	
fibrosis (CF); and 3) Patient is ho cystic fibrosis transmembrane co (listed in the FDA approved label specialist or pulmonologist; and coverage are met, an initial author following criteria are met: 1) Adh (AST/ALT) are assessed every 3 Symdeco [™] Strength	onductance regulator (CFTR) gen ing) based on in vitro data and/o 5) Baseline liver function tests (<i>I</i> prization will be given for 6 month erence to tezacaftor/ivacaftor the	e that is responsiv r clinical evidence; AST/ALT) are provi ns. Additional appr erapy is confirmed;	e to tezacaftor/ivacaftor and 4) Prescriber is a CF ded. If the criteria for ovals will be granted if the and 2) Liver function tests
Diagnosis (Attach copy of FD	A-cleared CF mutation test res	sults):	
Attach copy of baseline liver f			
	unction test (AST/ALT).		
Prescriber specialty: CF S		Other (spec	ify):
Prescriber specialty: CF S Renewal requests:		Other (spec	ify):
	pecialist	Other (specNo	ify):
Renewal requests:	pecialist	□ No s during first year	
Renewal requests: Patient is adherent to tezacaft Liver function tests (AST/ALT	pecialist	□ No s during first year	
Renewal requests: Patient is adherent to tezacaft Liver function tests (AST/ALT annually thereafter:Yes	pecialist	□ No s during first year	
Renewal requests: Patient is adherent to tezacaft Liver function tests (AST/ALT annually thereafter: Yes Tezacaftor/lvacaftor therapy s	pecialist	□ No s during first year	of treatment and

medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.



FAX Completed Form To 1 (800) 574-2515

Request for Prior Authorization TOPICAL ACNE AND ROSACEA PRODUCTS

Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB	
Patient address			
Provider NPI	Prescriber name	Phone	
Prescriber address		Fax	
Pharmacy name	Address	Phone	
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.			
Pharmacy NPI	Pharmacy fax	NDC	

Prior authorization is required for topical acne agents (topical antibiotics and topical retinoids) and topical rosacea agents. Payment for topical acne and topical rosacea agents will be considered under the following conditions:

- 1) Documentation of diagnosis.
- 2) For the treatment of acne vulgaris, benzoyl peroxide is required for use with a topical antibiotic or topical retinoid.
- 3) Payment for non-preferred topical acne products will be authorized only for cases in which there is documentation of previous trials and therapy failures with two preferred topical acne agents of a different chemical entity from the requested topical class (topical antibiotic or topical retinoid).
- 4) Payment for non-preferred topical rosacea products will be authorized only for cases in which there is documentation of a previous trial and therapy failure with a preferred topical rosacea agent.
- 5) Requests for non-preferred combination products may only be considered after documented trials and therapy failures with two preferred combination products.
- 6) Requests for topical retinoid products for skin cancer, lamellar ichthyosis, and Darier's disease diagnoses will receive approval with documentation of submitted diagnosis.
- 7) Trial and therapy failure with a preferred topical antipsoriatic agent will not be required for the preferred tazarotene (Tazorac) product for a psoriasis diagnosis.
- 8) Duplicate therapy with agents in the same topical class (topical antibiotic or topical retinoid) will not be considered.

The required trials may be overridden when documented evidence is provided that the use of these agents would be medically contraindicated.

Preferred
Acanya
Adapalene Gel
Azelex
Clindamycin
Differin
Epiduo
Erythromycin
MetroGel 1%
MetroLotion
Metronidazole 0.75% Cream
Retin-A
Tazorac

Non-Preferred				
Aczone	Fabior			
Adapalene/Benzoyl Peroxide	Finacea			
Adapalene Cream/Lotion	Klaron			
Atralin	MetroCream			
BenzaClin	Metronidazole Gel & Lotion			
Benzamycin	Noritate			
Benzamycin Pak	Onexton			
Cleocin T	Retin-A Micro			
Clindamycin/BPO	Sodium Sulfa/Sulf			
Clindamycin Phosphate-Tretinoin	Soolantra			
Dapsone Gel	Tretinoin			
Duac	Ziana			
Erythromycin/BPO				
Other (specify)				



Request for Prior Authorization TOPICAL ACNE AND ROSACEA PRODUCTS

(PLEASE PRINT - ACCURACY IS IMPORTANT)

Provider Help Desk 1 (877) 776-1567

Strength	Dosage Form	Dosage Instructions	Quantity	Days Supply
Diagnosis:				
lf acne vulgaris, d	ocument concurrent ber	zoyl peroxide use:		
Drug Name & Streng	gth:			
Dosing Instructions:		Start date:		
Non-Preferred Top	bical Acne or Rosacea P	roducts		
		eferred topical acne agents of a di he two trials must be preferred top		
Rosacea diagnosi	s: Document trial with one	preferred topical rosacea agent o	f a different chem	ical entity:
Preferred Trial 1: Na	ime/Dose:	Trial Dates	8:	
Failure reason:				
Preferred Trial 2: Na	me/Dose:	Trial Dates	8:	
Failure reason:				
Medical or contraind	ication reason to override ti	ial requirements:		
Other relevant inform	nation:			
Possible drug intera	ctions/conflicting drug thera	pies:		
Attach lab results a	and other documentation	as necessary.		

Prescriber signature (Must match prescriber listed above.)	Date of submission

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for continues to be eligible for Medicaid.



Request for Prior Authorization VALSARTAN/SACUBITRIL (ENTRESTO)

FAX Completed Form To 1 (800) 574-2515

> Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT - ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB
Patient address		
Provider NPI	Prescriber name	Phone
Prescriber address Fax		
Pharmacy name	Address	Phone
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.		
Pharmacy NPI	Pharmacy fax ND	

Prior authorization is required for valsartan/sacubitril (Entresto). Requests above the manufacturer recommended dosing will not be considered. Payment will be considered for patients when the following criteria are met:

- 1) Patient is 18 years of age or older; and
- 2) Patient has a diagnosis of NYHA Functional Class II, III, or IV heart failure; and
- 3) Patient has a left ventricular ejection fraction (LVEF) ≤40%; and
- 4) Patient is currently tolerating treatment with an ACE inhibitor or angiotensin II receptor blocker (ARB) at a therapeutic dose, where replacement with valsartan/sacubitril is recommended to further reduce morbidity and mortality; and
- 5) Is to be administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other ARB (list medications patient is currently taking for the treatment of heart failure); and
- 6) Will not be used in combination with an ACE inhibitor or ARB; and
- 7) Will not be used in combination with aliskiren (Tekturna) in diabetic patients; and
- 8) Patient does not have a history of angioedema associated with the use of ACE inhibitor or ARB therapy; and
- 9) Patient is not pregnant; and
- 10) Patient does not have severe hepatic impairment (Child Pugh Class C); and
- 11) Prescriber is a cardiologist or has consulted with a cardiologist (telephone consultation is acceptable).

The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.

Non-Preferred

Entresto

Strength	Dosage Instructions	Quantity	Days Supply
	-	-	

Diagnosis:

Request for Prior Authorization VALSARTAN/SACUBITRIL (ENTRESTO)

(PLEASE PRINT - ACCURACY IS IMPORTANT)

Trial Information:			
Is patient currently tolerating treatment with an ACE inhibitor or ARB at a therapeutic dose? 🗌 Yes 🗌 No			
If Yes, Provide: Drug Name & Dose: Therapy S	apy Start Date:		
Medical or contraindication reason to override ACE Inhibitor/ARB trial require	ments:		
Will Entresto be used in combination with ACE inhibitor or ARB?		🗌 Yes	🗌 No
Does patient have a history of angioedema associated with ACE inhibitor or A	ARB therapy?	🗌 Yes	🗌 No
Provide heart failure therapies to be used in conjunction with Entresto:			
If patient is diabetic, will Entresto be used in combination with aliskiren (Tektu	urna)?	🗌 Yes	🗌 No
Provide patient's left ventricular ejection fraction: D	Date obtained:		
Results:			
If female of child-bearing years, confirmed negative serum pregnancy test?		🗌 Yes	🗌 No
If yes, please list Prescriber: D	Date of pregnan	cy test:	
Does patient have severe hepatic impairment (Child Pugh Class C)?		🗌 Yes	🗌 No
Is Prescriber a cardiologist? Yes No If no, note consultation with	cardiologist:		
Consultation date: Physician name & phone:			
Attach lab results and other documentation as necessary.			

Prescriber signature (Must match prescriber listed above.)	Date of submission

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.



Request for Prior Authorization Vesicular Monoamine Transporter (VMAT) 2 Inhibitors FAX Completed Form To 1 (800) 574-2515

Provider Help Desk 1 (877) 776-1567

•	/
(PLEASE PRINT -	- ACCURACY IS IMPORTANT

IA Medicaid Member ID #	mber ID # Patient name				
Patient address	Patient address				
Provider NPI	Prescriber name	Phone			
Prescriber address Fax					
Pharmacy name	Address	Phone			
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.					
Pharmacy NPI	Pharmacy fax NDC				

Prior authorization is required for VMAT 2 inhibitors. Payment for non-preferred agents will be considered only for cases in which there is documentation of previous trial and therapy failure with a preferred agent (when applicable, based on diagnosis). Payment will be considered under the following conditions:

Tardive Dyskinesia (Ingrezza or Austedo)

- 1. Patient meets the FDA approved age; and
- 2. Patient has a diagnosis of tardive dyskinesia (TD) based on the presence of ALL of the following: a. Involuntary athetoid or choreiform movements
 - b. Documentation or claims history of current or prior chronic use (≥ 3 months or 1 month in patients ≥ 60 years old) of a dopamine receptor blocking agent (e.g., antipsychotic, metoclopramide, prochlorperazine, droperidol, promethazine, etc.)
 - c. Symptoms lasting longer than 4-8 weeks; and
- 3. Prescribed by or in consultation with a neurologist or psychiatrist; and
- 4. Prescriber has evaluated the patient's current medications for consideration of a dose reduction, withdrawal, or change of the dopamine receptor blocking agent causing the TD; and
- 5. Documentation of baseline AIMS (Abnormal Involuntary Movement Scale) Score (attach AIMS); and
- 6. For Ingrezza:
 - a. Will not be used concurrently with MAO inhibitors (e.g., isocarboxazid, phenelzine, rasagiline, safinamide, selegiline, tranylcypromine, etc.) or strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, phenobarbital, rifampin and related agents, St. John's wort, etc.); and
 - b. Will not be used concurrently with other VMAT2 inhibitors; and
 - c. Is prescribed within the FDA approved dosing; or
- 7. For Austedo:
 - a. Patient is not suicidal, or does not have untreated/inadequately treated depression;
 - b. Patient does not have hepatic impairment;
 - c. Will not be used concurrently with MAO inhibitors, reserpine, or other VMAT2 inhibitors; and
 - d. Patients that are taking a strong CYP2D6 inhibitor (e.g., quinidine, paroxetine, fluoxetine, bupropion) or are poor CYP2D6 metabolizers, the daily dose does not exceed 36mg per day (18mg twice daily); and
 - e. Is prescribed within the FDA approved dosing.

If criteria for coverage are met, initial requests will be given for 3 months. Continuation of therapy will be considered when the following criteria are met:

- 1. Patient continues to meet the criteria for initial approval; and
- 2. Documentation of improvement in TD symptoms as evidenced by a reduction of AIMS score from baseline (attach current AIMS).

Request for Prior Authorization Vesicular Monoamine Transporter (VMAT) 2 Inhibitors

(PLEASE PRINT – ACCURACY IS IMPORTANT)

Chorea associated with Huntington's disease (Austedo or tetrabenazine)

- 1. Patient meets the FDA approve age; and
- 2. Patient has a diagnosis of Huntington's disease with chorea symptoms; and
- 3. Prescribed by or in consultation with a neurologist or psychiatrist; and
- 4. Is prescribed within the FDA approved dosing; and
- 5. Patient is not suicidal, or does not have untreated or inadequately treated depression; and
- 6. Patient does not have hepatic impairment; and
- 7. Patient does not have concurrent therapy with MAO inhibitors, reserpine, or other VMAT2 inhibitors; and
- 8. For tetrabenazine, patients requiring doses above 50mg per day have been tested and genotyped for the drug metabolizing enzyme CYP2D6 to determine if they are a poor metabolizer or extensive metabolizer; and
- 9. In patients that are taking a strong CYP2D6 inhibitor (e.g., quinidine, paroxetine, fluoxetine, bupropion) or are poor CYP2D6 metabolizers, the daily dose does not exceed the following:
 - a. Austedo 36mg per day (18mg single dose) or
 - b. Tetrabenazine 50mg per day (25mg single dose)

If criteria for coverage are met, initial requests will be given for 3 months. Continuation of therapy will be considered when the following criteria are met:

- 1. Patient continues to meet the criteria for initial approval; and
- 2. Documentation of improvement in chorea symptoms is provided.

Preferred ereferred	Non-Preferred	<u>t</u>		
Ingrezza	Austedo	Tetrabenazine	C Xenazine	
Strength	Do	sing Instructions	Quantity	Days' Supply
InvoluntaryDocumentary	of the following athetoid or chor tion of a dopami			
Is prescriber a: If other, note co	neurologist	psychiatrist	other: /chiatrist:	
 Has prescriber withdrawal, or c 	evaluated the pathange of the do	atient's current medicati ppamine receptor blocki sults):	ons for consideration of ng agent causing the TE	a dose reduction, D?
• For Ingrezza:	ave concurrent th			lucers, or other VMAT2

Iowa Department of	of Human Services
--------------------	-------------------

Request for Prior Authorization Vesicular Monoamine Transporter (VMAT) 2 Inhibitors

(PLEASE PRINT – ACCURACY IS IMPORTANT)

For Austedo:
Is patient suicidal or have untreated or inadequately treated depression?
Does patient have hepatic impairment?
Does patient have concurrent therapy with MAO inhibitors, reserpine, or other VMAT2 inhibitors?
Is patient taking a strong CYP2D6 inhibitor?
Has patient been identified as a poor CYP2D6 metabolizer? 🗌 Yes 🗌 No
Renewal Requests:
Updated AIMS score from baseline (attach results): Date conducted:
Chorea associated with Huntington's disease (Austedo or Tetrabenazine):
Is prescriber a: neurologist psychiatrist other:
If other, note consultation date with a neurologist or psychiatrist:
Physician name, phone & specialty:
 Is patient suicidal or have untreated or inadequately treated depression? Yes No
Does patient have hepatic impairment? Yes No
 Does patient have concurrent therapy with MAO inhibitors, reserpine, or other VMAT2 inhibitors? Yes No
 Is patient taking a strong CYP2D6 inhibitor? Yes No
 Has patient been identified as a poor CYP2D6 metabolizer? Yes No
 For tetrabenazine doses above 50mg per day, has patient been tested and genotyped for the drug metabolizing enzyme CYP2D6 to determine if they are a poor or extensive metabolizer? Yes No
Renewal Requests:
Document improvement in chorea symptoms:

Attach lab results and other documentation as necessary.

Prescriber signature (Must match prescriber listed above.)	Date of submission	

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for continues to be eligible for Medicaid.



Date

Prescribed Drugs

Chapter III. Provider-Specific Policies

August 1, 2018

21

<u>Roflumilast (Daliresp)</u>

lowa

Department

of Human

Services

- Sapropterin dihydrochloride (Kuvan)
- Sedative/hypnotics-non-benzodiazepine
- <u>Select oncology agents</u>
- <u>Selected brand-name drugs</u>
- Serotonin 5-HT1 receptor agonists
- Short-acting opioids
- Smoking cessation therapy (oral)
- <u>Sodium oxybate (Xyrem)</u>
- <u>Tasimelteon (Hetlioz)</u>
- <u>Testosterone products</u>
- <u>Tezacaftor (Symdeko)</u>
- <u>Thrombopoietin receptor agonists</u>
- Topical acne and rosacea products
- Topical antifungals for onychomycosis
- <u>Topical corticosteroids</u>
- Valsartan/Sacubitril (Entresto)
- Vesicular Monamine
- <u>Vitamins, minerals and multiple vitamins</u>
- <u>Vorapaxar (Zontivity)</u>
- <u>Vusion ointment</u>

The enrolled prescriber requests prior authorizations, not the pharmacy. The process is primarily a **prescriber fax-only system** using the forms provided by the Iowa Medicaid Enterprise. The prescriber must request prior authorization by faxing the designated *Request for Prior Authorization* form to **800-574-2515**.

Additional prior authorization submission options include mail and electronic submission through the pharmacy provider portal.

- Mail: The prescriber should mail the prior authorization request to: Iowa Medicaid Enterprise, Pharmacy Medical PA, 100 Army Post Road, Des Moines, Iowa, 50315.
- Pharmacy Provider Portal: This is a web-based tool that allows prescribers to create and submit a web prior authorization. Prescribers should contact the Iowa Medicaid Prior Authorization Helpdesk at (515) 256-4607 (local calls) or 877-776-1567 for additional information.



Requests require the information on the applicable *Request for Prior Authorization* form, as noted in each subsection. Prior authorization forms may be obtained:

- From the website <u>http://www.iowamedicaidpdl.com/pa_forms</u> or
- By calling the drug prior authorization help desk at (515) 256-4607 (local calls) or 877-776-1567. (Requests for prior authorizations will **not** be taken at this number.)

The IME Drug Prior Authorization Unit will consider other conditions as listed in the compendia on an individual basis after reviewing documentation submitted regarding the medical necessity.

3. Completing a Prior Authorization Request

Each category of prior authorization uses a specific request form to reflect the criteria for approval. The following instructions refer to items common to all *Requests for Prior Authorization*.

IA MEDICAID MEMBER ID #: Copy this number directly from the member's *Medical Assistance Eligibility Card.* This number must be eight positions in length (seven numeric digits and one alphabetical character).

PATIENT NAME: Provide the first and last name of the member. Use the *Medical Assistance Eligibility Card* for verification.

DATE OF BIRTH (DOB): Copy the member's date of birth directly from the *Medical Assistance Eligibility* Card. Use two digits for each: month, day, year (i.e., 04/11/67).

PATIENT ADDRESS: Enter the member's home address.

PRESCRIBER NUMBER: Enter the national provider identifier (NPI) of the prescribing practitioner.

PRESCRIBER NAME: Enter the name of the enrolled prescribing practitioner.

PRESCRIBER PHONE NUMBER: Enter the prescriber's office phone number.

PRESCRIBER ADDRESS: Enter the prescriber's office address.



Date

23

PRESCRIBER FAX NUMBER: Enter the prescribing practitioner's office FAX number.

PHARMACY NAME: Enter the name of the pharmacy where the prescription will be filled.

PHARMACY ADDRESS: Enter the street address and city of the pharmacy.

PHARMACY PHONE NUMBER: Enter the phone number of the pharmacy.

PHARMACY NPI: Enter the pharmacy national provider identifier (NPI) number.

NDC: If available, enter the National Drug Code of the product being requested.

DRUG NAME: Provide the complete drug name of the product being requested.

STRENGTH: Enter the strength of the drug being requested.

DOSAGE INSTRUCTIONS: Enter the instructions for use for the requested product.

QUANTITY: Enter the quantity on the prescription (cannot exceed a one-month supply).

DAYS SUPPLY: Enter the number of days' supply requested (cannot exceed a one-month supply).

LENGTH OF THERAPY ON PRESCRIPTION (DATE RANGE): Provide an estimate of the duration of therapy. The prior authorization period granted will be subject to adjustment by the reviewer according to established criteria and individual consideration.

DIAGNOSIS: Enter the patient's diagnosis relevant to the requested product.

PREVIOUS THERAPY: Enter drug names, strengths, dosage instructions, and exact date ranges of other medications that have previously been tried and failed by patient.



Date

24

PERTINENT LAB DATA: Enter any laboratory 909 data that may affect the outcome of this request.

OTHER MEDICAL CONDITIONS TO CONSIDER: Enter any other medical conditions the patient has that may help the Prior Authorization Unit make a decision.

POSSIBLE DRUG INTERACTIONS/CONFLICTING DRUG THERAPIES: If the patient is taking any other medications that may negatively affect the requested product, list them here.

PRESCRIBER SIGNATURE: The prescriber must sign the form and the signature must match the prescriber name listed at the top of the request form.

DATE OF SUBMISSION: Enter the date the prior authorization request was submitted.

4. Submitting a Prior Authorization Request

Completed drug prior authorization requests must be submitted **via FAX** to the IME Drug Prior Authorization Unit at 800-574-2515.

Regular working hours for the provider help desk are Monday through Friday, 8:00 a.m. to 5:00 p.m.

State-recognized holidays are as follows:

- New Year's Day
- Martin Luther King Jr.'s birthday
- Memorial Day
- Independence Day
- Labor Day
- Veterans' Day
- Thanksgiving Day
- The Friday following Thanksgiving
- Christmas Day

Under the Health Insurance Portability and Accountability Act, there is an electronic transaction for prior authorization requests (278 transaction). However, there is no standard to use in submitting additional documentation electronically.



Therefore, if you submit a prior authorization request electronically, you must submit the additional documentation on paper using the following procedure:

Complete form 470-3970, *Prior Authorization Attachment Control*. To view a sample of this form on line, click <u>here</u>.

Complete the "attachment control number" with the same number submitted on the electronic prior authorization request. IME will accept up to 20 characters (letters or digits) in this number. If you do not know the attachment control number for the request, please contact the person in your facility responsible for electronic claims billing.

- **Staple** the additional information to the *Prior Authorization Attachment Control.*
- Fax the form with attachments to the Prior Authorization Unit at 800-574-2515 or mail the information to:

Iowa Medicaid Enterprise PO Box 36478 Des Moines, IA 50315

Once IME receives the paper attachment, it will manually be matched up to the electronic claim using the attachment control number and then processed.

5. Prior Authorization Response

The pharmacist reviewer will make a decision and respond within 24 hours of the request. In evaluating requests for prior authorization, the reviewer will consider the drug from the standpoint of published criteria only.

If a prior authorization request is denied, a letter of denial will be faxed to both the prescriber and the pharmacist. A letter of denial will be mailed to the member.

Upon approval of a prior authorization request, a letter of approval will be faxed to the prescriber and the pharmacy indicating the prior authorization number and dates of authorization.



NOTE: When approval of a request is granted, this does not indicate validity of the prescription, nor does it indicate that the member continues to be eligible for Medicaid. If you are not billing on the point-of-sale system, it is your responsibility to establish that the member continues to be eligible for Medicaid, either by:

- Calling the eligibility verification system (ELVS) at (515) 323-9639 (local calls) or 800-338-7752; or
- Checking the IME web portal; <u>http://www.edissweb.com</u>

D. BASIS OF PAYMENT FOR DRUGS

The amount of payment for drugs is based on several factors, in accordance with 441 IAC 79.1(8) and upper limits in 42 CFR 447.500 to 447.520.

340B actual acquisition cost (340B AAC) means the net cost of a drug paid by a pharmacy for drugs purchased through the 340B drug pricing program. A drug's 340B AAC includes discounts, rebates, chargebacks, and other adjustments to the price of the drug, but excludes dispensing fees.

Average actual acquisition cost (average AAC) is defined as retail pharmacies' average prices paid to acquire drug products.

- Average AAC is determined by the Department based on a survey of invoice prices paid by Iowa Medicaid retail pharmacies.
- Surveys are conducted at least once every six months, or more often at the Department's discretion.
- The average AAC is calculated as a statistical mean based on one reported cost per drug per pharmacy. The average AAC determined by the Department is published on the Iowa Medicaid Enterprise website.
- If no current average AAC has been determined for a drug, the wholesale acquisition cost (WAC) published by Medi-Span is used.

Federal upper limit (FUL) is defined as the upper limit for multiple-source drugs established in accordance with the methodology of the Centers for Medicare and Medicaid Services, as described in 42 CFR 447.514.

For drugs with no established FUL, the Department determines the allowable average actual acquisition cost in accordance with the provisions of federal drug regulation 42 CFR 447.512. This basis of payment is also applicable to compounded prescriptions.



Professional dispensing fee is added to the ingredient cost to cover the pharmacist's professional services and costs associated with transferring the drug to a Medicaid member. The dispensing fee is set based on cost of dispensing surveys of Iowa Medicaid participating pharmacies.

1. Reimbursement Effective April 1, 2017

The Medicaid program relies on information published by **Medi-Span** to classify drugs as brand or generic.

a. Generic and Nonprescription Drugs

For covered **generic** prescription drugs and for covered **nonprescription** drugs shall be the lowest of the following, as of the date of dispensing:

- Average actual acquisition cost (average AAC) plus the professional dispensing fee.
- The federal upper limit (FUL) plus the professional dispensing fee.
- The total submitted charge (represented by gross amount due and ingredient cost plus the professional dispensing fee).
- The provider's usual and customary charge to the general public.

b. Brand-Name Drugs

For covered **brand-name** prescription drugs shall be the lowest of the following, as of the date of dispensing:

- Average AAC plus the professional dispensing fee.
- The total submitted charge (represented by gross amount due and the ingredient cost plus the professional dispensing fee).
- The provider's usual and customary charge to the general public.

c. 340B Purchased Drugs

The submitted 340B covered entity actual acquisition cost (not to exceed the 340B ceiling price) plus the professional dispensing fee.



28

d. Federal Supply Schedule (FSS) Drugs

The provider's actual acquisition cost (not to exceed the FSS price) plus the professional dispensing fee.

e. Nominal Price (NP) Drugs

The provider's actual acquisition cost (not to exceed the NP price) plus the professional dispensing fee.

f. Indian Health Facilities

Indian health facility pharmacies are paid a special daily rate for all Medicaid-covered services rended to American Indian or Alaskan native persons who are Medicaid-eligible. The pharmacies should bill at their usual and customary charge. Pharmacy claims will be paid at one pharmacy encounter rate payment per date of service.

2. Drugs Subject to Federal Upper Limit (FUL)


a. FUL Development

The Centers for Medicare and Medicaid Services (CMS) establishes federal upper limits (FUL) for reimbursement for multiple-source drugs. These reimbursement levels are updated periodically and are available on the Centers for Medicare and Medicaid Services web page at <u>https://www.medicaid.gov/medicaid/prescription-drugs/federal-upper-limits/index.html</u>.

b. Reimbursement for FUL Drugs

For the drug groups on the <u>Preferred Drug List</u> where brand-name products are preferred over generic products, the FUL rate will continue to apply when the generic version of the drug is dispensed.

However, the payment for preferred brand name products (which no longer require prior authorization before dispensing) equals the lower of the average acquisition cost (average AAC) or the submitted charges, as opposed to the FUL rate.



Nonpreferred brand products require prior authorization before dispensing. If authorized, payment equals the lower of the the average acquisition cost (average AAC) or the submitted charges, as opposed to the FUL rate with a prior authorization. The DAW=1 is no longer required for brand reimbursement.

Prior authorization is required for selected brand-name drugs as determined by the Department for which there is available, an "A" rated bioequivalent generic product as determined by the federal Food and Drug Administration.

For prior authorization to be considered, evidence of a treatment failure with the bioequivalent generic drug must be provided. A copy of a completed form 470-4119, *Request for Prior Authorization: Selected Brand Name Drugs*, shall be considered as evidence of treatment failure.

The list of selected brand-name drugs includes the drugs on the Federal Upper Limit (FUL) list at <u>http://www.mslc.com/Iowa/AACList.aspx</u>. Prior authorization **is not required** for brand name drugs that have been designated by the Department as **preferred** (payable) under the Iowa Medicaid Preferred Drug List (PDL).

3. Reimbursement for Unit-Dose Packaging

Additional reimbursement of one cent per dose shall be added to the allowable ingredient cost of a prescription for an oral solid if the drug is dispensed to a patient in a nursing home in unit dose packaging prepared by the pharmacist. Unit-dose reimbursements are permitted only for patients with Plan 300 eligibility.

Claim the additional reimbursement by placing a "3" in "Unit Dose Indicator" (field 429-DT) for electronic claims, as explained under <u>Point of Sale Claim</u> <u>Submission</u>, or a "09" in the Basis Cost (field 80) on the paper claim form, as explained under <u>Paper Claim Submission</u>. The additional reimbursement will be automatically added, possibly resulting in reimbursement that is higher than your submitted charge.

Credits: Payment may be made only for unit-dose-packaged drugs that are **consumed** by the patient. Any previous charges for intact unit-dose packages returned to the pharmacy must be credited to the Medicaid program. Such credits may be shown on future billings. If no additional billings are to be made, direct a refund in the drug cost component.



In accordance with state and federal law, proper crediting to Iowa Medicaid is **required** for the return of unused medications upon therapy discontinuation or a member's discharge, transfer, or death.

Both the long-term-care pharmacy and the nursing facility are subject to financial review by the state to ensure that medications are being returned to the pharmacy when permitted by state and federal law and proper credits are applied to the Iowa Medicaid program.

4. Reimbursement for Vaccinations

a. Vaccine for Children (VFC) Program

In order for pharmacies who administer VFC influenza vaccinations for children age 18 and under to be reimbursed:

- Pharmacy must be enrolled in the VFC Program through the Iowa Department of Public Health and follow that process to qualify.
- Pharmacy must meet the Iowa Board of Pharmacy requirements to administer.
- Pharmacy must bill only for administration of influenza vaccinations. Claims must be submitted on a CMS 1500 claim form with appropriate codes. Reimbursement will be based on the physician fee schedule. No payment is made for the vaccine.

For more information, see the Iowa Department of Public Health web page: <u>http://www.idph.iowa.gov/immtb/immunization</u>

b. Other Vaccines

Reimbursement for vaccines is made in the same manner as for other prescription drugs. When administered by the pharmacy meeting the Iowa Board of Pharmacy requirements, no administration fee is paid.



31

E. BILLING SYSTEM

Iowa Medicaid Enterprise provides for on-line, real-time processing of Medicaid pharmacy claims. Through electronic submission, you are able to submit claims more accurately. You also receive your Medicaid payments sooner than if you submitted paper claims.

Point-of-sale (POS) transactions are handled by the Iowa Medicaid Enterprise Pharmacy Point of Sale (POS) Unit. POS will handle the overrides for prospective drug utilization review edits such as high dose, therapeutic duplication, refill too soon, excessive days supply, dose consolidation, duplicate claim, or immunosuppressant drugs.

Providers that wish to exercise the point of sale billing option must complete the Iowa DHS Point of Sale Agreement. Please visit <u>www.iowamedicaidpos.com</u> to complete this agreement. You may call the (Point of Sale) POS Helpdesk at 877-463-7671 or locally at 515-256-4608.

1. Point of Sale Claim Submission

For point-of-sale (POS) submitters, refer to your POS Payer Sheet for claim submission instructions explanation of the data fields for the electronic billing format. (To view the instruction on line, click <u>here</u>.)

The Afforable Care Act (ACA) requires that providers who prescribe or are indicated as a referring provider on a Medicaid claim must be enrolled as a participating provider in the program. Pharmacy claims submitted with a National Provider Identifier (NPI) that is not enrolled with the Iowa Medicaid program will be denied. Providers may contact Provider Services at 800-338-7909 or 256-4609 (local) for questions regarding provider enrollment.

The Iowa Medicaid Enterprise eliminated the procedure of paying pharmacy claims and then billing the primary insurance company on behalf of the members ("pay and chase") effective January 16, 2007, except for children under age 21 and pregnant women.

 For members under age 21, pharmacy claims may be processed through Pharmacy Point of Sale System with Iowa Medicaid as the primary insurer.



- For members who are pregnant, bill claims through the Pharmacy Point of Sale System with Iowa Medicaid as the primary insurer. To get a \$0.00 copayment, enter code "2" in the pregnancy indicator code field (NCPDP field 335-2C).
- For **all other** Medicaid members with other prescription insurance, that insurance is primary and Medicaid is secondary.
 - Ask the member for the primary prescription insurance card.
 - If a member has primary pharmacy insurance, submit the claim to the primary insurance first and then the copay to Medicaid last, using a "8" in the OTHER COVERAGE CODE field (field 308-C8).
 - If a member has primary pharmacy insurance and the claim is not covered by the primary insurance, submit the claim to Medicaid using a "3" in the OTHER COVERAGE CODE field (field 308-C8).
 - If a member has Iowa Medicaid pharmacy insurance only (or does not have the primary prescription insurance information), enter a "1" in the OTHER COVERAGE CODE field (field 308-C8).

a. Claims Rejected Due to Other Insurance Coverage

When a claim is submitted with a blank field or a zero in the OTHER COVERAGE CODE field but the Iowa Medicaid eligibility file has third-party liability (TPL) information, the Medicaid claim will be denied and you will receive a rejection code of 41, "Submit to Primary Payer."

The Point-of-Sale System will give the policy number and the type of coverage. Most times the insurance company name is given. However, for the less common companies, a code is given in place of the name.

Use the primary prescription insurance billing information to bill the primary insurance. If necessary, you may contact the IME Provider Services for the name and address of the health insurance company.

After billing the other company, resubmit the claim with one of the following codes the OTHER COVERAGE CODE field:

 Use code 1 if the member states that there is no other insurance coverage. If the claim has already been rejected with a reject code of 41 "Submit to Primary Payer," Iowa Medicaid's eligibility file conflicts with the primary third-party insurance company's information. See <u>Correction of Insurance Information</u>.



Date

33

- Use code **3** if other coverage does exist but the drug is not covered under the primary insurance plan.
- Use code **8** when payment is not collected. Example: The primary third-party insurance is 100 percent major medical.

b. Correction of Insurance Information

The Department makes every attempt to keep current data regarding other insurance Medicaid members may have. However, if the primary insurance is no longer valid or has changed, the Department's records need to be corrected. The pharmacy can facilitate this in one of three ways:

- Instruct the client to notify the Department; or
- Complete form 470-2826, *Insurance Questionnaire*, available on the IME website (<u>http://dhs.iowa.gov/ime/providers/forms</u>), and FAX the form to Revenue Collections at (515) 725-1352; or
- Notify the Department by e-mailing <u>Revcoll@dhs.state.ia.us</u> or by calling (515) 256-4619 (local) or 1-866-810-1206. The minimum information necessary for insurance carriers to verify the other insurance coverage is the following:
 - Member last name
 - Member first name
 - State identification number or social security number
 - Date of birth
 - Policy number
 - Full insurance company name

For example, if the company is Blue Cross/Blue Shield, include which state the policy is from, as most every state has a BC/BS carrier. (In Iowa, it's Wellmark.)

2. Claiming Payment for Retroactively Eligible Member

For Iowa Medicaid prescription drug claims involving claims for a member whose Medicaid eligibility was determined retroactively, call the IME Point of Sale (POS) Unit at (515) 256-4608 (local calls) or 877-463-7671. Have the following information available:

- The pharmacy's national provider identifier.
- The member's Iowa Medicaid number, name, and date of birth.



- The drug's name, strength, quantity, and dates requested for reimbursement.
- The date the pharmacy was made aware the member had Medicaid coverage for the state of Iowa.

For medications payable on Iowa Medicaid, the POS staff will put an override on the point-of-sale system for the pharmacy to rebill the claims for reimbursement.

3. Claim Attachment Control, Form 470-3969

If you want to submit electronically a claim that requires an attachment, you must submit the attachment on paper using the following procedure:

• Complete form 470-3969, *Claim Attachment Control*. To view a sample of this form on line, click <u>here</u>.

Complete the "attachment control number" with the same number submitted on the electronic claim. IME will accept up to 20 characters (letters or digits) in this number. If you do not know the attachment control number for the claim, please contact the person in your facility responsible for electronic claims billing.


- **Staple** the additional information to form 470-3969. Do **not** attach a paper claim.
- Mail the *Claim Attachment Control* with attachments to:

Medicaid Claims PO Box 150001 Des Moines, IA 50315

Once IME receives the paper attachment, it will manually be matched up to the electronic claim using the attachment control number and then processed.

4. Paper Claim Submission

Traditional Universal Claim forms are no longer accepted. The new universal claim forms PUCF-D01PT (VER 1.2) can be ordered by calling CommuniForm at 800-564-8140, or online at <u>https://www.ncpdp.org/Products/Universal-Claim-Forms</u>.



The following table contains information that will aid in the completion of the pharmacy claim form. The table follows the form by field name, giving a brief description of the information to be entered, and whether providing information in that field is required, optional, or conditional on the individual member's situation.

FIELD NAME/DESCRIPTION	INSTRUCTIONS
1 – CARDHOLDER ID	MANDATORY . Enter the member's Medicaid ID number. Copy this directly from the <i>Medical</i> <i>Assistance Eligibility Card</i> . It consists of seven numeric characters followed by a letter, i.e., 1234567A.
2 – group id	Not used. Leave blank.
3 – last	Not used . Submit information under Patient segment.
4 – FIRST	Not used . Submit information under Patient segment.
5 – PLAN NAME	IAMED
6 – BIN NUMBER	011933
7 – PROCESSOR CONTROL NUMBER	ΙΑΡΟΡ
8 – CMS PART D	OPTIONAL.
PATIENT	
9 – PATIENT'S LAST NAME	REQUIRED . Must be submitted.
10 – patient's first name	REQUIRED . Must be submitted.
11 – PERSON CODE	NOT USED.
12 – date of birth	REQUIRED . Enter the member's birth date using a two-digit entry for each of the following: month, day, and year.
13 – PATIENT GENDER CODE	REQUIRED . Enter the gender.



CARDHOLDER

NUMBER

QUALIFIER

22 - CITY

23 – STATE

Provider and Chapter

Prescribed Drugs

Chapter III. Provider-Specific Policies

Page

Date August 1, 2018

FIELD NAME/DESCRIPTION INSTRUCTIONS NOT USED. 14 – RELATIONSHIP TO 15 – PATIENT RESIDENCE OPTIONAL. PHARMACY **OPTIONAL**. For office use only. 16 – DOCUMENT CONTROL **MANDATORY**. Enter the pharmacy's national 17 – SERVICE PROVIDER ID provider identifier (NPI). 18 – SERVICE PROVIDER ID MANDATORY. Enter "01" for national provider identifier (NPI). 19 – PHARMACY NAME **REQUIRED**. Enter the pharmacy's name. **OPTIONAL**. Entering the pharmacy's area code and 20 – PHONE NUMBER phone number may expedite processing of the claim. 21 – ADDRESS **REQUIRED**. Enter the pharmacy's street address. **REQUIRED**. Enter the pharmacy's city. **REQUIRED**. Enter the pharmacy's state.

24 – ZIP	REQUIRED . Enter the pharmacy's zip code.
PRESCRIBER	
25 – SIGNATURE OF PROVIDER	REQUIRED . Enter the signature of the representative completing the form.
26 – DATE	REQUIRED . Enter the date of the completed claim.
27 – prescriber id	REQUIRED . Enter the national provider identifier (NPI) of the prescribing practitioner.
28 – ID QUALIFIER	01 = NPI
29 – PRESCRIBER LAST NAME	REQUIRED.

36



Provider and Chapter

Prescribed Drugs

Chapter III. Provider-Specific Policies

Page

Date

August 1, 2018

FIELD NAME/DESCRIPTION	INSTRUCTIONS		
PHARMACIST			
30 – PHARMACIST ID	NOT USED.		
31 – ID QUALIFIER	NOT USED.		
CLAIM			
32 – PRESCRIPTION SERV. REF# (RX NUMBER)	MANDATORY . Enter the prescription number you have assigned to the prescription being billed. This number must be all numeric . No alpha characters are allowed.		
33 – PRESCRIPTION SERV. REF# (RX NUMBER) QUALIFIER	1 = RX BILLING		
34 – FILL #	REQUIRED . Enter "00" for a new prescription, and 01-99 for refills.		
35 – date written	REQUIRED . Enter the date the prescription was written using a two-digit entry for each of the following: month, day, and year. CCYYMMDD		
36 – DATE OF SERVICE	MANDATORY . Enter the date the prescription was filled using a two-digit entry for each of the following: month, day, and year. CCYYMMDD		
37 – SUBMISSION CLARIFICATION	OPTIONAL . Enter "20" if 340B claim. Enter "08" if compound claim.		
38 – PRESCRIPTION ORIGIN	OPTIONAL.		
39 – PHARMACY SERVICE TYPE	NOT USED.		
40 – SPECIAL PACKAGING INDICATOR	OPTIONAL.		



Provider and Chapter Department

Prescribed Drugs

Chapter III. Provider-Specific Policies

Page

Date August 1, 2018

38

FIELD NAME/DESCRIPTION INSTRUCTIONS **MANDATORY**. Enter the national drug code (NDC) 41 – PRODUCT/SERVICE ID found on the drug's label. All of the numerals in the NDC, including the package size, must be current and exactly match the NDC of the product actually dispensed. Be careful to copy the NDC exactly as it appears, including leading zeros. If the product number is only three digits long, enter a leading zero. For a compound, "0" must appear in this field. List each ingredient, NDC, guantity, and charge in the COMPOUND section. 00 = COMPOUND42 – PRODUCT/SERVICE ID 03 = NDCQUALIFIER 43 – PRODUCT DESCRIPTION **REQUIRED**. **REQUIRED**. Give the number of tablets, capsules, 44 – QUANTITY DISPENSED etc. or the **metric measurement** for liquids, creams, etc. Be sure the billed quantity, when divided by the number of days' supply, is an appropriate amount for that therapeutic class of drugs. If the quantity is a fractional amount, use a decimal point. **REQUIRED**. Enter the number of days the 45 – DAYS SUPPLY prescription will last. 46 – DAW CODE (MAC Leave blank. OVERRIDE) 47 – PRIOR AUTH # **CONDITIONAL**. Leave blank unless one of the SUBMITTED following applies: 1 = 72 hour supply 4 = Pregnant5 = Nursing facility vaccine 7 = Mental health drugs48 – PA TYPE **CONDITIONAL**. Enter code "2" if a number was entered in the "PRIOR AUTH # SUBMITTED" box. Otherwise, leave blank.



Provider and Chapter

Prescribed Drugs

Chapter III. Provider-Specific Policies

Page

Date August 1, 2018

FIELD NAME/DESCRIPTION	INSTRUCTIONS	
49 – OTHER COVERAGE CODE	CONDITIONAL . To determine whether the member has drug coverage under other insurance, check the member's eligibility using the Eligibility Verification System (ELVS) or the IME web portal.	
	 If a member has Iowa Medicaid pharmacy insurance only and no other primary insurance, leave this field blank or enter a zero. 	
	• Enter code "1" if the member states there is no other insurance but the claim has already been rejected with a reject code of 41 "Submit to Primary Payer." Iowa Medicaid's eligibility file conflicts with the primary third-party insurance company's information.	
	 Enter code "3" if other coverage does exist and the drug is not covered under the primary insurance plan. NOTE: Also allowed for Part D excluded drugs. 	
	 Enter code "8" when billing is for patient financial responsibility. 	
	Only the indicator "06 = Patient Pay Amount" will be accepted as an other payer-patient responsibility amount qualifier.	
50 – DELAY REASON	NOT USED.	
51 – LEVEL OF SERVICE	NOT USED.	
52 – PLACE OF SERVICE	OPTIONAL.	
53 – QUANTITY PRESCRIBED	OPTIONAL.	
CLINICAL		
54 – DIAGNOSIS CODE	NOT USED.	
55 – DIAGNOSIS CODE QUALIFIER	NOT USED.	



Provider and Chapter

Prescribed Drugs

Chapter III. Provider-Specific Policies

Page

Date

August 1, 2018

FIELD NAME/DESCRIPTION	INSTRUCTIONS	
DUR		
56 – DUR/PPS CODE REASON	Leave blank.	
57 – DUR/PPS CODE SERVICE	Leave blank.	
58 – DUR/PPS CODE RESULT	Leave blank.	
59 – LEVEL OF EFFORT	Leave blank.	
60 – PROCEDURE MODIFIER	Leave blank.	
COB OTHER PAYMENTS		
COB1 – PRIMARY		
61 – OTHER PAYER ID	REQUIRED FOR COB. Primary payer.	
62 – OTHER PAYER ID QUALIFIER	REQUIRED FOR COB . Primary payer.	
63 – OTHER PAYER DATE	REQUIRED FOR COB. Primary payer.	
	If the patient has other insurance coverage, enter the date the claim was paid or rejected by the other insurer.	
64 – OTHER PAYER REJECT CODES	CONDITIONAL . If the patient has other insurance coverage but the claim was rejected, enter the rejection codes assigned by the other insurer (if known).	
COB1 – SECONDARY		
65 – OTHER PAYER ID	REQUIRED FOR COB . Payer ID of primary payer.	
66 – OTHER PAYER ID QUALIFIER	REQUIRED FOR COB.	
67 – OTHER PAYER DATE	REQUIRED FOR COB.	
	If the patient has other insurance coverage, enter the date the claim was paid or rejected by the other insurer.	
68 – OTHER PAYER REJECT CODES	CONDITIONAL . If the patient has other insurance coverage but the claim was rejected, enter the rejection codes assigned by the other insurer (if known).	



Provider and Chapter

Prescribed Drugs

Chapter III. Provider-Specific Policies

Page

Date

41

August 1, 2018

FIELD NAME/DESCRIPTION	INSTRUCTIONS		
COMPOUND			
69 – DOSAGE FORM DESCRIPTION CODE	Mandatory.		
70 – DISPENSING UNIT FORM INDICATOR	MANDATORY.		
71 – ROUTE OF ADMINISTRATION	OPTIONAL.		
72 – INGREDIENT COMPONENT COUNT	MANDATORY.		
73 – PRODUCT NAME	REQUIRED . Submit for each compound component.		
74 – PRODUCT ID	REQUIRED . Submit for each compound component.		
75 – PRODUCT ID QUALIFIER	REQUIRED . Submit for each compound component.		
76 – INGREDIENT QTY	REQUIRED . Submit for each compound component.		
77 – INGREDIENT DRUG COST	OPTIONAL . Submit for each compound component.		
78 – BASIS OF COST	OPTIONAL . Submit for each compound component. Enter "08" if 340B claim. Enter "17" if FSS drugs. Enter "16" if NP drugs.		
PRICING	·		
79 – USUAL & CUSTOMARY CHARGE	REQUIRED . Enter the usual and customary charge.		
80 – BASIS OF COST DETERMINATION	CONDITIONAL . Enter code "09" to indicate unit dose drug. Enter "08" if 340B claim. Enter "17" if FSS drugs. Enter "16" if NP drugs. Otherwise, leave blank.		
81 – INGREDIENT COST SUBMITTED	REQUIRED . Enter the pharmacy's submitted product component cost of the dispensed prescription. Amount also included in the gross amount due.		
	340B, FSS, and NP pricing submitted in this field when applicable.		



Provider and Chapter

Prescribed Drugs

Chapter III. Provider-Specific Policies

Page

Date August 1, 2018

FIELD NAME/DESCRIPTION	INSTRUCTIONS	
82 – DISPENSING FEE SUBMITTED	REQUIRED . Enter the pharmacy's usual and customary dispensing fee. Enter zeros if no dispensing fee is charged for the prescription.	
83 – PROFESSIONAL SERVICE FEE SUBMITTED	REQUIRED . Enter the pharmacy's usual and customary dispensing fee. Enter zeros if no dispensing fee is charged for the prescription.	
84 – INCENTIVE AMOUNT SUBMITTED	Leave blank.	
85 – OTHER AMOUNT SUBMITTED	Leave blank.	
86 – SALES TAX SUBMITTED	NOT USED.	
87 – GROSS AMOUNT DUE	REQUIRED . Enter the total charge for this item. The total claim charge must be equal to the sum of the submitted ingredient cost submitted and the submitted dispensing fee.	
88 – PATIENT PAID AMOUNT	Leave blank.	
89 – OTHER PAYER AMOUNT PAID #1	NOT USED.	
90 – OTHER PAYER AMOUNT PAID #2	NOT USED.	
91 – OTHER PAYER-PATIENT RESPONSIBILITY AMOUNT #1	REQUIRED FOR IA COB CLAIMS.	
92 – OTHER PAYER-PATIENT RESPONSIBILITY AMOUNT #2	REQUIRED FOR IA COB CLAIMS.	
93 – NET AMOUNT DUE	REQUIRED . Enter the total price less the deductible amount. NOTE: If resubmitting a claim that is over 12 months old, the word "resubmit" must clearly appear on the claim to avoid denials for timely filing. This procedure can be used only if the original submission was within the last 12 months.	



Date

43

F. EDITS AND SPECIAL BILLING INFORMATION

1. Claims for Deceased Members

Submit claims for all Iowa Medicaid members using the dispensing date. Pharmacy claims must be billed before a member's date of death for claims processing. Failure to bill before the date of death may result in claim recoupment for any claims processed after that date of death.

2. Common Billing Errors

Medications can often be described using three measures: each, grams, and milliliters. It is important to choose the correct unit of measure when billing.

Medication	Correct Unit for Billing	Quantity	Days' Supply
Bactroban cream (mupirocin)	Grams	Varies; should be divisible by 15 grams	Varies
Bactroban ointment (mupirocin)	Grams	Varies; should be divisible by 22 grames	Varies
Byetta 5 mcg (exenatide)	MI (Submit in decimal format; do not round)	1.2 ml	30
Byetta 10 mcg (exenatide)	MI (Submit in decimal format; do not round)	2.4 ml	30
Copaxone (glatiramer)	Each	1	30
Diastat ACDL gel (diazepam)	Each (kit contains 2 syringes; bill # of kits)	1	Varies
Enbrel 25 mg	Each	1	1
Enbrel 25 mg/0.5 ml (etanercept)	MI (Submit in decimal format; do not round)	Varies claims should be divisible by 0.5 ml	30
Enbrel SureClick (etanercept)	MI (Submit in decimal format; do not round)	Varies should be divisible by .98 ml	30
Fragmin (dalteparin)	MI (Submit in decimal format; do not round)	Varies	Varies



Provider and Chapter

Page

Date

Prescribed Drugs

Chapter III. Provider-Specific Policies

August 1, 2018

Medication	Correct Unit for Billing	Quantity	Days′ Supply	
Gamunex 10% (immune globulin)	MI (Each vial is 10 ml)	Varies	Varies	
Humira (adalimumab)	Each (kit contains 2 syringes)	2	30	
Influenza vaccines	MI (Submit in decimal format; do not round)	0.5 ml	1	
Kineret (anakinra)	MI (Submit in decimal format; do not round)	Varies; should be divisible by 0.67	30	
Lovenox (enoxaparin)	MI (Submit in decimal format; do not round)	Varies	Varies	
Miacalcin NS (calcitonin)	MI (Submit in decimal format; do not round)	3.7	30	
Nascobal (cyanocobalamin)	MI (Submit in decimal format; do not round)	Varies; claims should be divisible by 2.3 ml	30	
Neupogen 400 mcg (filgrastim)	MI (Submit in decimal format; do not round)	Varies; claims should be divisible by 1.6 ml	30	
Neupogen 600 mcg (filgrastim)	MI (Submit in decimal format; do not round)	Varies; claims should be divisible by 0.5 ml	30	
Pegasys (peginterferon Alfa-2a)	Each (kit contains 4 syringes)	1	28	
Peranex HC (lidocaine/ hydrocortisone)	Each	1	Varies	
Proair HFA (albuterol)	Grams	8.5 grams	30	
Proventil HFA (albuterol)	Grams	6.7 grams	30	
Rebif pack (interferon Beta-1a)	MI (Submit in decimal format; do not round)	4.2 ml	30	
Rebif syringe (interferon Beta-1a)	MI (Submit in decimal format; do not round)	6 ml	30	
Remicade (infliximab)	Each	1	Varies	
Restasis (cyclosporine)	Each	32/64	30	
Risperdal Consta (risperidone)	Each	2	28	



lowa

Department of Human

Services

Provider and Chapter

Page

Date

Prescribed Drugs

Chapter III. Provider-Specific Policies

August 1, 2018

Medication	Correct Unit for Billing	Quantity	Days' Supply
Stadol nasal spray 10 mg/ml (butorphanol)	MI (Submit in decimal format; do not round)	Varies; claims should be divisible by 2.5 ml	Varies
Synagis 50 mg (palivizumab)	MI (Submit in decimal format; do not round)	0.5 ml	30
Synagis 100 mg (palivizumab)	MI	1 ml	30
Ventolin HFA (albuterol)	Grams	18 grams	30
Xopenex HFA (levalbuterol)	Grams	Varies; claims should be divisible by 15 grams	Varies


3. Compounded Prescriptions

Iowa Medicaid will process claims for compounded prescriptions in the NCPDP D.Ø format using the multiple ingredient functionality. All applicable edits, including <u>Preferred Drug List</u> (PDL) rules, apply to each NDC submitted. Providers must submit the NDCs for the active ingredients dispensed to create the compound.

A dispensing fee will be added to the claim when a drug within the compound is reimbursed at EAC. There will be no additional fee paid to prepare the compounded prescription. Providers need to submit the quantity of the active ingredients used in the compound for reimbursement, not the quantity of the total amount of the compound made.

4. Coverage of Active Pharmaceutical Ingredients (APIs) and Excipients

Medicaid will cover certain API and excipient products, although the manufacturers have not entered into a rebate agreement with CMS. These products are identified on the API & Excipients Prescribed Drug list located on the website <u>www.iowamedicaidpdl.com</u> under the Preferred Drug Lists tab. Pharmacies shall provide these products and bill Medicaid through the point of sale system. Prior authorizations (PA) will be submitted through the Pharmacy PA system. Payment will be made in the same manner as prescription drugs.



5. Date of Birth Verification

Point of sale edits for the exact date of birth from the eligibility file for Iowa Medicaid members. Field # 304-C4 (Date of Birth) on the National Council for Prescription Drug Programs (NCPDP) Payer Sheet is mandatory. The NCPDP rejection message will state "09-Missing/Invalid Date of Birth." Claims should be resubmitted with the correct date of birth for the member.

6. Override Codes

A 72-hour emergency supply of medication may be dispensed using prior authorization type code "1" as a point of sale override. The provision for a 72-hour supply can be used in an emergency situation only one time per member, per drug.

A seven-day override of the prior authorization requirement will be allowed while the prescriber is requesting prior authorization for certain mental health drugs. The override applies to drugs that are deemed to have a significant variation in therapeutic or side effect profile from other drugs in the same therapeutic class. See the Preferred Drug List at: <u>www.iowamedicaidpdl.com</u>


The pharmacy may use a prior authorization type code "7" as a point of sale override for applicable mental health drugs. The seven-day provision can be used only one time per member, per drug, per 30 days.

7. Proper Reporting of NDCs

The Iowa Medicaid Program can cover only drugs from manufacturers who have signed national Medicaid drug rebate agreements with the Centers for Medicare and Medicaid Services (CMS). Drug companies sign the agreements for specific drug manufacturer codes called national drug codes (NDC).

Since rebates are determined by Iowa Medicaid's utilization data, it is imperative that pharmacies and providers bill Iowa Medicaid using the correct NDC number of the drug actually dispensed or administered. Reimbursement is only made for the specific NDC dispensed or administered.

If a provider is dispensing or administering one drug and billing for an NDC different from the drug being dispensed or administered, it is considered fraud, which can result in claims being recouped, sanctions, and termination of provider agreements. The Program Integrity Unit will be monitoring for this in their reviews.



8. Prospective Drug Utilization Review (Pro-DUR)

The goal of Prospective DUR is to identify potential drug therapy concerns to allow the pharmacist to use professional judgment regarding the need for intervention, such as whether or not to contact the prescribing physician. The following prospective DUR edits will cause claims to deny:

Edit	Number and Message	Reason for the Denial	* Override Provided
Age Edits	75 - PRIOR AUTHORIZATION REQUIRED	Certain medications are payable only for specific age groups.	PA required.
Cost Effective- ness	75 - PRIOR AUTHORIZATION REQUIRED	Certain strengths should be substituted with more cost-effective strengths of the same medication.	PA required.
Dosage Form	75 - PRIOR AUTHORIZATION REQUIRED Additional text: NONPREFERRED	Certain dosage forms should be substituted with more cost-effective dosage forms of the same medication.	PA required.
Excessive Days Supply	19 - M/I DAYS SUPPLY Additional text: EXCEEDS ALLOWABLE DAYS SUPPLY	The supply submitted is more than 31 days.	Request an exception to policy if there is a valid reason why a supply more than 31 days is required.
15-Day Initial Prescription Supply Limit	76 - PLAN LIMITS EXCEEDED	The supply submitted is more than 15 days on select drugs.	PA required. See <u>Quantity Limit</u> <u>Override</u> .
Gender Edits	70 –product/ Service not covered – gender- specific drug	Certain medications are payable only for a specific gender.	PA required.



Provider and Chapter

Prescribed Drugs


Page

Date

Chapter III. Provider-Specific Policies

August 1, 2018

Edit	Number and Message	Reason for the Denial	* Override Provided
High Dollar Claims	78 - COST EXCEEDS MAXIMUM Additional text: CLAIM EXCEEDS \$5,000.00, PLEASE CALL POS HELPDESK	All claims submitted in excess of \$5,000 will be rejected. After verifying that the quantity and days' supply of the claim are correct, contact the Pharmacy POS Help Desk. See below.	A one-time override will be granted if quantity and days' supply are accurate and consistent. Additional medical documentation is required for longer overrides.
Hospice Edits	75 - PRIOR AUTHORIZATION REQUIRED – NOT COVERED FOR HOSPICE MEMBER	If member has hospice coverage and medication is required to be paid by hospice.	Override may be considered if hospice does not provide payment. Call POS Helpdesk.
Incarcer- ation Edit	65 - PATIENT IS NOT COVERED Service not covered for recipient, limited benefits for date	Pharmacy claims submitted through POS for members identified as being incarcerated will reject.	No override provided. Member must update incarceration status, if applicable.
Quantity Limits	76 - PLAN LIMITS EXCEEDED	If the quantity submitted exceeds the established quantity limit.	PA required. See <u>Quantity Limit</u> <u>Override</u> .
Refill Too Soon	79 - REFILL TOO SOON Additional text: RX NUMBER/FILL DATE/NPI OR NABP/DATE FOR NEXT FILL	If less than 90% of the previously paid claim for that medication has not been used. See <u>Refill</u> <u>Too Soon</u> .	If there is a change in dose; lost, stolen or destroyed drug; or travel.
Step Therapy Edits	75 - PRIOR AUTHORIZATION REQUIRED	Certain therapeutic drug classes are subject to step therapy edits as designated on the Preferred Drug List.	PA required.



Edit	Number and Message	Reason for the Denial	* Override Provided
Tablet Splitting	19 - m/I DAYS SUPPLY Additional text: MUST SPLIT TABLETS	Certain medications that are scored and easily halved should be split to facilitate more cost- effective use of the drugs.	PA required.
Therapeutic Duplication	88 - DUR REJECT MESSAGE Additional text: SITUATIONAL	If a second claim submitted is a therapeutic duplication of a drug already submitted and reimbursed.	PA required.

* Always verify that the quantity and days' supply on the claim are correct; then for an override contact: Pharmacy POS Help Desk at 877-463-7671 or (515) 256-4608 (local)

a. Age Edits

Certain medications are payable only for specific age groups:

Drug Name/Class	Age Edit	Prior Authorization (PA) Requirement
Drugs FDA indicated for the treatment of Alzheimer's dementia (donepezil, galantamine, memantine, and rivastigmine)	Payable for members 40 years of age and older	PA is required for members under 40 years of age.
Aldara (imiquimod)	Payable for members 12 years of age and older	PA is required for members under 12 years of age.
Antipsychotics	Payable for members 5 years of age or older for risperidone and 6 years of age or older for all other anti- psychotics.	PA is required for members under 5 years of age for risperidone and under 6 years of age for all other antipsychotics.
Asmanex 110 mcg	Payable for members less than 12 years of age.	PA is required for members 12 years of age and older.



Page

Prescribed Drugs

Chapter III. Provider-Specific Policies

Date

August 1, 2018

Drug Name/Class	Age Edit	Prior Authorization (PA) Requirement
Benznidazole	Payable for members 2 through 11 years of age.	PA is required for members under 2 years of age and over 11 years of age.
Brovana	Payable for members 18 years of age and older.	PA is required for members under 18 years of age.
Clorazepate	Payable for members 9 years of age and older.	PA is required for members under 9 years of age.
Codeine Containing Products	Payable for members 18 years of age and older.	PA is required for members under 18 years of age.
Complera	Payable for members 18 years of age and older.	PA is required for members under 18 years of age.
Edurant	Payable for members 18 years of age and older.	PA is required for members under 18 years of age.
Eligard	Payable for members 18 years of age and older.	PA is required for members under 18 years of age.
Erivedge	Payable for members 18 years of age and older.	PA is required for members under 18 years of age.
Femara (letrozole)	Payable for members 50 years of age and older.	PA is required for member under 50 years of age.
Flurazepam	Payable for members 15 years of age and older.	PA is required for members under 15 years of age.
Foradil	Payable for members 5 years of age and older.	PA is required for members under 5 years of age.
Guanfacine ER	Payable for members 6 through 17 years of age.	PA is required for members under 6 years of age and over 17 years of age.



Provider and Chapter

Page

Date

Prescribed Drugs

Chapter III. Provider-Specific Policies

August 1, 2018

Drug Name/Class	Age Edit	Prior Authorization (PA) Requirement
Inlyta	Payable for members 18 years of age and older.	PA is required for members under 18 years of age.
Isentress 25 mg and 100 mg chewable tablets	Payable for members less than 12 years of age.	PA is required for members 12 years of age and older.
Jakafi	Payable for members 18 years of age and older.	PA is required for members under 18 years of age.
Nuvigil (armodafinil)	Payable with a PA for members 17 years of age and older	PA is required for members under 17 years of age.
OTC Polyethylene glycol 3350 powder	Payable for members 0 to 12 years of age. PA required for members 13 to 18 years of age. Not covered for members 19 years of age or over.	PA is required for members 13-18 years of age.
Oxazepam	Payable for members 6 years of age and older.	PA is required for members under 6 years of age.
Perforomist	Payable for members 18 years of age and older.	PA is required for members under 18 years of age.
Provigil (modafinil)	Payable for members 16 years of age and older	PA is required for members under 16 years of age and 21 years of age and older
Revlimid	Payable for members 18 years of age and older.	PA is required for members under 18 years of age.
Serevent	Payable for members 4 years of age and older.	PA is required for members under 4 years of age.
Singulair 4 mg granules	Payable for members less than 2 years of age	PA is required for members 2 years of age and older.



Provider and Chapter

Prescribed Drugs

Page

Chapter III. Provider-Specific Policies

Date August 1, 2018

52

Drug Name/Class	Age Edit	Prior Authorization (PA) Requirement
Stribild	Payable for members 18 years of age and older.	PA is required for members under 18 years of age.
Tramadol Containing Products	Payable for members 18 years of age and older.	PA is required for members under 18 years of age.
Veregen (sinecatechins)	Payable for members 18 years of age and older.	PA is required for members under 18 years of age.
Zytiga	Payable for members 18 years of age and older.	PA is required for members under 18 years of age.

Cost Effectiveness Edit b.

Drug	Dosage	Alternative
Buspirone tablet	30 mg	Deny. Use two buspirone 15 mg tablets.
Clindamycin capsule	300 mg	Deny. Use multiples of clindamycin 150 mg capsule.
Hydroxyzine pamoate capsules	100 mg	Deny. Use hydroxyzine pamoate 50 mg capsules.
Imipramine pamoate capsules		Deny. Use imipramine HCL tablets.
Prozac or fluoxetine HCL capsules	40 mg	Deny. Use two fluoxetine HCL 20 mg capsules.
Rheumatrex		Deny. Use methotrexate.

Dosage Form Edits с.

Form	Drug	Dosage	Alternative
Prozac tablets	fluoxetine	20 mg	Deny. Use the capsule dosage form.
Zantac capsules	ranitidine	150 mg	Deny. Use the tablet dosage form.
Zantac capsules	ranitidine	300 mg	Deny. Use the tablet dosage form.



Date

53

d. Excessive Days Supply

The claim will be rejected if the supply submitted is more than 31 days. If there is a valid reason why a supply of more than 31 days is required, request an exception to policy.

e. Gender Edits

Drug Name/Class	Gender Edit
Prenatal vitamins	Payable for female members

f. High-Dollar Claims

All claims in excess of \$5,000 submitted through the pharmacy point of sale system will be rejected with a denial message stating, "Claim exceeds \$5,000, please call POS Help Desk at 877-463-7671 or (515) 256-4608 locally."

After verifying that the quantity and days' supply on the claim are correct, contact the Pharmacy POS Help Desk for consideration of an override. A technician or pharmacist will review the information submitted and determine if an override shall be issued.

As a part of this process, the Iowa Medicaid Program Integrity Unit may request additional medical documentation regarding the case from the prescriber or pharmacy. This policy is intended to help ensure that proper billing procedures are being followed.

g. Hospice Edits

For members enrolled in hospice, medications in the following therapeutic categories should be submitted to hospice for coverage consideration. If hospice does not provide payment for a medication in one of the below categories, or if the member is no longer enrolled in hospice, the pharmacy may call the POS Helpdesk for coverage consideration.

Analgesics — non-narcotic
Analgesics — opioid
Antianxiety agents
Antidiarrheals
Antiemetics
Antihistamines

Antispasmodics Cough/Cold/Allergy Hypnotics Laxatives Muscle relaxant combinations Ophthalmic agents



h.

Date

Refill Too Soon

The claim will be denied if not enough time has elapsed for the member to use 90 percent of the supply issued under previously paid claim for that medication. An override will be considered if:

- There is a change in dose;
- The previously issued supply has been lost, stolen or destroyed; or
- The member is traveling and will not be able to pick up the next refill at the normal time.

i. Step Therapy Edits

Certain therapeutic drug classes are subject to step therapy edits as designated on the Preferred Drug List. Antipsychotics-Atypicals:

Step 1: Preferred generic drugs. No PA required.

Step 2: Preferred brand name drugs. No PA required if a preferred generic trial is found in the paid claims system in the past 12 months.

Step 3: Nonpreferred drugs. PA required.

j. Tablet Splitting

Certain medications that are scored and easily halved should be split to facilitate more cost-effective use of the drugs.

Drug Product	Quantity	Days' Supply	Comments
Lexapro 5 mg	15	30	Use 10 mg tablets to obtain 5 mg daily dose
Lexapro 10 mg	15	30	Use 20 mg tablets to obtain 10 mg daily dose

k. Therapeutic Duplication

If a second claim submitted is a therapeutic duplication of a drug already submitted and reimbursed, overlapping claims will be considered on an individual basis.



Iowa

Department of Human

Services

Provider and Chapter

Page

Date

Prescribed Drugs

Chapter III. Provider-Specific Policies

August 1, 2018

55

Deny regardless of prescriber		
Antipsychotics	Duplicate therapy edit on all antipsychotics for members 0 – 17 years of age. A 30 day grace period is allowed for transition between antipsychotic medications. After 30 days of concomitant use, provide prescriber verified documentation of the necessity of the duplication in the treatment plan.	
Antipsychotics	After 12 weeks (84 days) of concomitant oral and injectable antipsychotic medication use for members 18 years of age and older, provide prescriber verified documentation of the necessity in the treatment plan.	
Nonsteroidal anti- inflammatory drugs (NSAIDs)	After 60 days of concomitant use, provide prescriber verified documentation of the necessity of the duplication in the treatment plan.	

9. Status Change for Preferred Brand Name Drugs

When the status of a previously preferred brand-name drug changes to nonpreferred, pharmacies are given a transition period of up to 30 days to allow utilization of existing stock of the brand-name product.


If additional stock remains beyond this period, pharmacies may call the Point of Sale (POS) Helpdesk at 877-463-7671 or 515-256-4608 (local) to request an override for the nonpreferred brand-name drug with a recent status change.

10. Travel or Vacation Supplies of Medication

Requests of medications for travel or vacation should be planned well in advance of the departure date.

The pharmacy can process the first month's prescriptions as usual, and then may call the Point of Sale (POS) Helpdesk at 877-463-7671 or 515-256-4608 (local) to obtain up to a one-month supply of medications to total up to a 60-day supply of medication.

Exceptions to policy will not be granted if other sources for payment are available.



11. 340B Drug Pricing Program

In order to become eligible to participate in the 340B Program, the provider must submit a request to the Office of Pharmacy Affairs (OPA) within the Health Resources and Services Administration (HRSA). The OPA website is <u>http://www.hrsa.gov/opa/</u>. The online registration is available at the following link: <u>https://340bregistration.hrsa.gov/</u>.

It is very important that the OPA has accurate and up-to-date information, particularly your exact name and street address. It your responsibility to:

- Contact the OPA with any changes in your information; and
- Tell your wholesaler or manufacturer that you are registered for 340B discount prices when you place an order.

Providers must enroll with Iowa Medicaid in order to bill and receive reimbursement for self-adminsitered drugs purchased through the 340B Program.

a. Covered Entity (CE)

The covered entity (CE) has full responsibility and accountability for compliance with all requirements to prevent diversion of covered drugs to individuals other than patients of the CE, and to prevent situations in which a drug is subject to both the 340B discount and a Medicaid rebate claim.

Use of a contract pharmacy arrangement (single or multiple) does not lessen a CE's duty to ensure that the 340B Program is being administered in compliance with the statute and HRSA guidelines.

It is imperative that all CEs participating in the 340B Program not only comply with program requirements but also be able to document compliance with those requirements in the event of an audit.

To prevent duplicate discounts, HRSA requires CEs to indicate on OPA website if they purchase drugs at 340B pricing for Medicaid patients (Medicaid Exclusion File), so Medicaid does not bill for rebates. HRSA directs CEs to follow state guidelines when billing for 340B drugs. CEs may not use a contracted pharmacy unless it has reached an agreement with the state Medicaid agency on a method to prevent duplicate discounts.



57

Date August 1, 2018

b. Iowa Medicaid Billing/Reimbursement for CE Outpatient In-House Pharmacy or Contracted Pharmacy

340B requirements below are reviewed through a postpayment review. Overbillings are subject to recoupment.

(1) 340B Covered Entities

The CE must decide if they are carving Medicaid "OUT" or "IN," and that decision applies to both fee-for-service and managed care claims.

All 340B CEs that use 340B drugs and serve Medicaid FFS members must do one of the following:

- Medicaid CARVE OUT all prescriptions from the 340B program when Medicaid is a payor for any portion of the claim:
 - Use non-340B drugs for all Medicaid members you serve.
 - Bill Medicaid only for drugs purchased outside the 340B program billed in accordance with existing state Medicaid reimbursement methodologies, allowing rebates to be collected where appropriate.
 - Do not list the 340B entity's NPI on the HRSA Medicaid Exclusion File.

This allows rebates to be collected by Medicaid where appropriate.

- Medicaid **CARVE IN** all prescriptions into the 340B program:
 - Use 340B drugs for all Medicaid members you serve.
 - Inform OPA at the time of 340B enrollment that you intend to purchase and dispense 340B drugs for Medicaid members.
 - Do not bill Medicaid for 340B acquired drugs if your NPI is not listed on the HRSA Medicaid Exclusion File.
 - Purchase all drugs billed to Medicaid on the CE's NPI under 340B unless the product is not eligible for 340B pricing.

This ensures these claims are excluded from Medicaid rebate.



58

• Billing:

Submit pharmacy claims for 340B-acquired drugs to Medicaid at your 340B AAC and with values of "08" in Basis of Cost Determination field 423-DN **OR** in Compound Ingredient Basis of Cost Determination field 490-UE **AND** also insert "20" in the Submission Clarification Code field 420-DK.

If the product is not eligible for 340B pricing do not include the basis of cost determination or submission clarification code values and bill at the regular Medicaid rate.

(2) 340B Contract Pharmacies

Contract pharmacies may not submit claims to Medicaid FFS for 340B-acquired drugs. A 340B contract pharmacy must **carve out** Medicaid FFS from its 340B operation.

12. Interpreter Services

Translation and interpretative services may be covered, whether done orally or through sign language. Interpreters must provide only interpretation services for your pharmacy. The services must facilitate access to Medicaid covered services.

In order for translation and interpretation services to be covered by Iowa Medicaid, the services must meet the following criteria:

- Provided by interpreters who provide only interpretive services.
- Interpreters may be employed or contracted by the billing provider.
- The interpretive services must facilitate access to Medicaid-covered services.

Providers may only bill for these services if offered in conjunction with an otherwise Medicaid covered service. Medical staff that are bilingual are not reimbursed for the interpretation but only for their medical services. Reimbursable time may include the interpreter's travel and wait time.

a. Documentation of the Service

The billing provider must document in the patient's record the:

- Interpreter's name or company,
- Date and time of the interpretation,
- Service duration (time in and time out), and
- The cost of providing the service.



b. Qualifications

It is the responsibility of the billing provider to determine the interpreter's competency. Sign language interpreters should be licensed pursuant to 645 Iowa Administrative Code Chapter 361. Oral interpreters should be guided by the standards developed by the National Council on Interpreting in Health Care (www.ncihc.org)

The following are instructions for billing interpretive services when that service is provided by an outside commercial translation service.

- Bill code T1013 on the professional CMS-1500 claim form:
 - For telephonic interpretive services use modifier "UC" to indicate that the payment should be made at \$1.70 per minute.
 - The lack of the UC modifier will indicate that the charge is being made for the 15 minute face-to-face unit.
- Enter the number of minutes actually used for the provision of the service.
- Special note: Because the same code is being used but a conditional modifier may be necessary, any claim where the UC modifier is NOT used and the units exceed 24 will be paid at 24 units.

G. REMITTANCE ADVICE AND FIELD DESCRIPTIONS

1. Remittance Advice Explanation

To simplify your accounts receivable reconciliation and posting functions, you will receive a comprehensive *Remittance Advice* with each Medicaid payment. The *Remittance Advice* is also available on magnetic computer tape for automated account receivable posting. To view a sample of this form on line, click <u>here</u>.

The *Remittance Advice* is separated into categories indicating the status of those claims listed below. Categories of the *Remittance Advice* include paid claims and denied claims:

- **Paid** indicates all processed claims, credits and adjustments for which there is full or partial reimbursement.
- **Denied** represents all processed claims for which no reimbursement is made.



Note that claim credits or recoupments (reversed) appear as regular claims with the exception that the transaction control number contains a "1" in the twelfth position and reimbursement appears as a negative amount.

An adjustment to a previously paid claim produces two transactions on the *Remittance Advice*. The first appears as a credit to negate the claim; the second is the replacement or adjusted claim, containing a "2" in the twelfth position of the transaction control number.

If the total of the credit amounts exceeds that of reimbursement made, the resulting difference (amount of credit less the amount of reimbursement) is carried forward and no check is issued. Subsequent reimbursement will be applied to the credit balance, as well, until the credit balance is exhausted.

A detailed field-by-field description of each informational line follows. It is important to study these examples to gain a thorough understanding of each element as each *Remittance Advice* contains important information about claims and expected reimbursement.

Regardless of one's understanding of the *Remittance Advice*, it is sometimes necessary to contact IME Provider Services with questions. When doing so, keep the *Remittance Advice* handy and refer to the transaction control number of the particular claim. This will result in timely, accurate information about the claim in question.

Field Name Field		Field Description
А	R.A. No.	Remittance Advice number
В	Warrant Number	Check number (usually zeros). Contact IME for check number.
С	Provider Name	Name of the pay-to provider as registered with IME
D	Provider Address	Address registered with IME for the mailing of <i>Remittance Advice</i> and paper checks
E	Important IME Information	Reminders and updates from IME
F	Run Date	Date the Remittance Advice was created
G	Date Paid	Date the <i>Remittance Advice</i> was mailed and check was released

2. Remittance Advice Field Descriptions



Provider and Chapter

Prescribed Drugs

Chapter III. Provider-Specific Policies

Page

Date

August 1, 2018

	Field Name	Field Description
Н	Prov. Number	National provider identifier (NPI) of the billing (pay-to) provider
I	Page	Page number
J	Number of Claims	Number of claims processed for each defined status
К	Billed Amount of All Claims	Total dollar amount of claims billed for each defined status
L	Subtotal Amount Paid	Amount paid for each defined status
М	Amount of Deposit	Total check amount for claims paid on this <i>Remittance Advice</i>
N	EOB Code	Explanation of benefits (EOB) code or denial code
0	EOB Description	Description of the denial EOB
Р	Number of Claims Posting EOB	Number of claims that denied for the EOB code described
Q	Total Billed Amt.	Total amount billed to Iowa Medicaid for claims in this status section
R	Total Other Sources	Third party insurance payment or spenddown amount applied for claims in this status section
S	Total Paid by Mcaid	Total amount paid by Medicaid for claims in this status section
Т	Copay Amt.	Members' copayment amount (applied per date of service, when applicable) for claims in this status

1	Patient Name	Name of the member as shown on the Medical Assistance Eligibility Card (last name and first initial)
2	Recipient Ident Num	Member identification number (7 digits+letter)
3	Trans-Control- Number	17-digit transaction control number assigned to each claim
4	Dispense Date	Date of service
5	National Drug Code	11-digit NDC number
6	Sub Units	Number of units billed
7	Rx No.	Prescription number
8	Billed Amt.	Total amount billed to Iowa Medicaid for this claim
9	Other Sources	Third party insurance payment or spenddown amount applied to this claim



Provider and Chapter

Prescribed Drugs

Chapter III. Provider-Specific Policies

Page

Date August 1, 2018

	Field Name	Field Description
10	Paid by Mcaid	Total amount paid by Medicaid on this claim
11	Copay Amt.	Member's copay amount (applied per date of service, when applicable)
12	Source of Payment	Allowed charge source codes are as follows:
		 A Anesthesia B Billed charge C Percentage of charges D Inpatient per diem rate E EAC priced plus dispense fee F Fee schedule G FMAC priced plus dispense fee H Encounter rate I Prior authorization rate K Denied L Maximum suspend ceiling M Manually priced N Provider charge rate O Professional component P Group therapy Q EPSDT total over 17 R EPSDT total over 17 S EPSDT partial over 17 SP Not yet priced T EPSDT partial under 18 U Gynecology fee V Obstetrics fee W Child fee X Medicare or coinsurance deductibles Y Immunization replacement Z Batch bill APG O APG 1 No payment APG 3 HMO/PHP rate 4 System parameter rate 5 Statewide per diem 6 DRG auth or new 7 Inlier/outlier adjust 8 DRG ADR



Provider and Chapter

Prescribed Drugs

Chapter III. Provider-Specific Policies

Page

Date

August 1, 2018

Field Name		Field Description
13	EOB	Explanation of benefits (EOB) code, if denied. A description of the code can be found on the summary page of the <i>Remittance Advice</i> (Field O).
14	Practitioner	Name of prescribing provider
15	Drug Name	Name and dosage of drug dispensed
16	Adj-R	Reason code indicating the reason for the adjustment
17	TCN-to-Credit	17-digit TCN number of the claim being credited